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Preamble (UPDATED)
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
and therapies as they are introduced and tested in the
detection, management, or prevention of disease states. Rig-
orous and expert analysis of the available data documenting
relative benefits and risks of those procedures and therapies
can produce helpful guidelines that improve the effectiveness
of care, optimize patient outcomes, and favorably affect the
overall cost of care by focusing resources on the most
effective strategies.
The American College of Cardiology Foundation (ACCF)
and the American Heart Association (AHA) have jointly
engaged in the production of such guidelines in the area of
cardiovascular disease since 1980. This effort is directed by
the ACCF/AHA Task Force on Practice Guidelines, whose
charge is to develop and revise practice guidelines for
important cardiovascular diseases and procedures.
Experts in the subject under consideration are selected
from both organizations and charged with examining
subject-specific data and writing or updating these guide-
lines. The process includes additional representatives from
other medical practitioner and specialty groups where
appropriate. Writing groups are specifically charged to
perform a formal literature review, weigh the strength of
evidence for or against a particular treatment or procedure,
and include estimates of expected health outcomes where
data exist. Patient-specific modifiers, comorbidities, and
issues of patient preference that might influence the choice
of particular tests or therapies are considered, as are
frequency of follow-up and cost-effectiveness. When avail-
able, information from studies on cost will be considered;
however, review of data on efficacy and clinical outcomes will
constitute the primary basis for preparing recommendations in
these guidelines.
The ACCF/AHA Task Force on Practice Guidelines makes
every effort to avoid any actual, potential, or perceived conflicts
of interest that might arise as a result of an outside relationship
or personal interest of a member of the writing committee.
Specifically, all members of the writing committee, as well as
peer reviewers of the document, are asked to provide disclosure
statements of all such relationships that might be perceived as
real or potential conflicts of interest. Writing committee mem-
bers are also strongly encouraged to declare a previous relation-
ship with industry that may be perceived as relevant to guideline
development. If a writing committee member develops a new
relationship during his or her tenure, he or she is required to
he indiv
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 notify the guideline writing staff in writing. The continued
participation of the writing committee member will be reviewed
by the parent task force, reported orally to all members of the
writing panel at each meeting, and updated and reviewed by the
writing committee as changes occur. Please refer to the meth-
odology manual for the ACCF/AHA guideline writing commit-
tees for further description and the relationships with industry
policy.1 See Appendix 1 for a list of writing committee member
relationships with industry and Appendix 2 for a listing of peer
reviewer relationships with industry that are pertinent to this
guideline.
The practice guidelines produced are intended to assist
healthcare providers in clinical decision making by describ-
ing a range of generally acceptable approaches for the
diagnosis, management, or prevention of specific diseases or
conditions. These guidelines attempt to define practices that
meet the needs of most patients in most circumstances. These
guideline recommendations reflect a consensus of expert
Table 1. Applying Classification of Recommendations and Level
*Data available from clinical trials or registries about the usefulness/efficacy
myocardial infarction, history of heart failure, and prior aspirin use. A recommen
Many important clinical questions addressed in the guidelines do not lend the
be a very clear clinical consensus that a particular test or therapy is useful o
†In 2003, the ACCF/AHA Task Force on Practice Guidelines developed
recommendations have been written in full sentences that express a complet
the rest of the document (including headings above sets of recommendations
increase readers’ comprehension of the guidelines and will allow queries at topinion after a thorough review of the available, currentscientific evidence and are intended to improve patient care.
If these guidelines are used as the basis for regulatory/payer
decisions, the ultimate goal is quality of care and serving the
patient’s best interests. The ultimate judgment regarding care
of a particular patient must be made by the healthcare
provider and patient in light of all of the circumstances
presented by that patient.
The 2005 guidelines were approved for publication by the
governing bodies of the ACCF and the AHA and have been
officially endorsed by the American College of Chest Physi-
cians, the International Society for Heart and Lung Trans-
plantation, and the Heart Rhythm Society. The summary
article including recommendations was published in the
September 20, 2005, issues of both the Journal of the
American College of Cardiology and Circulation. The full-
text guideline is posted on the World Wide Web sites of the
ACC (www.acc.org) and the AHA (my.americanheart.
org). Copies of the full text and the summary article are
ence
rent subpopulations, such as gender, age, history of diabetes, history of prior
ith Level of Evidence B or C does not imply that the recommendation is weak.
to clinical trials. Even though randomized trials are not available, there may
ve.
f suggested phrases to use when writing recommendations. All guideline
ht, such that a recommendation, even if separated and presented apart from
still convey the full intent of the recommendation. It is hoped that this will
idual recommendation level.of Evid
in diffe
dation w
mselves
r effecti
a list o
e thoug
), wouldavailable from both organizations.
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 The current document is a re-publication of the “ACC/
AHA 2005 Guideline Update for the Diagnosis and Manage-
ment of Chronic Heart Failure in the Adult,”2 revised to
incorporate updated recommendations and text from a fo-
cused update performed during 2008.3 Recommendations
have been updated with new information that has emerged
from clinical trials or other ACCF/AHA guideline or consen-
sus documents. In addition, the writing committee felt that a
new section, the Hospitalized Patient, was necessary to
address the increasingly recognized problem of the patient
with acute decompensated heart failure, as opposed to the
patient with chronic heart failure. Heart failure is now the
single most common reason why patients over 65 years are
admitted to the hospital, and the updated guidelines review
important management principles for this population. For
easy reference, this online-only version denotes sections that
have been updated.
Elliott M. Antman, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines, 2003–2005
Sidney C. Smith, Jr, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines, 2006–2008
1. Introduction (UPDATED)
Heart failure (HF) is a major and growing public health
problem in the United States. Approximately 5 million
patients in this country have HF, and over 550 000 patients
are diagnosed with HF for the first time each year.4 The
disorder is the primary reason for 12 to 15 million office visits
and 6.5 million hospital days each year.5 From 1990 to 1999,
the annual number of hospitalizations has increased from
approximately 810 000 to over 1 million for HF as a primary
diagnosis and from 2.4 to 3.6 million for HF as a primary or
secondary diagnosis.6 In 2001, nearly 53 000 patients died of
HF as a primary cause. The number of HF deaths has
increased steadily despite advances in treatment, in part
because of increasing numbers of patients with HF due to
better treatment and “salvage” of patients with acute myocar-
dial infarctions (MIs) earlier in life.4
Heart failure is primarily a condition of the elderly,7 and
thus the widely recognized “aging of the population” also
contributes to the increasing incidence of HF. The incidence
of HF approaches 10 per 1000 population after age 65,4 and
approximately 80% of patients hospitalized with HF are more
than 65 years old.8 Heart failure is the most common
Medicare diagnosis-related group (i.e., hospital discharge
diagnosis), and more Medicare dollars are spent for the
diagnosis and treatment of HF than for any other diagnosis.9
The total estimated direct and indirect costs for HF in 2005
were approximately $27.9 billion.4 In the United States,
approximately $2.9 billion annually is spent on drugs for the
treatment of HF.4
1.1. Evidence Review (UPDATED)
The ACCF and the AHA first published guidelines for the
evaluation and management of HF in 1995 and published
revised guidelines in 2001.10 Since that time, a great deal of
progress has been made in the development of both pharma-
cological and nonpharmacological approaches to treatmentfor this common, costly, disabling, and potentially fatal
disorder. The number of available treatments has increased,
but this increase has rendered clinical decision making far
more complex. The timing and sequence of initiating treat-
ments and the appropriateness of prescribing them in combi-
nation are uncertain. The increasing recognition of the exis-
tence of clinical HF in patients with a normal ejection fraction
(EF) (see Section 4.3.2.1) has also led to heightened aware-
ness of the limitations of evidence-based therapy for this
important group of patients. For these reasons, the 2 organi-
zations believed that it was appropriate to reassess and update
these guidelines, fully recognizing that the optimal therapy of
HF remains a work in progress and that future advances will
require that the guideline be updated again.
The recommendations listed in the 2005 guideline are
evidence based whenever possible. Pertinent medical litera-
ture in the English language was identified through a series of
computerized literature searches (including Medline and EM-
BASE) and a manual search of selected articles. References
selected and published in this document are representative but
not all inclusive. Recommendations relevant to a class of
drugs specify the use of the drugs shown to be effective in
clinical trials unless there is reason to believe that such drugs
have a broad class effect.
In 2005, the committee elected to focus this document on
the prevention of HF and on the diagnosis and management
of chronic HF in the adult patient with normal or low LVEF.
Other guidelines are relevant to the HF population, and
include the ACC/AHA Guidelines for the Management of
Patients With ST-Elevation Myocardial Infarction11 and the
ACC/AHA 2002 Update of the Guidelines for the Manage-
ment of Unstable Angina and Non-ST Elevation Myocardial
Infarction.12 These guidelines have excluded HF in children,
both because the underlying causes of HF in children differ
from those in adults and because none of the controlled trials
of treatments for HF have included children. We have not
considered the management of HF due to primary valvular
disease (see ACC/AHA Guidelines on the Management of
Patients With Valvular Heart Disease)13 or congenital mal-
formations, and we have not included recommendations for
the treatment of specific myocardial disorders (e.g., hemo-
chromatosis, sarcoidosis, or amyloidosis).
For the 2009 focused update, late-breaking clinical trials
presented at the 2005, 2006, and 2007 annual scientific
meetings of the ACCF, AHA, and European Society of
Cardiology, as well as selected other data, from 2005 through
November 2007, were reviewed by the standing guideline
writing committee along with the parent task force to identify
those trials and other key data that might impact guideline
recommendations. On the basis of the criteria/considerations
noted earlier, recent trial data and other clinical information
were considered important enough to prompt a focused
update of the ACCF/AHA 2005 Guideline Update for the
Diagnosis and Management of Chronic Heart Failure in the
Adult.2 In addition, the guidelines writing committee thought
that a new section on the management of the hospitalized
patient with HF should be included in this update. A number
of recent HF trials reviewed for this update, were, in fact,
performed on hospitalized patients, and a number of newer
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 therapies are under development for this population. More-
over, there is increasing government and other third-party
payer interest in the prevention of HF hospitalizations, and
rehospitalizations. Quality indicators about the process of
discharging the HF patient have already been developed, and
data about rehospitalizations for HF by hospital have been
made public. Thus, the committee thought that a new section
about this important aspect of HF care should be added to the
update.
When considering the new data for the focused update, the
writing group faced the task of weighing evidence from
studies enrolling large numbers of subjects outside North
America. While noting that practice patterns and the rigor
applied to data collection, as well as the genetic makeup of
subjects, might influence the observed magnitude of a treat-
ment’s effect, the writing group believed that the data were
relevant to formulation of recommendations for the manage-
ment of HF in North America.
1.2. Organization of Committee and Relationships
With Industry (UPDATED)
The 2005 writing committee was composed of 15 members
who represented the ACCF and AHA, as well as invited
participants from the American College of Chest Physicians,
the Heart Failure Society of America, the International
Society for Heart and Lung Transplantation, the American
Academy of Family Physicians, and the American College of
Physicians. Both the academic and private practice sectors
were represented.
For the 2009 focused update, all members of the 2005 HF
writing committee were invited to participate; those who
agreed (referred to as the 2009 Focused Update Writing
Group) were required to disclose all relationships with
industry relevant to the data under consideration1 as were all
peer reviewers of the document (see Appendixes 4 and 5 for
a listing of relationships with industry for the 2009 Focused
Update Writing Group and peer reviewers, respectively).
Each recommendation required a confidential vote by the
writing group members before and after external review of
the document. Writing group members who had a significant
(greater than $10 000) relationship with industry relevant to a
recommendation were required to recuse themselves from
voting on that recommendation.
1.3. Review and Approval (NEW)
The 2005 Guideline document was reviewed by 3 official
reviewers nominated by the ACCF, 3 official reviewers
nominated by the AHA, 1 reviewer nominated by the Amer-
ican Academy of Family Physicians, 2 reviewers nominated
by the American College of Chest Physicians, 1 reviewer
nominated by the American College of Physicians, 4 review-
ers nominated by the Heart Failure Society of America, and 1
reviewer nominated by the International Society for Heart
and Lung Transplantation. In addition, 9 content reviewers
and the following committees reviewed the document:
ACCF/AHA Committee to Develop Performance Measures
for Heart Failure, ACCF/AHA Committee to Revise Guide-
lines for the Management of Patients With Acute Myocardial
Infarction, ACCF/AHA/ESC Committee to Update Guide-lines on the Management of Patients with Atrial Fibrillation,
ACCF/AHA Committee to Update Guidelines on Coronary
Artery Bypass Graft Surgery, ACCF Committee to Develop
Data Standards on Heart Failure, AHA Quality of Care and
Outcomes Research Interdisciplinary Working Group Steer-
ing Committee, and AHA Council on Clinical Cardiology
Committee on Heart Failure and Transplantation.
The 2009 focused update was reviewed by 2 external
reviewers nominated by both the ACCF and AHA, as well as
a reviewer from the ACCF/AHA Task Force on Practice
Guidelines, 10 organizational reviewers representing the
American College of Chest Physicians, the American College
of Physicians, the American Academy of Family Physicians,
the Heart Failure Society of America, and the International
Society for Heart and Lung Transplantation, and 14 individ-
ual content reviewers. All information about reviewers’
relationships with industry was collected and distributed to
the writing committee and is published in this document (see
Appendix 5 for details).
The 2009 focused update was approved for publication by
the governing bodies of the ACCF and the AHA and
endorsed by the International Society for Heart and Lung
Transplantation.
1.4. Stages of Heart Failure (UPDATED)
The HF writing committee previously developed a new
approach to the classification of HF,2 one that emphasized
both the development and progression of the disease. In
doing so, they identified 4 stages involved in the develop-
ment of the HF syndrome. The first 2 stages (A and B) are
clearly not HF but are an attempt to help healthcare
providers with the early identification of patients who are
at risk for developing HF. Stages A and B patients are best
defined as those with risk factors that clearly predispose
toward the development of HF. For example, patients with
coronary artery disease, hypertension, or diabetes mellitus
who do not yet demonstrate impaired left ventricular (LV)
function, hypertrophy, or geometric chamber distortion
would be considered Stage A, whereas patients who are
asymptomatic but demonstrate LV hypertrophy (LVH)
and/or impaired LV function would be designated as Stage
B. Stage C then denotes patients with current or past
symptoms of HF associated with underlying structural
heart disease (the bulk of patients with HF), and Stage D
designates patients with truly refractory HF who might be
eligible for specialized, advanced treatment strategies,
such as mechanical circulatory support, procedures to
facilitate fluid removal, continuous inotropic infusions, or
cardiac transplantation or other innovative or experimental
surgical procedures, or for end-of-life care, such as hospice.
This classification recognizes that there are established
risk factors and structural prerequisites for the develop-
ment of HF and that therapeutic interventions introduced
even before the appearance of LV dysfunction or symp-
toms can reduce the population morbidity and mortality of
HF. This classification system is intended to complement
but in no way to replace the New York Heart Association
(NYHA) functional classification, which primarily gauges
the severity of symptoms in patients who are in Stage C or
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 Stage D. It has been recognized for many years that the
NYHA functional classification reflects a subjective as-
sessment by a healthcare provider and can change fre-
quently over short periods of time. It has also been
recognized that the treatments used may not differ signif-
icantly across the classes. Therefore, the committee be-
lieved that a staging system was needed that would reliably
and objectively identify patients during the course of their
developing disease and that would be linked to treatments
uniquely appropriate at each stage of illness. According to
this new staging approach, patients would only be ex-
pected to either not advance at all or to advance from one
stage to the next, unless progression of the disease was
slowed or stopped by treatment, and spontaneous reversal
of this progression would be considered unusual. For
instance, although symptoms (NYHA functional class)
might vary widely over time (in response to therapy or to
progression of disease) in a patient who has already
developed the clinical syndrome of HF (Stage C), the
patient could never return to Stage B (never had HF), and
therapies recommended for Stage C will be appropriate
even if this patient is in NYHA class I. This new
classification scheme adds a useful dimension to our
thinking about HF that is similar to that achieved by
staging or risk assessment systems for other disorders
(e.g., those used in the approach to cancer).
2. Characterization of Heart Failure as a
Clinical Syndrome
2.1. Definition of Heart Failure
Heart failure is a complex clinical syndrome that can result
from any structural or functional cardiac disorder that impairs
the ability of the ventricle to fill with or eject blood. The
cardinal manifestations of HF are dyspnea and fatigue, which
may limit exercise tolerance, and fluid retention, which may
lead to pulmonary congestion and peripheral edema. Both
abnormalities can impair the functional capacity and quality
of life of affected individuals, but they do not necessarily
dominate the clinical picture at the same time. Some patients
have exercise intolerance but little evidence of fluid retention,
whereas others complain primarily of edema and report few
symptoms of dyspnea or fatigue. Because not all patients
have volume overload at the time of initial or subsequent
evaluation, the term “heart failure” is preferred over the older
term “congestive heart failure.”
The clinical syndrome of HF may result from disorders of
the pericardium, myocardium, endocardium, or great vessels,
but the majority of patients with HF have symptoms due to an
impairment of LV myocardial function. Heart failure may be
associated with a wide spectrum of LV functional abnormal-
ities, which may range from patients with normal LV size and
preserved EF to those with severe dilatation and/or markedly
reduced EF. In most patients, abnormalities of systolic and
diastolic dysfunction coexist, regardless of EF. Patients with
normal EF may have a different natural history and may
require different treatment strategies than patients with re-
duced EF, although such differences remain controversial
(see Section 4.3.2.1).Coronary artery disease, hypertension, and dilated cardio-
myopathy are the causes of HF in a substantial proportion of
patients in the Western world. As many as 30% of patients
with dilated cardiomyopathy may have a genetic cause.14
Valvular heart disease is still a common cause of HF. In fact,
nearly any form of heart disease may ultimately lead to the
HF syndrome.
It should be emphasized that HF is not equivalent to
cardiomyopathy or to LV dysfunction; these latter terms
describe possible structural or functional reasons for the
development of HF. Instead, HF is defined as a clinical
syndrome that is characterized by specific symptoms (dys-
pnea and fatigue) in the medical history and signs (edema,
rales) on the physical examination. There is no single diag-
nostic test for HF because it is largely a clinical diagnosis that
is based on a careful history and physical examination.
2.2. Heart Failure as a Symptomatic Disorder
The approach that is most commonly used to quantify the
degree of functional limitation imposed by HF is one first
developed by the NYHA. This system assigns patients to 1 of
4 functional classes, depending on the degree of effort needed
to elicit symptoms: patients may have symptoms of HF at rest
(class IV), on less-than-ordinary exertion (class III), on
ordinary exertion (class II), or only at levels of exertion that
would limit normal individuals (class I). Although the func-
tional class tends to deteriorate over periods of time, most
patients with HF do not typically show an uninterrupted and
inexorable worsening of symptoms. Instead, the severity of
symptoms characteristically fluctuates even in the absence of
changes in medications, and changes in medications and diet
can have either favorable or adverse effects on functional
capacity in the absence of measurable changes in ventricular
function. Some patients may demonstrate remarkable recov-
ery, sometimes associated with improvement in structural and
functional abnormalities. Usually, sustained improvement is
associated with drug therapy, and that therapy should be
continued indefinitely.
The mechanisms responsible for the exercise intolerance
of patients with chronic HF have not been defined clearly.
Although HF is generally regarded as a hemodynamic
disorder, many studies have indicated that there is a poor
relation between measures of cardiac performance and the
symptoms produced by the disease. Patients with a very
low EF (see Section 4.3.2.1) may be asymptomatic,
whereas patients with preserved LVEF may have severe
disability. The apparent discordance between EF and the
degree of functional impairment is not well understood but
may be explained in part by alterations in ventricular
distensibility, valvular regurgitation, pericardial restraint,
cardiac rhythm, conduction abnormalities, and right ven-
tricular function.14 In addition, in ambulatory patients,
many noncardiac factors may contribute substantially to
exercise intolerance. These factors include but are not
limited to changes in peripheral vascular function, skeletal
muscle physiology, pulmonary dynamics, neurohormonal
and reflex autonomic activity, and renal sodium handling.
The existence of these noncardiac factors may explain why
the hemodynamic improvement produced by therapeutic
n; FHx
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 agents in patients with chronic HF may not be immediately
or necessarily translated into clinical improvement. Al-
though pharmacological interventions may produce rapid
changes in hemodynamic variables, signs and symptoms
may improve slowly over weeks or months or not at all.
2.3. Heart Failure as a Progressive Disorder
Left ventricular dysfunction begins with some injury to, or
stress on, the myocardium and is generally a progressive
process, even in the absence of a new identifiable insult to the
heart. The principal manifestation of such progression is a
change in the geometry and structure of the LV, such that the
chamber dilates and/or hypertrophies and becomes more
spherical—a process referred to as cardiac remodeling. This
change in chamber size and structure not only increases the
hemodynamic stresses on the walls of the failing heart and
depresses its mechanical performance but may also increase
regurgitant flow through the mitral valve. These effects, in
turn, serve to sustain and exacerbate the remodeling process.
Cardiac remodeling generally precedes the development of
symptoms (occasionally by months or even years), continues
after the appearance of symptoms, and contributes substan-
tially to worsening of symptoms despite treatment. Progres-
sion of coronary artery disease, diabetes mellitus, hyperten-
sion, or the onset of atrial fibrillation may also contribute to
the progression of HF. The development of structural abnor-
malities can have 1 of 3 outcomes: 1) patients die before
Figure 1. Stages in the Development of Heart Failure/Recommen
inhibitor; ARB, angiotensin II receptor blocker; EF, ejection fractio
ventricular; LVH, left ventricular hypertrophy; and MI, myocardialdeveloping symptoms (in Stage A or B), 2) patients developsymptoms controlled by treatment, or 3) patients die of progres-
sive HF. Sudden death can interrupt this course at any time.
Although several factors can accelerate the process of LV
remodeling, there is substantial evidence that the activation of
endogenous neurohormonal systems plays an important role
in cardiac remodeling and thereby in the progression of HF.
Patients with HF have elevated circulating or tissue levels of
norepinephrine, angiotensin II, aldosterone, endothelin, vaso-
pressin, and cytokines, which can act (alone or in concert) to
adversely affect the structure and function of the heart. These
neurohormonal factors not only increase the hemodynamic
stresses on the ventricle by causing sodium retention and
peripheral vasoconstriction but may also exert direct toxic
effects on cardiac cells and stimulate myocardial fibrosis,
which can further alter the architecture and impair the
performance of the failing heart. Neurohormonal activation
also has direct deleterious effects on the myocytes and
interstitium, altering the performance and phenotype of these
cells.
The development of HF can be appropriately characterized
by considering 4 stages of the disease, as described in the
Introduction. This staging system recognizes that HF, like
coronary artery disease, has established risk factors and
structural prerequisites; that the development of HF has
asymptomatic and symptomatic phases; and that specific
treatments targeted at each stage can reduce the morbidity
herapy by Stage ACEI indicates angiotensin-converting enzyme
CM, family history of cardiomyopathy; HF, heart failure; LV, left
ion.ded Tand mortality of HF (Figure 1).
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 3. Initial and Serial Clinical Assessment of
Patients Presenting With Heart Failure
(UPDATED)
The changes in this section are made to clarify the role of
functional assessment of the HF patient, beyond the NYHA
functional classification, and to expand on the use of B-type
natriuretic peptide (BNP) and N-terminal pro-B-type natri-
uretic peptide (NT-proBNP) testing within the context of the
overall evaluation of the patient (Table 2).
Recommendations for Initial Clinical Assessment of
Patients Presenting With Heart Failure
Class I
1. A thorough history and physical examination should
be obtained/performed in patients presenting with HF
to identify cardiac and noncardiac disorders or behav-
iors that might cause or accelerate the development or
progression of HF. (Level of Evidence: C)
2. A careful history of current and past use of alcohol,
illicit drugs, current or past standard or “alternative
therapies,” and chemotherapy drugs should be ob-
tained from patients presenting with HF. (Level of
Evidence: C)
3. In patients presenting with HF, initial assessment
should be made of the patient’s ability to perform
routine and desired activities of daily living. (Level of
Evidence: C)
4. Initial examination of patients presenting with HF
should include assessment of the patient’s volume
status, orthostatic blood pressure changes, measure-
ment of weight and height, and calculation of body
Table 2. Evaluation of the Cause of Heart Failure—The History
History to include inquiry re:
Hypertension
Diabetes
Dyslipidemia
Valvular heart disease
Coronary or peripheral vascular
disease
Myopathy
Rheumatic fever
Mediastinal irradiation
History or symptoms of sleep-
disordered breathing
Exposure to cardiotoxic agents
Current and past alcohol
consumption
Smoking
Collagen vascular disease
Exposure to sexually transmitted
diseases
Thyroid disorder
Pheochromocytoma
Obesity
Family history to include inquiry re:
Predisposition to atherosclerotic
disease (history of MIs,
strokes, PAD)
Sudden cardiac death
Myopathy
Conduction system disease (need
for pacemaker)
Tachyarrhythmia
Cardiomyopathy (unexplained HF)
Skeletal myopathy
HF indicates heart failure; MI, myocardial infarction; and PAD, peripheral
arterial disease.mass index. (Level of Evidence: C)5. Initial laboratory evaluation of patients presenting
with HF should include complete blood count, urinal-
ysis, serum electrolytes (including calcium and magne-
sium), blood urea nitrogen, serum creatinine, fasting
blood glucose (glycohemoglobin), lipid profile, liver
function tests, and thyroid-stimulating hormone. (Level of
Evidence: C)
6. Twelve-lead electrocardiogram and chest radiograph
(posterior-anterior and lateral) should be performed ini-
tially in all patients presenting with HF. (Level of Evi-
dence: C)
7. Two-dimensional echocardiography with Doppler
should be performed during initial evaluation of pa-
tients presenting with HF to assess LVEF, left ventric-
ular size, wall thickness, and valve function. Radionu-
clide ventriculography can be performed to assess
LVEF and volumes. (Level of Evidence: C)
8. Coronary arteriography should be performed in patients
presenting with HF who have angina or significant isch-
emia unless the patient is not eligible for revasculariza-
tion of any kind.15–19 (Level of Evidence: B)
Class IIa
1. Coronary arteriography is reasonable for patients
presenting with HF who have chest pain that may or
may not be of cardiac origin who have not had
evaluation of their coronary anatomy and who have no
contraindications to coronary revascularization. (Level
of Evidence: C)
2. Coronary arteriography is reasonable for patients
presenting with HF who have known or suspected
coronary artery disease but who do not have angina
unless the patient is not eligible for revascularization of
any kind. (Level of Evidence: C)
3. Noninvasive imaging to detect myocardial ischemia
and viability is reasonable in patients presenting
with HF who have known coronary artery disease
and no angina unless the patient is not eligible for
revascularization of any kind.20 (Level of Evidence: B)
4. Maximal exercise testing with or without measurement
of respiratory gas exchange and/or blood oxygen sat-
uration is reasonable in patients presenting with HF to
help determine whether HF is the cause of exercise
limitation when the contribution of HF is uncertain.
(Level of Evidence: C)
5. Maximal exercise testing with measurement of respi-
ratory gas exchange is reasonable to identify high-risk
patients presenting with HF who are candidates for
cardiac transplantation or other advanced treat-
ments.21–23 (Level of Evidence: B)
6. Screening for hemochromatosis, sleep-disturbed breathing,
or human immunodeficiency virus is reasonable in selected
patients who present with HF. (Level of Evidence: C)
7. Diagnostic tests for rheumatologic diseases, amyloid-
osis, or pheochromocytoma are reasonable in patients
presenting with HF in whom there is a clinical suspi-
cion of these diseases. (Level of Evidence: C)
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 8. Endomyocardial biopsy can be useful in patients pre-
senting with HF when a specific diagnosis is suspected
that would influence therapy.24 (Level of Evidence: C)
9. Measurement of natriuretic peptides (BNP and
NT-proBNP) can be useful in the evaluation of patients
presenting in the urgent care setting in whom the
clinical diagnosis of HF is uncertain. Measurement of
natriuretic peptides (BNP and NT-proBNP) can be
helpful in risk stratification.25–32 (Level of Evidence: A)
Class IIb
1. Noninvasive imaging may be considered to define the
likelihood of coronary artery disease in patients with
HF and LV dysfunction. (Level of Evidence: C)
2. Holter monitoring might be considered in patients
presenting with HF who have a history of MI and are
being considered for electrophysiologic study to docu-
ment VT inducibility. (Level of Evidence: C)
Class III
1. Endomyocardial biopsy should not be performed in the
routine evaluation of patients with HF.24 (Level of
Evidence: C)
2. Routine use of signal-averaged electrocardiography is
not recommended for the evaluation of patients pre-
senting with HF. (Level of Evidence: C)
3. Routine measurement of circulating levels of neuro-
hormones (e.g., norepinephrine or endothelin) is not
recommended for patients presenting with HF. (Level
of Evidence: C)
Recommendations for Serial Clinical Assessment of
Patients Presenting With Heart Failure
Class I
1. Assessment should be made at each visit of the ability
of a patient with HF to perform routine and desired
activities of daily living. (Level of Evidence: C)
2. Assessment should be made at each visit of the volume
status and weight of a patient with HF. (Level of Evi-
dence: C)
3. Careful history of current use of alcohol, tobacco, illicit
drugs, “alternative therapies,” and chemotherapy
drugs, as well as diet and sodium intake, should be
obtained at each visit of a patient with HF. (Level of
Evidence: C)
Class IIa
1. Repeat measurement of EF and the severity of struc-
tural remodeling can be useful to provide information
in patients with HF who have had a change in clinical
status or who have experienced or recovered from a
clinical event or received treatment that might have
had a significant effect on cardiac function. (Level of
Evidence: C)Class IIb
1. The value of serial measurements of BNP to guide
therapy for patients with HF is not well established.
(Level of Evidence: C)
3.1. Initial Evaluation of Patients
3.1.1. Identification of Patients (UPDATED)
In general, patients with LV dysfunction or HF present to the
healthcare provider in 1 of 3 ways:
1. With a syndrome of decreased exercise tolerance. Most
patients with HF seek medical attention with complaints of
a reduction in their effort tolerance due to dyspnea and/or
fatigue. These symptoms, which may occur at rest or
during exercise, may be attributed inappropriately by the
patient and/or healthcare provider to aging, other physio-
logical abnormalities (e.g., deconditioning), or other med-
ical disorders (e.g., pulmonary disease). Therefore, in a
patient whose exercise capacity is limited by dyspnea or
fatigue, the healthcare provider must determine whether
the principal cause is HF or another abnormality. Eluci-
dation of the precise reason for exercise intolerance can be
difficult because several disorders may coexist in the same
patient. A clear distinction can sometimes be made only
by measurements of gas exchange or blood oxygen satu-
ration or by invasive hemodynamic measurements during
graded levels of exercise (see ACC/AHA 2002 Guideline
Update for Exercise Testing).33
2. With a syndrome of fluid retention. Patients may present
with complaints of leg or abdominal swelling as their
primary (or only) symptom. In these patients, the impair-
ment of exercise tolerance may occur so gradually that it
may not be noted unless the patient is questioned carefully
and specifically about a change in activities of daily living.
3. With no symptoms or symptoms of another cardiac or
noncardiac disorder. During their evaluation for a disor-
der other than HF (e.g., abnormal heart sounds or abnor-
mal electrocardiogram or chest x-ray, hypertension or
hypotension, diabetes mellitus, an acute myocardial in-
farction (MI), an arrhythmia, or a pulmonary or systemic
thromboembolic event), patients may be found to have
evidence of cardiac enlargement or dysfunction.
A variety of approaches have been used to quantify the
degree of functional limitation imposed by HF. The most
widely used scale is the NYHA functional classification,34 but
this system is subject to considerable interobserver variability
and is insensitive to important changes in exercise capacity.
These limitations may be overcome by formal tests of
exercise tolerance. Measurement of the distance that a patient
can walk in 6 minutes may have prognostic significance and
may help to assess the level of functional impairment in the
very sick, but serial changes in walking distance may not
parallel changes in clinical status. Maximal exercise testing,
with measurement of peak oxygen uptake, has been used to
identify appropriate candidates for cardiac transplantation, to
determine disability, and to assist in the formulation of an
exercise prescription, but its role in the general management
of patients with HF has not been defined.
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 3.1.2. Identification of a Structural and Functional
Abnormality (UPDATED)
A complete history and physical examination are the first
steps in evaluating the structural abnormality or cause respon-
sible for the development of HF. Direct inquiry may reveal
prior or current evidence of MI, valvular disease, or congen-
ital heart disease, whereas examination of the heart may
suggest the presence of cardiac enlargement, murmurs, or a
third heart sound. Although the history and physical exami-
nation may provide important clues about the nature of the
underlying cardiac abnormality, identification of the struc-
tural abnormality leading to HF generally requires invasive or
noninvasive imaging of the cardiac chambers or great vessels.
The single most useful diagnostic test in the evaluation of
patients with HF is the comprehensive 2-dimensional echo-
cardiogram coupled with Doppler flow studies to determine
whether abnormalities of myocardium, heart valves, or peri-
cardium are present and which chambers are involved. Three
fundamental questions must be addressed: 1) Is the LV
ejection fraction (EF) preserved or reduced? 2) Is the struc-
ture of the LV normal or abnormal? 3) Are there other
structural abnormalities such as valvular, pericardial, or right
ventricular abnormalities that could account for the clinical
presentation? This information should be quantified with a
numerical estimate of EF, measurement of ventricular dimen-
sions and/or volumes, measurement of wall thickness, and
evaluation of chamber geometry and regional wall motion.
Right ventricular size and systolic performance should
be assessed. Atrial size should also be determined semi-
quantitatively and left atrial dimensions and/or volumes
measured. All valves should be evaluated for anatomic and
flow abnormalities to exclude the presence of primary
valve disease. Secondary changes in valve function, par-
ticularly the severity of mitral and tricuspid valve insuffi-
ciency, should be determined.
Noninvasive hemodynamic data acquired at the time of
echocardiography are an important additional correlate for
patients with preserved or reduced EF. Combined quantifica-
tion of the mitral valve inflow pattern, pulmonary venous
inflow pattern, and mitral annular velocity provides data
about characteristics of LV filling and left atrial pressure.
Evaluation of the tricuspid valve regurgitant gradient coupled
with measurement of inferior vena caval dimension and its
response during respiration provides an estimate of systolic
pulmonary artery pressure and central venous pressure.
Stroke volume may be determined with combined dimension
measurement and pulsed Doppler in the LV outflow tract.35
However, abnormalities can be present in any of these
parameters in the absence of HF. No single parameter
necessarily correlates specifically with HF; however, a totally
normal filling pattern argues against clinical HF.
A comprehensive echocardiographic evaluation is impor-
tant, because it is common for patients to have more than 1
cardiac abnormality that contributes to the development of
HF. Furthermore, the study may serve as a baseline for
comparison, because measurement of EF and the severity of
structural remodeling can provide useful information in
patients who have had a change in clinical status or who have
experienced or recovered from a clinical event or receivedtreatment that might have had a significant effect on cardiac
function.
Other tests may be used to provide information regarding
the nature and severity of the cardiac abnormality. Radionu-
clide ventriculography can provide highly accurate measure-
ments of LV function and right ventricular EF, but it is unable
to directly assess valvular abnormalities or cardiac hypertro-
phy. Magnetic resonance imaging or computed tomography
may be useful in evaluating chamber size and ventricular
mass, detecting right ventricular dysplasia, or recognizing the
presence of pericardial disease, as well as in assessing cardiac
function and wall motion.36
Magnetic resonance imaging may also be used to identify
myocardial viability and scar tissue.37 Chest radiography can
be used to estimate the degree of cardiac enlargement and
pulmonary congestion or to detect the presence of pulmonary
disease. A 12-lead electrocardiogram may demonstrate evi-
dence of prior MI, LV hypertrophy, cardiac conduction
abnormality (e.g., left bundle-branch block), or a cardiac
arrhythmia. However, because of their low sensitivity and
specificity, neither the chest x-ray nor the electrocardiogram
should form the primary basis for determining the specific
cardiac abnormality responsible for the development of HF.
3.1.3. Evaluation of the Cause of Heart Failure
Identification of the condition responsible for the cardiac
structural and/or functional abnormalities may be important,
because some conditions that lead to LV dysfunction are
potentially treatable and/or reversible. Efforts to identify a
cause frequently allow the detection of coexistent conditions
that may contribute to or exacerbate the severity of symp-
toms. However, it may not be possible to discern the cause of
HF in many patients presenting with this syndrome, and in
others, the underlying condition may not be amenable to
treatment. Hence, clinicians should focus their efforts on
diagnoses that have implications for therapy.
3.1.3.1. History and Physical Examination
Evaluation of potential causative factors begins with a
thorough history and careful physical examination (see
Table 2). Healthcare providers should inquire about a
history of hypertension; diabetes mellitus; dyslipidemia;
tobacco use; coronary, valvular, or peripheral vascular
disease; rheumatic fever; heart murmur or congenital heart
disease; personal or family history of myopathy; medias-
tinal irradiation; sleep-disturbed breathing; and exposure
to cardiotoxic agents, including ephedra, and antineoplas-
tic agents such as anthracyclines, trastuzumab (Herceptin,
an antibody for the treatment of breast cancer), or high-
dose cyclophosphamide. Heart failure may occur years
after exposure to anthracyclines or mediastinal irradiation.
Patients should be questioned carefully about illicit drug
use, current and past alcohol consumption, symptoms
suggestive of sleep-disturbed breathing, and exposure to
sexually transmitted diseases. The history and physical
evaluation should include specific consideration of noncar-
diac diseases such as collagen vascular disease, bacterial
or parasitic infection, obesity, thyroid excess or deficiency,
amyloidosis, and pheochromocytoma. The physical exam-
ination should document specific signs of right or left HF,
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 with particular attention to the presence of elevated jugular
venous pressure and a third heart sound, because these
have been shown to have prognostic significance.38
A detailed family history should be obtained not only to
determine whether there is a familial predisposition to ath-
erosclerotic disease but also to identify relatives with cardio-
myopathy, sudden unexplained death, conduction system
disease, and skeletal myopathies. Recent studies suggest that
as many as 30% of cases of idiopathic dilated cardiomyopa-
thy may be familial, and polymorphisms in genes encoding
cardiac proteins may provide important prognostic informa-
tion.39 However, the cost-effectiveness of family screening has
not been established, and determination of the genotype of
patients with familial cardiomyopathies or investigation of
genetic polymorphisms is not routinely performed. Instead,
an electrocardiogram and echocardiogram should be consid-
ered in first-degree relatives of patients with a dilated cardio-
myopathy, and families with multiple cases of dilated cardio-
myopathy should be referred to a center with expertise in
genetic analysis and counseling.
3.1.3.2. Laboratory Testing (UPDATED)
Laboratory testing may reveal the presence of disorders or
conditions that can lead to or exacerbate HF. The initial
evaluation of patients with HF should include a complete
blood count, urinalysis, serum electrolytes (including calcium
and magnesium), glycohemoglobin, and blood lipids, as well
as tests of both renal and hepatic function, a chest radiograph,
and a 12-lead electrocardiogram. Thyroid function tests
(especially thyroid-stimulating hormone) should be mea-
sured, because both hyperthyroidism and hypothyroidism can
be a primary or contributory cause of HF. A fasting trans-
ferrin saturation is useful to screen for hemochromatosis;
several mutated alleles for this disorder are common in
individuals of Northern European descent, and affected pa-
tients may show improvement in LV function after treatment
with phlebotomy and chelating agents. Magnetic resonance
imaging of the heart or liver may be needed to confirm the
presence of iron overload. Screening for human immunode-
ficiency virus (HIV) is reasonable and should be considered
for all high-risk patients. However, other clinical signs of
HIV infection typically precede any HF symptoms in those
patients who develop HIV cardiomyopathy. Serum titers of
antibodies developed in response to infectious organisms are
occasionally measured in patients with a recent onset of HF
(especially in those with a recent viral syndrome), but the
yield of such testing is low, and the therapeutic implications
of a positive result are uncertain (see a recent review of the
role of endomyocardial biopsy,24 and Section 3.1.3.4, Eval-
uation of the Possibility of Myocardial Disease. Assays for
connective tissue diseases and for pheochromocytoma should
be performed if these diagnoses are suspected, and serum
titers of Chagas disease antibodies should be checked in
patients with nonischemic cardiomyopathy who have traveled
in or immigrated from an endemic region.
Several recent assays have been developed for natriuretic
peptides (BNP and NT-proBNP). Several of the natriuretic
peptides are synthesized by and released from the heart.
Elevated plasma BNP levels have been associated withreduced LVEF,40 LV hypertrophy, elevated LV filling pres-
sures, and acute MI and ischemia, although they can occur in
other settings, such as pulmonary embolism and chronic
obstructive pulmonary disease.
Natriuretic peptides are sensitive to other biological fac-
tors, such as age, sex, weight, and renal function.41 Elevated
levels lend support to a diagnosis of abnormal ventricular
function or hemodynamics causing symptomatic HF.42 Trials
with these diagnostic markers suggest use in the urgent-care
setting, where they have been used in combination with
clinical evaluation to differentiate dyspnea due to HF from
dyspnea of other causes,15 and suggest that its use may reduce
both the time to hospital discharge and the cost of treatment.43
BNP levels tend to be less elevated in HF with preserved EF
than in HF with low EF and are lower in obese patients.44,45
Levels of natriuretic peptides may be elevated meaningfully
in women and in people over 60 years of age who do not have
HF, and thus these levels should be interpreted cautiously in
such individuals when distinguishing between cardiac and
noncardiac causes of dyspnea. Elevated natriuretic peptide
levels may lend weight to a suspected diagnosis of HF or
trigger consideration of HF when the diagnosis is unknown
but should not be used in isolation to confirm or exclude the
presence of HF.43,46
3.1.3.3. Evaluation of the Possibility of Coronary Artery
Disease
Coronary artery disease is believed to be the underlying cause
in approximately two thirds of patients with HF and low EF
and also contributes to the progression of HF through
mechanisms that include endothelial dysfunction, ischemia,
and infarction. Recent cohort studies suggest that there is less
often a history of prior MI in patients with HF and preserved
EF, although coronary artery disease is often evident on
angiography or at autopsy.47–49 Therefore, it may be useful to
define the presence, anatomic characteristics, and functional
significance of coronary artery disease in selected patients
who present with this syndrome.
PATIENTS WITH CORONARY ARTERY DISEASE AND ANGINA. Coronary
artery bypass grafting has been shown to improve symptoms
and survival in patients with modestly reduced EF (variably
defined in clinical trials) and angina, although patients with
HF or markedly reduced EFs were not included in these
studies.15 An ongoing National Institutes of Health–funded
trial is evaluating the utility of surgical revascularization in
such patients. Because revascularization is recommended in
individuals with significant ischemic chest pain regardless of
the degree of ischemia or viability, there would appear to be
little role for noninvasive cardiac testing in such patients.
Clinicians should proceed directly to coronary angiography in
patients who have angina and impaired ventricular function.16
PATIENTS WITH CORONARY ARTERY DISEASE AND NO ANGINA. Con-
trolled trials have not addressed the issue of whether coronary
revascularization can improve clinical outcomes in patients
with HF who do not have angina. Nevertheless, the ACC/
AHA 2004 Guideline Update for Coronary Artery Bypass
Graft Surgery16 recommends revascularization in patients
with a significant left main stenosis and in patients who have
Hunt et al 2009 ACCF/AHA Heart Failure Guidelines e403
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 large areas of noninfarcted but hypoperfused and hypocon-
tractile myocardium on noninvasive testing.
Observational studies have shown that revascularization
can favorably affect LV function in some patients with
impaired yet viable myocardium, but it is not clear how such
patients should be identified because the sensitivity and
specificity of an abnormal imaging test have not been
validated in patients with HF.50 Additional studies are needed
to determine whether the possibility of myocardial ischemia
or viability should be evaluated routinely to assess the
contribution of coronary artery disease in patients with HF
and reduced LVEF who do not have angina (see the ACC/
AHA/ASE 2003 Guideline Update for the Clinical Applica-
tion of Echocardiography51 and the ACC/AHA/ASNC Guide-
lines for Clinical Use of Cardiac Radionuclide Imaging).52
PATIENTS IN WHOM THE POSSIBILITY OF CORONARY ARTERY
DISEASE HAS NOT BEEN EVALUATED. Up to one third of patients
with nonischemic cardiomyopathy complain of chest pain,
which may resemble angina or may be atypical in nature.
Because coronary revascularization would play a role in the
management of these patients if their chest pain were related
to the presence of coronary artery disease, coronary angiog-
raphy is generally recommended in these circumstances to
define the presence or absence of large-vessel coronary
obstructions. Although many healthcare providers perform
noninvasive testing before coronary angiography in these
patients, inhomogeneous nuclear images and abnormal wall-
motion patterns are common in patients with a nonischemic
cardiomyopathy. Hence, in most situations, clinicians should
proceed directly to coronary angiography in patients who
have HF and chest pain.
How should healthcare providers evaluate patients with HF
due to LV dysfunction who do not have chest pain and who
do not have a history of coronary artery disease? The use of
coronary angiography appears reasonable in young patients to
exclude the presence of congenital coronary anomalies. In
older patients, however, efforts to detect the presence of
coronary artery disease may not be worthwhile, because
revascularization has not been shown to improve clinical
outcomes in patients without angina.16 Nevertheless, the
observation that revascularization might have a favorable
effect on LV function has led some experts to suggest that
coronary artery disease should be excluded whenever possi-
ble, especially in patients with diabetes mellitus or other
states associated with silent myocardial ischemia. Only cor-
onary arteriography can reliably demonstrate or exclude the
presence of obstructed coronary vessels, because perfusion
deficits and segmental wall-motion abnormalities suggestive
of coronary artery disease are commonly present in patients
with a nonischemic cardiomyopathy on noninvasive imaging.
In patients in whom coronary artery disease has been
excluded previously as the cause of LV dysfunction,
repeated invasive or noninvasive assessment for ischemia
is generally not indicated unless there is a change in
clinical status that suggests the interim development of
ischemic disease.3.1.3.4. Evaluation of the Possibility of Myocardial
Disease
One half of patients with HF and low EF have normal or
near-normal coronary arteries on coronary angiography, and
myocardial disorders are responsible for the development of
cardiomyopathy in most such individuals.17 Most patients
with a cardiomyopathy have no identifiable causative factor
(i.e., idiopathic dilated cardiomyopathy), but in some pa-
tients, the cardiomyopathy is related to a systemic disorder
(e.g., hypertension, diabetes mellitus, hyperthyroidism,
hemochromatosis, or hypocalcemia), exposure to a cardio-
toxic agent (alcohol, cocaine, methamphetamine, anthracy-
cline, or trastuzumab), or the presence of myocardial inflam-
mation or infiltration.
Although some of these conditions may be detected by
endomyocardial biopsy, the overall usefulness of endomyo-
cardial biopsy in the evaluation of patients with a cardiomy-
opathy of unknown cause is not clear.53 Most patients with a
nonischemic cardiomyopathy show nonspecific changes on
biopsy (including hypertrophy, cell loss, and fibrosis), and it
has not been established conclusively how biopsy findings
(even when positive) affect patient management.54 For exam-
ple, an endomyocardial biopsy might detect inflammatory cell
infiltrates attributed to viral myocarditis in some patients with
acute or even chronic HF. Nevertheless, many patients with
biopsy-proven myocarditis improve with supportive care
only, without specific antiviral or anti-inflammatory treat-
ment; the prognosis of these patients has not been influenced
clearly by immunosuppression.55 Similarly, an endomyocar-
dial biopsy can be used to make a diagnosis of sarcoidosis and
amyloidosis, but changes characteristic of these disorders are
often missed on histological evaluation, and there is no
conclusive evidence that treatment can favorably affect the
course of these diseases.
Examples of cases in which a biopsy might be helpful
usually occur in a setting in which the cause of the cardio-
myopathy is already suspected because of other supportive
data. Tissue obtained by biopsy can be used to make the
diagnosis of hemochromatosis, endocardial fibroelastosis,
and Loeffler’s syndrome in patients in whom these disor-
ders are suspected on clinical grounds. Biopsy tissue may
also be used to assess the risk of continued anthracycline
therapy in patients with cancer, especially when combined
with imaging of ventricular function.56,57 Biopsies can
confirm the presence of cardiac disorders that often might
weigh against eligibility for heart transplantation (e.g.,
amyloidosis). Finally, the biopsy can be used to identify
patients with giant-cell myocarditis, who generally
progress rapidly to death and are unresponsive to treatment
and who thus may be considered for mechanical circula-
tory support or immediate heart transplantation.58
However, endomyocardial biopsy is not indicated in the
routine evaluation of cardiomyopathy. Although the risk of a
serious complication is less than 1% in centers experienced in
this technique, biopsies should be performed only when there is
a strong reason to believe that the results will have a meaningful
effect on subsequent therapeutic decisions or prognosis and
only by operators experienced in its performance.
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 3.2. Ongoing Evaluation of Patients
Once the nature and cause of the structural abnormalities
leading to the development of HF have been defined, health-
care providers should focus on the clinical assessment of
patients, both during the initial presentation and during
subsequent visits. This clinical assessment should identify
symptoms and their functional consequences and should
evaluate the short- and long-term risks of disease progression
and death whenever appropriate. This ongoing review of the
patient’s clinical status is critical to the appropriate selection
and monitoring of treatments.
3.2.1. Assessment of Functional Capacity
During the initial and subsequent visits, healthcare providers
should inquire about the type, severity, and duration of
symptoms that occur during activities of daily living and that
may impair the patient’s functional capacity. Questions re-
garding the ability to perform specific tasks may provide
greater insight than general inquiries about what symptoms
the patient is experiencing, because many patients curtail
their activities to limit discomfort. Patients with modest
limitations of activity should be asked about their participa-
tion in sports or their ability to perform strenuous exercise,
whereas patients with substantial limitations of activity
should be asked about their ability to get dressed without
stopping, take a shower or bath, climb stairs, or perform
specific routine household chores. A useful approach is to ask
patients to describe activities that they would like to do but
can no longer perform, because changes in the ability to
perform specific tasks are generally related to important
changes in clinical status or course. Ideally, these inquiries
should be coupled with direct observations of the patient
during a walk around the clinic or up the stairs.
A variety of approaches have been used to quantify the
degree of functional limitation imposed by HF. The most
widely used scale is the NYHA functional classification,34 but
this system is subject to considerable interobserver variability
and is insensitive to important changes in exercise capacity.
These limitations may be overcome by formal tests of
exercise tolerance. Measurement of the distance that a patient
can walk in 6 minutes may have prognostic significance and
may help to assess the level of functional impairment in the
very sick, but serial changes in walking distance may not
parallel changes in clinical status. Maximal exercise testing,
with measurement of peak oxygen uptake, has been used to
identify appropriate candidates for cardiac transplantation, to
determine disability, and to assist in the formulation of an
exercise prescription, but its role in the general management
of patients with HF has not been defined.
3.2.2. Assessment of Volume Status
It is critically important for healthcare providers to evaluate
the fluid or volume status of patients with HF during the
initial visit and each follow-up examination. This assessment
plays a pivotal role in determining the need for diuretic
therapy and in detecting sodium excesses or deficiencies that
may limit efficacy and decrease the tolerability of drugs used
to treat HF. The physical examination is the primary step in
evaluating the presence and severity of fluid retention inpatients with HF. At each visit, healthcare providers should
record the patient’s body weight and sitting and standing
blood pressures and determine the degree of jugular venous
distension and its response to abdominal pressure, the pres-
ence and severity of organ congestion (pulmonary rales and
hepatomegaly), and the magnitude of peripheral edema in the
legs, abdomen, presacral area, and scrotum, as well as ascites
in the abdomen.
The most reliable sign of volume overload is jugular
venous distention.59–61 Right-sided filling pressures are ele-
vated in the basal state or with abdominal compression
(hepatojugular reflux) in many patients with chronically
elevated elevated left-sided filling pressures.62 Most patients
with peripheral edema should also be considered to have
volume overload, but the possibility of noncardiac causes for
edema may limit the utility of this sign in some patients. In
contrast, most patients with chronic HF do not have rales.
This is true even in patients with end-stage disease who have
markedly elevated left-sided filling pressures. The pres-
ence of rales generally reflects the rapidity of onset of HF
rather than the degree of volume overload. Indeed, many
patients with chronic HF have elevated intravascular
volume in the absence of peripheral edema or rales.
Studies using 131I-tagged albumin have demonstrated
plasma volume expansion in more than 50% of patients in
whom clinical volume overload was not recognized.63
Short-term changes in fluid status are best assessed by
measuring changes in body weight; however, changes in
body weight may be less reliable during long periods of
follow-up, because many patients may gain nonfluid
weight and others may lose skeletal muscle mass and body
fat as HF progresses due to the development of cardiac
cachexia.
The majority of patients with clinical evidence of volume
overload do not exhibit hypoperfusion, even though cardiac
performance may be severely depressed. Clinical signs of
hypoperfusion become most apparent when cardiac output
declines markedly or abruptly. Clues that suggest the pres-
ence of such a marked reduction in cardiac output include
narrow pulse pressure, cool extremities, altered mentation,
Cheyne-Stokes respiration, resting tachycardia, and a dispro-
portionate elevation of blood urea nitrogen relative to serum
creatinine. Renal dysfunction in HF is poorly understood and
appears to be mediated by interactions between the heart and
kidney beyond those primarily due to depressed cardiac
output.41
3.2.3. Laboratory Assessment (UPDATED)
Serum electrolytes and renal function should be monitored
routinely in patients with HF. Of particular importance is the
serial measurement of serum potassium concentration, be-
cause hypokalemia is a common adverse effect of treatment
with diuretics and may cause fatal arrhythmias and increase
the risk of digitalis toxicity, whereas hyperkalemia may
complicate therapy with angiotensin-converting enzyme
(ACE) inhibitors, angiotensin II receptor blockers (ARBs),
and aldosterone antagonists. Worsening renal function may
require adjustment of the doses of diuretics, renin-
angiotensin-aldosterone system antagonists, digoxin, and
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 noncardiac medications. Development of hyponatremia or
anemia may be a sign of disease progression and is associated
with impaired survival.
Serum BNP levels have been shown to parallel the clinical
severity of HF as assessed by NYHA functional class in broad
populations. Levels are higher in hospitalized patients and tend
to decrease during aggressive therapy for decompensation (see
Section 3.1.3.2, Laboratory Testing).42 Indeed, there is an
increasing body of evidence demonstrating the power of the
addition of BNP (or NT-proBNP) levels in the assessment of
prognosis in a variety of cardiovascular disorders. However, it
cannot be assumed that BNP levels can be used effectively as
targets for adjustment of therapy in individual patients. Many
patients taking optimal doses of medications continue to show
markedly elevated levels of BNP, and some patients demonstrate
BNP levels within the normal range despite advanced HF. The
use of BNP measurements to guide the titration of drug doses
has not been shown conclusively to improve outcomes more
effectively than achievement of the target doses of drugs shown
in clinical trials to prolong life.64 Ongoing trials will help to
determine the role of serial BNP (or other natriuretic peptides)
measurements in both diagnosis and management of HF.
Serial chest radiographs are not recommended in the
management of chronic HF. Although the cardiothoracic ratio
is commonly believed to reflect the cardiac dilatation that is
characteristic of HF, enlargement of the cardiac silhouette
primarily reflects changes in right ventricular volume rather
than LV function, because the right ventricle forms most of
the border of dilated hearts on radiographs. Similarly,
changes in the radiographic assessment of pulmonary vascu-
lar congestion are too insensitive to detect any but the most
extreme changes in fluid status.65
Repeat assessment of EF may be most useful when the patient
has demonstrated a major change in clinical status. Both im-
provement and deterioration may have important implications
for future care, although the recommended medical regimen
should be continued in most cases. Improvement may reflect
recovery from a previous condition, such as viral myocarditis or
hypothyroidism, or may occur after titration of recommended
therapies for chronic HF. Thus, it is appropriate to obtain a
repeat EF after some period of optimal medical therapy, typi-
cally 4 to 6 months, to decide about the implantation of an
implantable cardioverter-defibrillator (ICD). Deterioration may
reflect gradual disease progression or a new event, such as
recurrent MI. Routine assessment of EF at frequent, regular,
or arbitrary intervals is not recommended.
There has been no established role for periodic invasive or
noninvasive hemodynamic measurements in the management of
HF. Most drugs used for the treatment of HF are prescribed on
the basis of their ability to improve symptoms or survival rather
than their effect on hemodynamic variables. Moreover, the initial
and target doses of these drugs are selected on the basis of
experience in controlled trials and are not based on the changes
they may produce in cardiac output or pulmonary wedge
pressure. Nevertheless, invasive hemodynamic measurements
may assist in the determination of volume status and in distin-
guishing HF from other disorders that may cause circulatory
instability, such as pulmonary diseases and sepsis. Measure-
ments of cardiac output and pulmonary wedge pressure througha pulmonary artery catheter have also been used in patients with
refractory HF to assess pulmonary vascular resistance, a deter-
minant of eligibility for heart transplantation. Cardiac output can
also be measured by noninvasive methods.
3.2.4. Assessment of Prognosis (UPDATED)
Although both healthcare providers and patients may be
interested in defining the prognosis of an individual patient
with HF, the likelihood of survival can be determined reliably
only in populations and not in individuals. However, some
attempt at prognostication in HF may provide better informa-
tion for patients and their families to help them appropriately
plan for their futures. It also identifies patients in whom
cardiac transplantation or mechanical device therapy should
be considered.
Multivariate analysis of clinical variables has helped to
identify the most significant predictors of survival, and
prognostic models have been developed and validated.66
Decreasing LVEF, worsening NYHA functional status, de-
gree of hyponatremia, decreasing peak exercise oxygen
uptake, decreasing hematocrit, widened QRS on 12-lead
electrocardiogram, chronic hypotension, resting tachycardia,
renal insufficiency, intolerance to conventional therapy, and
refractory volume overload are all generally recognized key
prognostic parameters, although the actual prognostic models
incorporating them are not widely used in clinical
practice.66,67 Although elevated circulating levels of neuro-
hormonal factors have also been associated with high mor-
tality rates, the routine assessment of neurohormones such as
norepinephrine or endothelin is neither feasible nor helpful in
clinical management. Likewise, elevated BNP (or NT-
proBNP) levels predict higher risk of HF and other events
after MI, whereas marked elevation in BNP levels during
hospitalization for HF may predict rehospitalization and
death. Nonetheless, the BNP measurement has not been
clearly shown to supplement careful clinical assessment for
management.
Because treatment of HF has improved over the past 10
years, the older prognostic models need to be revalidated,68
and newer prognostic models may have to be developed.
Outcomes have been improved for most high-risk patients,
which has resulted in a shift in the selection process for
patients referred for heart transplantation.68 Routine use of
ambulatory electrocardiographic monitoring, T-wave alter-
nans analysis, heart rate variability measurement, and signal-
averaged electrocardiography have not been shown to pro-
vide incremental value in assessing overall prognosis,
although ambulatory electrocardiographic monitoring can be
useful in decision making regarding placement of ICDs.69
4. Therapy
4.1. Patients at High Risk for Developing
Heart Failure (Stage A)
Recommendations
Class I
1. In patients at high risk for developing HF, systolic anddiastolic hypertension should be controlled in accor-
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 dance with contemporary guidelines. (Level of Evi-
dence: A)
2. In patients at high risk for developing HF, lipid
disorders should be treated in accordance with con-
temporary guidelines. (Level of Evidence: A)
3. For patients with diabetes mellitus (who are all at high
risk for developing HF), blood sugar should be con-
trolled in accordance with contemporary guidelines.
(Level of Evidence: C)
4. Patients at high risk for developing HF should be
counseled to avoid behaviors that may increase the risk
of HF (e.g., smoking, excessive alcohol consumption,
and illicit drug use). (Level of Evidence: C)
5. Ventricular rate should be controlled or sinus rhythm
restored in patients with supraventricular tachyar-
rhythmias who are at high risk for developing HF.
(Level of Evidence: B)
6. Thyroid disorders should be treated in accordance
with contemporary guidelines in patients at high risk
for developing HF. (Level of Evidence: C)
7. Healthcare providers should perform periodic evalua-
tion for signs and symptoms of HF in patients at high
risk for developing HF. (Level of Evidence: C)
8. In patients at high risk for developing HF who have
known atherosclerotic vascular disease, healthcare
providers should follow current guidelines for second-
ary prevention. (Level of Evidence: C)
9. Healthcare providers should perform a noninvasive eval-
uation of LV function (i.e., LVEF) in patients with a
strong family history of cardiomyopathy or in those
receiving cardiotoxic interventions. (Level of Evidence: C)
Class IIa
1. Angiotensin converting enzyme inhibitors can be use-
ful to prevent HF in patients at high risk for developing
HF who have a history of atherosclerotic vascular
disease, diabetes mellitus, or hypertension with associ-
ated cardiovascular risk factors. (Level of Evidence: A)
2. Angiotensin II receptor blockers can be useful to
prevent HF in patients at high risk for developing HF
who have a history of atherosclerotic vascular disease,
diabetes mellitus, or hypertension with associated car-
diovascular risk factors. (Level of Evidence: C)
Class III
1. Routine use of nutritional supplements solely to pre-
vent the development of structural heart disease should
not be recommended for patients at high risk for
developing HF. (Level of Evidence: C)
Table 3 describes cardiovascular medications useful for
treatment of various stages of HF. Many conditions or
behaviors that are associated with an increased risk of
structural heart disease can be identified before patients show
any evidence of structural abnormalities. Because early mod-
ification of many of these factors can reduce the risk of HF, the
recommendation of appropriate medical interventions to patients
with these risk factors provides the earliest opportunity to reduce
the impact of HF on public and individual health.4.1.1. Control of Risk
4.1.1.1. Treatment of Hypertension
Elevated levels of diastolic and especially systolic blood
pressure are major risk factors for the development of HF,70,71
and long-term treatment of both systolic and diastolic hyper-
tension has been shown to reduce the risk of HF.72–74 A
Table 3. Cardiovascular Medications Useful for Treatment of
Various Stages* of Heart Failure
Drug Stage A Stage B Stage C
ACE Inhibitors
Benazepril H — —
Captopril H, DN Post MI HF
Enalapril H, DN HF HF
Fosinopril H — HF
Lisinopril H, DN Post MI HF
Moexipril H — —
Perindopril H, CV Risk — —
Quinapril H — HF
Ramipril H, CV Risk Post MI Post MI
Trandolapril H Post MI Post MI
Angiotensin Receptor Blockers
Candesartan H — HF
Eprosartan H — —
Irbesartan H, DN — —
Losartan H, DN CV Risk —
Olmesartan H — —
Telmisartan H — —
Valsartan H, DN Post MI Post MI, HF
Aldosterone Blockers
Eplerenone H Post MI Post MI
Spironolactone H — HF
Beta Blockers
Acebutolol H — —
Atenolol H Post MI —
Betaxolol H — —
Bisoprolol H — HF
Carteolol H — —
Carvedilol H Post MI HF, Post MI
Labetalol H — —
Metoprolol succinate H — HF
Metoprolol tartrate H Post MI —
Nadolol H — —
Penbutolol H — —
Pindolol H — —
Propranolol H Post MI —
Timolol H Post MI —
Digoxin — — HF
Asymptomatic CV Risk indicates reduction in future cardiovascular events;
DN, diabetic nephropathy; H, hypertension; HF, heart failure; LVSD, asymp-
tomatic left ventricular systolic dysfunction; and Post MI, reduction in heart
failure or other cardiac events following myocardial infarction.
*See Figure 1 for explanation of stages of heart failure.number of large, controlled studies have quite uniformly
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 demonstrated that optimal blood pressure control decreases
the risk of new HF by approximately 50%.75 Because
approximately one fourth of the American population is
hypertensive, and the lifetime risk of developing hypertension
in the United States exceeds 75%,76 strategies to control
hypertension are certainly a vital part of any effort to prevent
HF. The subsequent structural abnormalities that occur in
patients with hypertension, including LVH or MI (e.g., Stage
B HF), portend an even higher number of adverse cardiovas-
cular outcomes. Left ventricular hypertrophy is an indepen-
dent cardiovascular risk factor that is as potent as age or
systolic blood pressure in predicting MI, stroke, sudden
death, or HF.77 In the Framingham Heart Study, hypertension
accounted for 39% of HF cases in men and 59% in women.70
In addition, the benefits of treating hypertension in patients
who have had a prior MI (Stage B) are even more dramatic,
with an 81% reduction in the incidence of HF.73
Healthcare providers should lower both systolic and dia-
stolic blood pressure in accordance with the recommenda-
tions provided in published guidelines, including the most
recently published report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure78; target levels of blood pressure are lower in
patients with associated major cardiovascular risk factors,
especially those with diabetes mellitus.79,80 When an antihy-
pertensive regimen is devised, optimal control of blood
pressure should remain the primary goal, with the choice of
drugs determined by the concomitant medical problems (e.g.,
coronary artery disease, diabetes, or renal disease). Diuretic-
based antihypertensive therapy has repeatedly been shown to
prevent HF in a wide range of target populations.81 ACE
inhibitors (ACEIs) and beta-blockers are also effective in the
prevention of HF,78 whereas calcium antagonists and alpha-
blockers are less effective in preventing HF syndrome.82
However, ACEIs and beta blockers, as single therapies, are
not superior to other antihypertensive drug classes in the
reduction of all cardiovascular outcomes.
Nevertheless, among patients with diabetes or other car-
diovascular complications,83,84 ACEIs have been most nota-
ble with respect to a reduction in the onset of HF and
new-onset diabetes. Likewise, compared with placebo, the
ARBs losartan85 and irbesartan86 significantly reduced the
incidence of HF in patients with type 2 diabetes mellitus and
nephropathy. Ultimately, an appropriate antihypertensive reg-
imen frequently consists of several drugs used in combination.
Although prevention of HF is the focus of these guidelines,
overall cardiovascular preventative strategies have also been the
subject of published guidelines.87
4.1.1.2. Treatment of Diabetes
Obesity and insulin resistance are important risk factors for
the development of HF.88,89 The presence of clinical diabetes
mellitus markedly increases the likelihood of HF in patients
without structural heart disease90 and adversely affects the
outcomes of patients with established HF.91,92 In a study of
patients with type 2 diabetes mellitus more than 50 years of
age who had urinary albumin greater than 20 mg per liter, 4%
of patients developed HF over the study period, of whom
36% died.93 The occurrence of HF represents a major andadverse prognostic turn in a diabetic patient’s life. There is a
differential gender effect associated with this risk; diabetes
mellitus only modestly increases the risk of HF for men, but
it increases the relative risk of HF more than 3-fold among
women.70 Healthcare providers should make every effort to
control hyperglycemia, although such control has not yet
been shown to reduce the subsequent risk of HF. In addition,
ACEIs or ARBs can prevent the development of end-organ
disease and the occurrence of clinical events in diabetic
patients, even in those who do not have hypertension.83,94
Long-term treatment with several ACEIs or ARBs has been
shown to decrease the risk of renal disease in diabetic
patients,95,96 and prolonged therapy with the ACEI ramipril
has been shown to lower the likelihood of cardiovascular
death, MI, and HF.83 Likewise, the use of ARBs in patients
with diabetes mellitus and hypertension or LVH has been
shown to reduce the incidence of first hospitalization for
HF, in addition to having other beneficial effects on renal
function.85,86,97
4.1.1.3. Management of the Metabolic Syndrome
The clustering of cardiovascular risk factors in individual
patients, termed the metabolic syndrome or syndrome X,
includes any 3 of the following criteria: abdominal adiposity,
hypertriglyceridemia, low high-density lipoprotein, hyperten-
sion, and fasting hyperglycemia. It is estimated that the
prevalence of the metabolic syndrome in the United States
exceeds 20% of individuals who are at least 20 years of age
and 40% of the population over 40 years of age.98 The major
adverse consequence of the metabolic syndrome is cardiovas-
cular disease in general and may include an increased
incidence of new HF.99 As noted previously, the appropriate
treatment of hypertension, diabetes mellitus, and dyslipide-
mia100 as they occur in isolation can significantly reduce the
development of HF. A number of trials are currently in
progress to determine the most effective intervention for
patients with the metabolic syndrome.
4.1.1.4. Management of Atherosclerotic Disease
Patients with known atherosclerotic disease (e.g., of the
coronary, cerebral, or peripheral blood vessels) are likely to
develop HF, and healthcare providers should seek to control
vascular risk factors in such patients according to recom-
mended guidelines.87 In one large-scale trial, long-term treat-
ment with an ACEI decreased the risk of the primary
endpoint of cardiovascular death, MI, and stroke in patients
with established vascular disease who were without evidence
of HF or reduced LVEF at the time of randomization but the
incidence of new HF was not a primary or secondary
endpoint, although it was improved.83 Among patients with
established coronary artery disease and no HF, another ACEI
significantly reduced incidence of death, MI, or cardiac arrest,
but again the incidence of new HF was neither a primary nor
a secondary end point.84 A more recent large trial of ACEI
versus placebo failed to show a reduction in the primary
composite endpoint, although a post hoc analysis did show
some reduction in HF hospitalization.101 The committee, in
reviewing the accruing data, decided to change the level of
recommendation for the use of ACEI for Stage A patients
from Class I in the 2001 document to Class IIa in this
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 document. Treatment of hyperlipidemia (in accordance with
published guidelines) has been shown to reduce the likeli-
hood of death and of HF in patients with a history of
MI.100,102–104
4.1.1.5. Control of Conditions That May Cause Cardiac
Injury
Many therapeutic and recreational agents can exert important
cardiotoxic effects, and patients should be strongly advised
about the hazards of smoking, as well as the use of alcohol,
cocaine, amphetamines, and other illicit drugs. Several epi-
demiological studies have revealed no correlation between
the amount of alcohol ingested and the subsequent develop-
ment of HF; nevertheless, the writing committee strongly
believed that any patient with a history of alcohol abuse or
with current substantial routine alcohol consumption and
new-onset HF without other obvious cause should be coun-
seled to become abstinent. Many HF programs limit alcoholic
beverage consumption to no more than 1 alcoholic beverage
serving daily for all patients with LV dysfunction, regardless
of cause.105,106 Several interventions used in the treatment of
cancer can injure the heart and lead to the development of HF,
even in patients with no other cardiovascular risk factors.
Such treatments include ionizing radiation that involves the
mediastinum107 and chemotherapeutic agents such as anthra-
cyclines, immunotherapy such as trastuzumab, or high-dose
cyclophosphamide.108–110 Patients who take trastuzumab in
combination with anthracyclines are at particular risk of HF.
Heart failure may occur years after initial exposure to
anthracyclines or mediastinal radiotherapy. Use of ephedra,
formerly a common ingredient in over-the-counter weight
loss preparations, may contribute to the development of HF as
well.111
4.1.1.6. Other Measures
There is no direct evidence that control of dietary sodium or
participation in regular exercise can prevent the development
of HF; however, in patients with hypertension or other
vascular disease, these efforts may have other health benefits
and may enhance a general sense of well-being. There is also
no evidence that routine use of nutritional supplements can
prevent dysfunction of or injury to the heart.
4.1.2. Early Detection of Structural Abnormalities
Asymptomatic patients with ventricular dilatation and re-
duced LVEF carry substantially higher risk for subsequent
morbidity and mortality than the general population. It would
be desirable to construct cost-effective strategies to identify
such patients in the interest of reducing their subsequent risk.
Limited information is available to support the cost-
effectiveness of broad population screening. Brain natriuretic
peptide levels represent a potential tool for this purpose.112
An analysis of the implications of elevated BNP has sug-
gested that the screening of asymptomatic people over the age
of 60 years with this blood test could yield cost-effective
improvement in clinical outcomes across the population.113
Certain patients are appropriate targets for more aggressive
screening on the basis of characteristics that denote an
increase in the risk for structural heart disease. Healthcare
professionals should perform echocardiographic evaluation inselected patients without apparent structural heart disease
who are at very high risk of a cardiomyopathy (e.g., those
with a strong family history of cardiomyopathy or those
receiving cardiotoxic interventions).114,115 Routine periodic
assessment of LV function in other patients is not recom-
mended.
4.2. Patients With Cardiac Structural
Abnormalities or Remodeling Who Have Not
Developed Heart Failure Symptoms (Stage B)
Recommendations
Class I
1. All Class I recommendations for Stage A should apply
to patients with cardiac structural abnormalities who
have not developed HF. (Levels of Evidence: A, B, and
C as appropriate)
2. Beta blockers and ACEIs should be used in all patients
with a recent or remote history of MI regardless of EF
or presence of HF (see Table 3). (Level of Evidence: A)
3. Beta blockers are indicated in all patients without a
history of MI who have a reduced LVEF with no HF
symptoms (see Table 3 and text). (Level of Evidence: C)
4. Angiotensin converting enzyme inhibitors should be
used in patients with a reduced EF and no symptoms
of HF, even if they have not experienced MI. (Level
of Evidence: A)
5. An ARB should be administered to post-MI patients
without HF who are intolerant of ACEIs and have a
low LVEF. (Level of Evidence: B)
6. Patients who have not developed HF symptoms should
be treated according to contemporary guidelines after
an acute MI. (Level of Evidence: C)
7. Coronary revascularization should be recommended in
appropriate patients without symptoms of HF in ac-
cordance with contemporary guidelines (see ACC/
AHA/ACP-ASIM Guidelines for the Management of
Patients With Chronic Stable Angina).712 (Level of
Evidence: A)
8. Valve replacement or repair should be recommended
for patients with hemodynamically significant valvular
stenosis or regurgitation and no symptoms of HF in
accordance with contemporary guidelines. (Level of
Evidence: B)
Class IIa
1. Angiotensin converting enzyme inhibitors or ARBs can
be beneficial in patients with hypertension and LVH
and no symptoms of HF. (Level of Evidence: B)
2. Angiotensin II receptor blockers can be beneficial in
patients with low EF and no symptoms of HF who are
intolerant of ACEIs. (Level of Evidence: C)
3. Placement of an ICD is reasonable in patients with
ischemic cardiomyopathy who are at least 40 days
post-MI, have an LVEF of 30% or less, are NYHA
functional class I on chronic optimal medical therapy,
and have reasonable expectation of survival with a
good functional status for more than 1 year. (Level of
Evidence: B)
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 Class IIb
1. Placement of an ICD might be considered in patients
without HF who have nonischemic cardiomyopathy and
an LVEF less than or equal to 30% who are in NYHA
functional class I with chronic optimal medical therapy
and have a reasonable expectation of survival with good
functional status for more than 1 year. (Level of Evidence:
C)
Class III
1. Digoxin should not be used in patients with low EF,
sinus rhythm, and no history of HF symptoms, because
in this population, the risk of harm is not balanced by
any known benefit. (Level of Evidence: C)
2. Use of nutritional supplements to treat structural heart
disease or to prevent the development of symptoms of
HF is not recommended. (Level of Evidence: C)
3. Calcium channel blockers with negative inotropic ef-
fects may be harmful in asymptomatic patients with
low LVEF and no symptoms of HF after MI (see text in
Stage C). (Level of Evidence: C)
Patients without HF symptoms but who have had an MI
or who have evidence of LV remodeling are at consider-
able risk of developing HF.116,117 In such patients, the
incidence of HF can be decreased by reducing the risk of
additional injury and by retarding the evolution and
progression of LV remodeling. Initial appropriate mea-
sures include those listed as Class I recommendations for
patients in Stage A (also see Section 5).
As is the case with patients who have no structural heart
disease, there is no evidence that the use of nutritional
supplements can prevent the development of HF in patients
with a recent or remote MI with or without LV remodeling.
The aldosterone antagonist eplerenone has been shown to
reduce morbidity and mortality in a population of patients
with low EF and HF after MI that has already been treated
with ACEIs and beta blockers.118,119 Other preventive mea-
sures have been addressed in related guidelines.120
4.2.1. Prevention of Cardiovascular Events
4.2.1.1. Patients With an Acute Myocardial Infarction
In patients who are experiencing an acute MI, the infusion of
a fibrinolytic agent or the use of percutaneous coronary
intervention can decrease the risk of developing HF,121 and
these interventions can reduce the risk of death, especially in
patients with a prior myocardial injury.122,123 Patients with an
acute infarction also benefit from the administration of both a
beta blocker and either an ACEI or ARB, which can decrease
the risk of reinfarction or death when initiated within days
after the ischemic event, especially in patients whose course
is complicated by HF.124 –130 Combined neurohormonal
blockade (beta blocker and ACEI or ARB) produces additive
benefits.131 For recommendations on the treatment of patients
with MI, see the ACC/AHA Guidelines for the Management of
Patients With ST-Elevation Myocardial Infarction.114.2.1.2. Patients With a History of MI but Normal Left
Ventricular Ejection Fraction
Both hypertension and hyperlipidemia should be treated
vigorously in patients with a history of MI, because the
benefits of treating these coronary risk factors are particularly
marked in patients with a prior ischemic event.72,73 Patients
with a recent MI should also receive treatment with ACEIs
and beta blockers,124,125,128,129,131 which have been shown to
reduce the risk of death when initiated days or weeks after an
ischemic cardiac event. Evidence from 2 large-scale studies
indicates that prolonged therapy with an ACEI can also
reduce the risk of a major cardiovascular event, even when
treatment is initiated months or years after MI.83,84
4.2.1.3. Patients With Hypertension and Left Ventricular
Hypertrophy
See Section 4.1.1.1.
4.2.1.4. Patients With Chronic Reduction of Left
Ventricular Ejection Fraction but No Symptoms
Long-term treatment with an ACEI has been shown to delay
the onset of HF symptoms and decrease the risk of death and
hospitalization for HF in asymptomatic patients with reduced
LVEF, whether due to a remote ischemic injury or to a
nonischemic cardiomyopathy.117,132 Although a recent trial
investigated patients with low EF and HF at the time of MI,
there are no studies that specifically address use of ARBs in
asymptomatic patients with reduced LVEF. Given results of
studies in symptomatic patients with low EF, ARBs may be
an appropriate alternative, particularly in patients who cannot
tolerate an ACEI. Furthermore, although controlled clinical
trials are lacking, the use of beta blockers in patients with a
low EF and no symptoms (especially those with coronary
artery disease) is also recommended.127,131 In such cases, the
same beta blockers should be used that were employed in the
large HF trials.
The use of ICD therapy in patients with chronic reduction
of LVEF but no symptoms has been evaluated in one large
trial including only patients with ischemic cardiomyopathy.
The trials assessing ICD for primary prophylaxis in nonisch-
emic cardiomyopathy have not included functional class I
patients and the efficacy of ICDs in this population as a whole
is unknown.133 The trial involving patients with ischemic
cardiomyopathy included a subset of asymptomatic patients
post-MI with LVEF 30% or less, and there was demonstrated
benefit of ICD placement (MADIT-II) in that subset. The
findings potentially apply to large numbers of patients, and
the number needed to treat to have benefit would be great.
The writing committee struggled with this issue since guide-
lines are meant to summarize current science and not take into
account economic issues or the societal impact of making a
recommendation. However, the committee recognizes that
economic impact and societal issues will clearly modulate
how these recommendations are implemented.
In contrast, there are no data to recommend the use of
digoxin in patients with asymptomatic reduction of LVEF,
except in those with atrial fibrillation. Because the only
reason to treat such patients is to prevent the progression of
HF, and because digoxin has a minimal effect on disease
progression in symptomatic patients,134 it is unlikely that
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 the drug would be beneficial in those with no symptoms.
Likewise, there are no data to recommend the routine use
of calcium channel blockers in patients with asymptomatic
reduction of LVEF, but they have not been shown to have
adverse effects and may be helpful for concomitant condi-
tions such as hypertension. However, the use of calcium
channel blockers with negative inotropic effects is not
recommended in asymptomatic patients with EF less than
40% after MI.135
Healthcare providers should pay particular attention to
patients whose cardiomyopathy is associated with a rapid
arrhythmia of supraventricular origin (e.g., atrial flutter or
atrial fibrillation). Although healthcare providers frequently
consider such tachycardias to be the result of an impairment
of ventricular function, these rhythm disorders may lead to or
exacerbate the development of a cardiomyopathy.136,137
Therefore, in patients with a reduced LVEF, every effort
should be made to control the ventricular response to these
tachyarrhythmias or to restore sinus rhythm (see Section 5,
Treatment of Special Populations).
4.2.1.5. Patients With Severe Valvular Disease But No
Symptoms
Valve replacement or repair surgery should be considered for
patients with severe aortic or mitral valve stenosis or regur-
gitation, even when ventricular function is impaired.138–141
Long-term treatment with a systemic vasodilator drug may
be considered for those with severe aortic regurgitation
who are deemed to be poor candidates for surgery. Several
studies142,143 have suggested that prolonged therapy with
hydralazine and nifedipine in patients with severe aortic
regurgitation and preserved LV function might act to
minimize structural changes in the ventricle and thereby
possibly delay the need for surgical intervention; however,
these drugs are often poorly tolerated in this setting, and no
trial has shown that these vasodilators can reduce the risk
of HF or death (see ACC/AHA Guidelines for the Man-
agement of Patients With Valvular Heart Disease).138
There are no long-term studies of vasodilator therapy in
patients with severe asymptomatic mitral regurgitation.
4.2.2. Early Detection of Heart Failure
As noted, the symptoms and signs of HF are often difficult to
identify because they are frequently confused with other
disorders or are attributed to aging, obesity, or lack of
conditioning. Limitations of exercise tolerance can occur so
gradually that patients may adapt their lifestyles (consciously
or subconsciously) to minimize symptoms and thus fail to
report them to healthcare providers. Hence, patients at risk
should be advised to inform their healthcare providers about
limitations of exercise tolerance or unexplained fatigue, and
healthcare providers should intensify their vigilance for the
signs and symptoms of HF in such individuals.
4.3. Patients With Current or Prior Symptoms of
HF (Stage C)
4.3.1. Patients With Reduced Left Ventricular
Ejection Fraction (UPDATED)
Changes in this section focused on 3 areas: recommendations
about electrical device therapy (e.g., cardiac resynchroniza-tion therapy [CRT] and ICDs), the use of a fixed dose
combination of hydralazine and isosorbide dinitrate in self-
identified African Americans, and the management of atrial
fibrillation in patients with HF. The previous version of the
guidelines had a number of possibly confusing recommenda-
tions about selection of patients for ICD implantation. The
writing group has tried to simplify the recommendations,
and keep them concordant with the most recent guidelines
covering the same issue.69,144 Updated trial information
has led to the change in the recommendations about the
use of hydralazine/isosorbide dinitrate and about the
management of atrial fibrillation (Table 3).
Recommendations
Class I
1. Measures listed as Class I recommendations for patients
in stages A and B are also appropriate for patients in
Stage C. (Levels of Evidence: A, B, and C as appropriate)
2. Diuretics and salt restriction are indicated in patients
with current or prior symptoms of HF and reduced
LVEF who have evidence of fluid retention (see Table
4). (Level of Evidence: C)
3. Angiotensin-converting enzyme inhibitors are recom-
mended for all patients with current or prior symp-
toms of HF and reduced LVEF, unless contraindi-
cated (see Table 3).145–157 (Level of Evidence: A)
4. Use of 1 of the 3 beta blockers proven to reduce
mortality (i.e., bisoprolol, carvedilol, and sustained
release metoprolol succinate) is recommended for all
stable patients with current or prior symptoms of HF
and reduced LVEF, unless contraindicated (see Table
3).158–176 (Level of Evidence: A)
5. Angiotensin II receptor blockers (see Table 3) are
recommended in patients with current or prior symp-
toms of HF and reduced LVEF who are ACEI-
intolerant (see text for information regarding patients
with angioedema).130,177–186 (Level of Evidence: A)
6. Drugs known to adversely affect the clinical status of
patients with current or prior symptoms of HF and
reduced LVEF should be avoided or withdrawn when-
ever possible (e.g., nonsteroidal anti-inflammatory
drugs, most antiarrhythmic drugs, and most calcium
channel blocking drugs; see text).187–193 (Level of Evi-
dence: B)
7. Exercise training is beneficial as an adjunctive approach
to improve clinical status in ambulatory patients with
current or prior symptoms of HF and reduced
LVEF.193a–193d (Level of Evidence: B)
8. An implantable cardioverter-defibrillator is recom-
mended as secondary prevention to prolong survival in
patients with current or prior symptoms of HF and
reduced LVEF who have a history of cardiac arrest,
ventricular fibrillation, or hemodynamically destabiliz-
ing ventricular tachycardia.194–196 (Level of Evidence: A)
9. Implantable cardioverter-defibrillator therapy is rec-
ommended for primary prevention of sudden cardiac
death to reduce total mortality in patients with non-
ischemic dilated cardiomyopathy or ischemic heart
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 disease at least 40 days post-MI, a LVEF less than or
equal to 35%, and NYHA functional class II or III
symptoms while receiving chronic optimal medical
therapy, and who have reasonable expectation of
survival with a good functional status for more than 1
year.144,196–202 (Level of Evidence: A)
10. Patients with LVEF of less than or equal to 35%, sinus
rhythm, and NYHA functional class III ambulatory
class IV symptoms despite recommended optimal med-
ical therapy and who have cardiac dyssynchrony, which
is currently defined as a QRS duration greater than
or equal to 0.12 seconds, should receive cardiac
resynchronization therapy, with or without an ICD,
unless contraindicated.203–218 (Level of Evidence: A)
11. Addition of an aldosterone antagonist is recom-
mended in selected patients with moderately severe to
severe symptoms of HF and reduced LVEF who can
be carefully monitored for preserved renal function
and normal potassium concentration. Creatinine
should be 2.5 mg per dL or less in men or 2.0 mg per
dL or less in women and potassium should be less
than 5.0 mEq per liter. Under circumstances where
monitoring for hyperkalemia or renal dysfunction is
not anticipated to be feasible, the risks may outweigh
the benefits of aldosterone antagonists.219–221 (Level of
Evidence: B)
12. The combination of hydralazine and nitrates is recom-
mended to improve outcomes for patients self-described
as African-Americans, with moderate-severe symptoms
on optimal therapy with ACEIs, beta blockers, and
Table 4. Oral Diuretics Recommended for Use in the Treatment
Drug Initial Daily Dose(s)
Loop Diuretics
Bumetanide 0.5 to 1.0 mg once or tw
Furosemide 20 to 40 mg once or tw
Torsemide 10 to 20 mg once
Thiazide Diuretics
Chlorothiazide 250 to 500 mg once or t
Chlorthalidone 12.5 to 25 mg once
Hydrochlorothiazide 25 mg once or twice
Indapamide 2.5 mg once
Metolazone 2.5 mg once
Potassium-Sparing Diuretics*
Amiloride 5 mg once
Spironolactone 12.5 to 25 mg once
Triamterene 50 to 75 mg twice
Sequential Nephron Blockade
Metolazone 2.5 to 10 mg once plus loop
Hydrochlorothiazide 25 to 100 mg once or twice plus
Chlorothiazide (IV) 500 to 1000 mg once plus loo
IV indicates intravenous; and mg, milligrams.
*Eplerenone, although also a diuretic, is primarily used in chronic heart fai
†Higher doses may occasionally be used with close monitoring.diuretics.222,223 (Level of Evidence: B)Class IIa
1. It is reasonable to treat patients with atrial fibrillation
and HF with a strategy to maintain sinus rhythm or
with a strategy to control ventricular rate alone224–228).
(Level of Evidence: A)
2. Maximal exercise testing with or without measurement
of respiratory gas exchange is reasonable to facilitate
prescription of an appropriate exercise program for
patients presenting with HF. (Level of Evidence: C)
3. Angiotensin II receptor blockers are reasonable to use
as alternatives to ACEIs as first-line therapy for pa-
tients with mild to moderate HF and reduced LVEF,
especially for patients already taking ARBs for other
indications.130,177–185 (Level of Evidence: A)
4. Digitalis can be beneficial in patients with current or
prior symptoms of HF and reduced LVEF to decrease
hospitalizations for HF.134,229–235 (Level of Evidence: B)
5. The addition of a combination of hydralazine and a
nitrate is reasonable for patients with reduced LVEF
who are already taking an ACEI and beta blocker for
symptomatic HF and who have persistent symp-
toms.222,236 (Level of Evidence: B)
6. For patients who have LVEF less than or equal to
35%, a QRS duration of greater than or equal to 0.12
seconds, and atrial fibrillation (AF), CRT with or
without an ICD is reasonable for the treatment of
NYHA functional class III or ambulatory class IV
heart failure symptoms on optimal recommended med-
nic Heart Failure
Maximum Total Daily Dose Duration of Action
10 mg 4 to 6 hours
600 mg 6 to 8 hours
200 mg 12 to 16 hours
1000 mg 6 to 12 hours
100 mg 24 to 72 hours
200 mg 6 to 12 hours
5 mg 36 hours
20 mg 12 to 24 hours
20 mg 24 hours
50 mg† 2 to 3 days
200 mg 7 to 9 hours
retic
ic
a suppressor of the rennin-angiotensin-aldosterone system.of Chro
ice
ice
wice
diuretic
loop diu
p diuret
lure asical therapy.2,237 (Level of Evidence: B)
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 7. For patients with LVEF of less than or equal to 35%
with NYHA functional class III or ambulatory class IV
symptoms who are receiving optimal recommended
medical therapy and who have frequent dependence on
ventricular pacing, CRT is reasonable.2 (Level of Evi-
dence: C)
Class IIb
1. A combination of hydralazine and a nitrate might be
reasonable in patients with current or prior symp-
toms of HF and reduced LVEF who cannot be given
an ACEI or ARB because of drug intolerance,
hypotension, or renal insufficiency.222,238,239 (Level of
Evidence: C)
2. The addition of an ARB may be considered in persis-
tently symptomatic patients with reduced LVEF who
are already being treated with conventional thera-
py130,177–185 (Level of Evidence: B)
Class III
1. Routine combined use of an ACEI, ARB, and aldoste-
rone antagonist is not recommended for patients with
current or prior symptoms of HF and reduced LVEF.
(Level of Evidence: C)
2. Calcium channel blocking drugs are not indicated as
routine treatment for HF in patients with current or
prior symptoms of HF and reduced LVEF.135,240–242
(Level of Evidence: A)
3. Long-term use of an infusion of a positive inotropic
drug may be harmful and is not recommended for
patients with current or prior symptoms of HF and
reduced LVEF, except as palliation for patients with
end-stage disease who cannot be stabilized with standard
medical treatment (see recommendations for Stage D).
(Level of Evidence: C)
4. Use of nutritional supplements as treatment for HF is
not indicated in patients with current or prior symp-
toms of HF and reduced LVEF. (Level of Evidence: C)
5. Hormonal therapies other than to replete deficiencies
are not recommended and may be harmful to patients
with current or prior symptoms of HF and reduced
LVEF. (Level of Evidence: C)
4.3.1.1. General Measures (UPDATED)
Measures listed as Class I recommendations for patients in
stage A or B are also appropriate for patients with current or
prior symptoms of HF (also see Section 5, Treatment of
Special Populations). In addition, moderate sodium restric-
tion, along with daily measurement of weight, is indicated to
permit effective use of lower and safer doses of diuretic drugs,
even if overt sodium retention can be controlled by the use of
diuretics. Immunization with influenza and pneumococcal
vaccines may reduce the risk of a respiratory infection.
Although most patients should not participate in heavy labor
or exhaustive sports, physical activity should be encouraged
(except during periods of acute exacerbation of the signs and
symptoms of HF, or in patients with suspected myocarditis),
because restriction of activity promotes physical decondition-ing, which may adversely affect clinical status and contribute
to the exercise intolerance of patients with HF.243–246
Three classes of drugs can exacerbate the syndrome of HF
and should be avoided in most patients:
1) Antiarrhythmic agents247 can exert important cardiode-
pressant and proarrhythmic effects. Of available agents,
only amiodarone and dofetilide248 have been shown not to
adversely affect survival.
2) Calcium channel blockers can lead to worsening HF and
have been associated with an increased risk of cardiovas-
cular events.249 Of available calcium channel blockers,
only the vasoselective ones have been shown not to
adversely affect survival.240,250
3) Nonsteroidal anti-inflammatory drugs can cause sodium
retention and peripheral vasoconstriction and can attenu-
ate the efficacy and enhance the toxicity of diuretics and
ACEIs.187–190 A discussion of the use of aspirin as a
unique agent is found later in this section (see Section
4.3.1.2.2.1, Angiotensin Converting Enzyme Inhibitors in
the Management of Heart Failure).
Patients with HF should be monitored carefully for
changes in serum potassium, and every effort should be made
to prevent the occurrence of either hypokalemia or hyperka-
lemia, both of which may adversely affect cardiac excitability
and conduction and may lead to sudden death.251 Activation
of both the sympathetic nervous system and renin-angiotensin
system can lead to hypokalemia,252,253 and most drugs used
for the treatment of HF can alter serum potassium.254 Even
modest decreases in serum potassium can increase the risks of
using digitalis and antiarrhythmic drugs,251,255 and even
modest increases in serum potassium may prevent the use of
treatments known to prolong life.256 Hence, many experts
believe that serum potassium concentrations should be tar-
geted in the 4.0 to 5.0 mEq per liter range. In some patients,
correction of potassium deficits may require supplementation
of magnesium and potassium.257 In others (particularly those
taking ACEIs alone or in combination with aldosterone
antagonists), the routine prescription of potassium salts may
be unnecessary and potentially deleterious.
Of the general measures that should be used in patients
with HF, possibly the most effective yet least used is close
observation and follow-up. Nonadherence with diet and
medications can rapidly and profoundly affect the clinical
status of patients, and increases in body weight and minor
changes in symptoms commonly precede by several days the
occurrence of major clinical episodes that require emergency
care or hospitalization. Patient education and close supervi-
sion, which includes surveillance by the patient and his or her
family, can reduce the likelihood of nonadherence and lead to
the detection of changes in body weight or clinical status
early enough to allow the patient or a healthcare provider an
opportunity to institute treatments that can prevent clinical
deterioration. Supervision need not be performed by a phy-
sician and may ideally be accomplished by a nurse or
physician’s assistant with special training in the care of
patients with HF. Such an approach has been reported to have
significant clinical benefits.258–261
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 Recommendations Concerning Aldosterone Antagonists.
The addition of low-dose aldosterone antagonists is recom-
mended in carefully selected patients with moderately severe
or severe HF symptoms and recent decompensation or with
LV dysfunction early after MI. These recommendations are
based on the strong data demonstrating reduced death and
rehospitalization in 2 clinical trial populations.118,256 The
entry criteria for these trials describe a broader population
than was actually enrolled, such that the favorable efficacy/
toxicity ratio may not be as applicable to patients at the
margins of trial eligibility. For both of these major trials,
patients were excluded for a serum creatinine level in excess
of 2.5 mg per dL, but few patients were actually enrolled with
serum creatinine levels over 1.5 mg per dL. In the trial of
patients after MI, there was a significant interaction between
serum creatinine and benefit of eplerenone. The average
serum creatinine of enrolled patients was 1.1 mg per dL,
above which there was no demonstrable benefit for survival.
To minimize the risk of life-threatening hyperkalemia in
patients with low LVEF and symptoms of HF, patients should
have initial serum creatinine less than 2.0 to 2.5 mg per dL
without recent worsening and serum potassium less than 5.0
mEq per dL without a history of severe hyperkalemia. In view
of the consistency of evidence for patients with low LVEF
early after MI and patients with recent decompensation and
severe symptoms, it may be reasonable to consider addition
of aldosterone antagonists to loop diuretics for some patients
with mild to moderate symptoms of HF; however, the writing
committee strongly believes that there are insufficient data or
experience to provide a specific or strong recommendation.
Because the safety and efficacy of aldosterone antagonist
therapy have not been shown in the absence of loop diuretic
therapy, it is not currently recommended that such therapy be
given without other concomitant diuretic therapy in chronic
HF. Although 17% of patients in the CHARM (Candesartan
in Heart Failure: Assessment of Reduction in Mortality and
Morbidity) add-on trial186 were receiving spironolactone, the
safety of the combination of ACEIs, ARBs, and aldosterone
antagonists has not been explored adequately, and this com-
bination cannot be recommended.
4.3.1.2. Drugs Recommended for Routine Use
Most patients with HF should be routinely managed with a
combination of 3 types of drugs: a diuretic, an ACEI or an
ARB, and a beta blocker.262 The value of these drugs has been
established by the results of numerous large-scale clinical
trials, and the evidence supporting a central role for their use
is compelling and persuasive. Patients with evidence of fluid
retention should take a diuretic until a euvolemic state is
achieved, and diuretic therapy should be continued to prevent
the recurrence of fluid retention. Even if the patient has
responded favorably to the diuretic, treatment with both an
ACEI and a beta blocker should be initiated and maintained
in patients who can tolerate them because they have been
shown to favorably influence the long-term prognosis of HF.
Therapy with digoxin as a fourth agent may be initiated at any
time to reduce symptoms, prevent hospitalization, control
rhythm, and enhance exercise tolerance.4.3.1.2.1. Diuretics. Diuretics interfere with the sodium reten-
tion of HF by inhibiting the reabsorption of sodium or
chloride at specific sites in the renal tubules. Bumetanide,
furosemide, and torsemide act at the loop of Henle (thus, they
are called loop diuretics), whereas thiazides, metolazone, and
potassium-sparing agents (e.g., spironolactone) act in the
distal portion of the tubule.263,264 These 2 classes of diuretics
differ in their pharmacological actions. The loop diuretics
increase sodium excretion up to 20% to 25% of the filtered
load of sodium, enhance free water clearance, and maintain
their efficacy unless renal function is severely impaired. In
contrast, the thiazide diuretics increase the fractional excre-
tion of sodium to only 5% to 10% of the filtered load, tend to
decrease free water clearance, and lose their effectiveness in
patients with impaired renal function (creatinine clearance
less than 40 mL per min). Consequently, the loop diuretics
have emerged as the preferred diuretic agents for use in most
patients with HF; however, thiazide diuretics may be pre-
ferred in hypertensive HF patients with mild fluid retention
because they confer more persistent antihypertensive effects.
Effect of Diuretics in the Management of HF. Controlled
trials have demonstrated the ability of diuretic drugs to
increase urinary sodium excretion and decrease physical
signs of fluid retention in patients with HF.265,266 In these
short-term studies, diuretic therapy has led to a reduction in
jugular venous pressures, pulmonary congestion, peripheral
edema, and body weight, all of which were observed within
days of initiation of therapy. In intermediate-term studies,
diuretics have been shown to improve cardiac function,
symptoms, and exercise tolerance in patients with HF.267–269
There have been no long-term studies of diuretic therapy in
HF, and thus, their effects on morbidity and mortality are not
known.
When using diuretics in patients with HF, healthcare
providers should keep several points in mind:
1) Diuretics produce symptomatic benefits more rapidly than
any other drug for HF. They can relieve pulmonary and
peripheral edema within hours or days, whereas the
clinical effects of digitalis, ACEIs, or beta blockers may
require weeks or months to become apparent.270,271
2) Diuretics are the only drugs used for the treatment of HF
that can adequately control the fluid retention of HF.
Although both digitalis and low doses of ACEIs can
enhance urinary sodium excretion,121,123 few patients with
HF and a history of fluid retention can maintain sodium
balance without the use of diuretic drugs. Attempts to
substitute ACEIs for diuretics can lead to pulmonary and
peripheral congestion.269
3) Diuretics should not be used alone in the treatment of
Stage C HF. Even when diuretics are successful in
controlling symptoms and fluid retention, diuretics alone
are unable to maintain the clinical stability of patients with
HF for long periods of time.269 The risk of clinical decom-
pensation can be reduced, however, when diuretics are
combined with an ACEI and a beta blocker.229
4) Appropriate use of diuretics is a key element in the
success of other drugs used for the treatment of HF. The
use of inappropriately low doses of diuretics will result in
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 fluid retention, which can diminish the response to ACEIs
and increase the risk of treatment with beta blockers.272
Conversely, the use of inappropriately high doses of
diuretics will lead to volume contraction, which can increase
the risk of hypotension with ACEIs and vasodilators272,273
and the risk of renal insufficiency with ACEIs and ARBs.274
Optimal use of diuretics is the cornerstone of any successful
approach to the treatment of HF.
PRACTICAL USE OF DIURETIC THERAPY. Selection of patients.
Diuretics should be prescribed to all patients who have
evidence of, and to most patients with a prior history of, fluid
retention. Diuretics should generally be combined with an
ACEI and a beta blocker. Few patients with HF will be able
to maintain dry weight without the use of diuretics.
PRACTICAL USE OF DIURETIC THERAPY. Initiation and mainte-
nance. The most commonly used loop diuretic for the
treatment of HF is furosemide, but some patients respond
favorably to other agents in this category (such as torsemide)
because of superior absorption and longer duration of ac-
tion.275,276 In outpatients with HF, therapy is commonly
initiated with low doses of a diuretic, and the dose is
increased until urine output increases and weight decreases,
generally by 0.5 to 1.0 kg daily. Further increases in the dose
or frequency (i.e., twice-daily dosing) of diuretic administra-
tion may be required to maintain an active diuresis and
sustain the loss of weight. The ultimate goal of diuretic
treatment is to eliminate clinical evidence of fluid retention,
such as jugular venous pressure elevation and peripheral
edema. Diuretics are generally combined with moderate
dietary sodium restriction.
If electrolyte imbalances are seen, these should be treated
aggressively and the diuresis continued. If hypotension or
azotemia is observed before the goals of treatment are
achieved, the physician may elect to slow the rapidity of
diuresis, but diuresis should nevertheless be maintained until
fluid retention is eliminated, even if this strategy results in
mild or moderate decreases in blood pressure or renal
function, as long as the patient remains asymptomatic. Ex-
cessive concern about hypotension and azotemia can lead to
the underutilization of diuretics and a state of refractory
edema. Persistent volume overload not only contributes to the
persistence of symptoms but may also limit the efficacy and
compromise the safety of other drugs used for the treatment
of HF.277
Once fluid retention has resolved, treatment with the
diuretic should be maintained to prevent the recurrence of
volume overload. Patients are commonly prescribed a fixed
dose of diuretic, but the dose of these drugs frequently may
need adjustment. In many cases, this adjustment can be
accomplished by having patients record their weight each day
and making changes in their diuretic dosage if the weight
increases or decreases beyond a specified range.
The response to a diuretic is dependent on the concentra-
tion of the drug and the time course of its entry into the
urine.148,149 Patients with mild HF respond favorably to low
doses because they absorb diuretics rapidly from the bowel
and deliver these drugs rapidly to the renal tubules. However,as HF advances, the absorption of the drug may be delayed by
bowel edema or intestinal hypoperfusion, and the delivery of
the drug and the response to a given intratubular concentra-
tion may be impaired by a decline in renal perfusion and
function.278–280 Consequently, the clinical progression of HF
is characterized by the need for increasing doses of diuretics.
Patients may become unresponsive to high doses of di-
uretic drugs if they consume large amounts of dietary sodium,
are taking agents that can block the effects of diuretics (e.g.,
nonsteroidal anti-inflammatory drugs, including cyclo-
oxygenase-2 inhibitors),188,189,281 or have a significant impair-
ment of renal function or perfusion.275 Diuretic resistance can
generally be overcome by the intravenous administration of
diuretics (including the use of continuous infusions),282 the
use of 2 or more diuretics in combination (e.g., furosemide
and metolazone),283–286 or the use of diuretics together with
drugs that increase renal blood flow (e.g., positive inotropic
agents).286
PRACTICAL USE OF DIURETIC THERAPY. Risks of treatment. The
principal adverse effects of diuretics include electrolyte and
fluid depletion, as well as hypotension and azotemia. Diuret-
ics may also cause rashes and hearing difficulties, but these
are generally idiosyncratic or are seen with the use of very
large doses, respectively.
Diuretics can cause the depletion of important cations
(potassium and magnesium), which can predispose patients to
serious cardiac arrhythmias, particularly in the presence of
digitalis therapy.287 The risk of electrolyte depletion is mark-
edly enhanced when 2 diuretics are used in combination. The
loss of electrolytes is related to enhanced delivery of sodium
to distal sites in the renal tubules and the exchange of sodium
for other cations, a process that is potentiated by activation of
the renin-angiotensin-aldosterone system.264 Potassium defi-
cits can be corrected by the short-term use of potassium
supplements or, if severe, by the addition of magnesium
supplements.288 Concomitant administration of ACEIs alone
or in combination with potassium-retaining agents (such as
spironolactone) can prevent electrolyte depletion in most
patients with HF who are taking a loop diuretic. When these
drugs are prescribed, long-term oral potassium supplementa-
tion frequently is not needed and may be deleterious.
Excessive use of diuretics can decrease blood pressure and
impair renal function and exercise tolerance,272–274,289 but
hypotension and azotemia may also occur as a result of
worsening HF, which may be exacerbated by attempts to
reduce the dose of diuretics. If there are no signs of fluid
retention, hypotension and azotemia are likely to be related to
volume depletion and may resolve after a reduction in
diuretic dose. The signs of fluid retention, hypotension and
azotemia, are likely to reflect worsening HF and a decline in
effective peripheral perfusion. This is an ominous clinical
scenario and necessitates considering the measures discussed
under Stage D HF. Tables 4 and 5 illustrate oral and
intravenous diuretics recommended for use in the treatment
of chronic HF.
4.3.1.2.2. Inhibitors of the Renin-angiotensin-aldosterone Sys-
tem. Inhibition of the renin-angiotensin-aldosterone system
can take place at multiple sites: at the level of the enzyme that
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 converts angiotensin I to angiotensin II (ACEIs), at the
angiotensin receptor (ARBs), or at the receptor for aldoste-
rone, which is under control of both the renin angiotensin
system and other systemic and local influences (aldosterone
antagonists). Angiotensin converting enzyme inhibitors are
the best-studied class of agents in HF, with multiple mecha-
nisms of benefit for both HF, coronary disease, and other
atherosclerotic vascular disease, as well as diabetic nephrop-
athy. During chronic therapy with ACEIs, the renin-
angiotensin system demonstrates partial “escape” from inhi-
bition with “normalization” of angiotensin levels, in part
owing to alternative local pathways for production of angio-
tensin. This leaves the potential for benefit from additional
therapy with ARBs and with the aldosterone antagonists.
4.3.1.2.2.1. ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN THE
MANAGEMENT OF HEART FAILURE. It is not clear whether the
effects of ACEIs can be explained solely by the suppression
of angiotensin II production, because ACE inhibition not only
interferes with the renin-angiotensin system but also en-
hances the action of kinins and augments kinin-mediated
prostaglandin production.290–292 In experimental models of
HF, ACEIs modify cardiac remodeling more favorably than
ARBs,293–296 and this advantage of ACEIs is abolished by the
coadministration of a kinin receptor blocker.293,295 Angioten-
sin converting enzyme inhibitors have been evaluated in more
than 7000 patients with HF who participated in more than 30
placebo-controlled clinical trials.146 All of these trials en-
rolled patients with reduced LVEF (EF less than 35% to 40%)
who were treated with diuretics, with or without digitalis.
These trials recruited many types of patients, including
women and the elderly, as well as patients with a wide range
of causes and severity of LV dysfunction. However, patients
with preserved systolic function, low blood pressure (less
Table 5. Intravenous Diuretic Medications Useful for the
Treatment of Severe Heart Failure
Drug Initial Dose Maximum Single Dose
Loop Diuretics
Bumetanide 1.0 mg 4 to 8 mg
Furosemide 40 mg 160 to 200 mg
Torsemide 10 mg 100 to 200 mg
Thiazide Diuretics
Chlorothiazide 500 mg 1000 mg
Sequential Nephron Blockade
Chlorothiazide 500 to 1000 mg (IV) once or twice plus loop
diuretics once; multiple doses per day
Metozalone (as Zaroxolyn
or Diulo)
2.5 to 5 mg PO once or twice daily with
loop diuretic
IV Infusions
Bumetanide 1-mg IV load then 0.5 to 2 mg per hour
infusion
Furosemide 40-mg IV load then 10 to 40 mg per
hour infusion
Torsemide 20-mg IV load then 5 to 20 mg per hour
infusion
IV indicates intravenous; kg, kilograms; mg, milligrams; and PO, by mouth.than 90 mm Hg systolic), or impaired renal function (serumcreatinine greater than 2.5 mg per mL) were not recruited or
represented a small proportion of patients who participated in
these studies.
Analysis of this collective experience indicates that ACEIs
can alleviate symptoms, improve clinical status, and enhance
the overall sense of well-being of patients with HF.145,147–157
In addition, ACEIs can reduce the risk of death and the
combined risk of death or hospitalization.155–157 These bene-
fits of ACE inhibition were seen in patients with mild,
moderate, or severe symptoms and in patients with or without
coronary artery disease.
PRACTICAL USE OF ACEIS. Selection of patients. Angiotensin
converting enzyme inhibitors should be prescribed to all
patients with HF due to LV systolic dysfunction with reduced
LVEF unless they have a contraindication to their use or have
been shown to be unable to tolerate treatment with these
drugs. Because of their favorable effects on survival, treat-
ment with an ACEI should not be delayed until the patient is
found to be resistant to treatment with other drugs.
In general, ACEIs are used together with a beta blocker.
Angiotensin converting enzyme inhibitors should not be
prescribed without diuretics in patients with a current or
recent history of fluid retention, because diuretics are needed
to maintain sodium balance and prevent the development of
peripheral and pulmonary edema.269 Angiotensin converting
enzyme inhibitors are often preferred over ARBs or direct-
acting vasodilators156,297 because of the greater experience
and weight of evidence in support of their effectiveness.
Patients should not be given an ACEI if they have
experienced life-threatening adverse reactions (angioedema
or anuric renal failure) during previous exposure to the drug
or if they are pregnant. They should take an ACEI with
caution if they have very low systemic blood pressures
(systolic blood pressure less than 80 mm Hg), markedly
increased serum levels of creatinine (greater than 3 mg per
dL), bilateral renal artery stenosis, or elevated levels of serum
potassium (greater than 5.5 mEq per liter). Finally, treatment
with an ACEI should not be initiated in hypotensive patients
who are at immediate risk of cardiogenic shock. Such patients
should first receive other forms of treatment for their HF and
then be re-evaluated for ACE inhibition once stability has
been achieved.
PRACTICAL USE OF ACEIS. Initiation and maintenance. Al-
though most of the evidence that supports an effect of ACEIs
on the survival of patients with HF is derived from experience
with enalapril, the available data suggest that there are no
differences among available ACEIs in their effects on symp-
toms or survival.146 Although some have suggested that drugs
in this class may differ in their ability to inhibit tissue ACE,
no trial has shown that tissue ACE inhibiting agents are
superior to other ACEIs in any clinical aspect of HF.
Nevertheless, in selecting among ACEIs, it is recommended
that preference be given to ACEIs that have been shown to
reduce morbidity and mortality in clinical trials in HF or
post-MI populations (captopril, enalapril, lisinopril, perindo-
pril, ramipril, and trandolapril), because these studies have
clearly defined a dose that is effective in modifying the
natural history of the disease. Such information is generally
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 lacking for ACEIs that have not been shown to be effective in
large-scale studies.
Treatment with an ACEI should be initiated at low doses
(see Table 5), followed by gradual increments in dose if lower
doses have been well tolerated. Renal function and serum
potassium should be assessed within 1 to 2 weeks of initiation
of therapy and periodically thereafter, especially in patients
with preexisting hypotension, hyponatremia, diabetes melli-
tus, or azotemia or in those taking potassium supplements.
Because fluid retention can blunt the therapeutic effects and
fluid depletion can potentiate the adverse effects of
ACE,274,277 healthcare providers should ensure that patients
are being given appropriate doses of diuretics before and
during treatment with these drugs. Most patients (85% to
90%) with HF can tolerate short- and long-term therapy with
these drugs.155–157
What dose of an ACEI should physicians try to achieve in
patients with HF? In controlled clinical trials that were
designed to evaluate survival, the dose of the ACEI was not
determined by a patient’s therapeutic response but was
increased until a target dose was reached.193–195 However,
these drugs are commonly prescribed in clinical practice at
much lower doses that are similar to those recommended for
initiation rather than maintenance of therapy. Which ap-
proach should be followed? In the controlled clinical trials of
ACEIs, low or intermediate doses were commonly prescribed
if higher doses could not be tolerated. In controlled trials with
newer agents for HF, intermediate doses rather than high
doses of ACEIs were generally used as background therapy.
Higher doses of an ACEI were better than low doses in
reducing the risk of hospitalization, but they showed similar
effects on symptoms and mortality.298,299 Clinicians should
attempt to use doses that have been shown to reduce the risk
of cardiovascular events in clinical trials. If these target doses
of an ACEI cannot be used or are poorly tolerated, interme-
diate doses should be used with the expectation that there are
likely to be only small differences in efficacy between low and
high doses. More importantly, clinicians should not delay the
institution of beta blockers in patients because of a failure to
reach target ACEI doses. Once the drug has been titrated to
the appropriate dose, patients can generally be maintained on
long-term therapy with an ACEI with little difficulty. Al-
though symptoms may improve in some patients within the
first 48 hours of therapy with an ACEI, the clinical responses
to these drugs are generally delayed and may require several
weeks, months, or more to become apparent.145,270 Even if
symptoms do not improve, long-term treatment with an ACEI
should be maintained to reduce the risk of death or hospital-
ization. Abrupt withdrawal of treatment with an ACEI can
lead to clinical deterioration and should be avoided300 in the
absence of life-threatening complications (e.g., angioedema).
Every effort should be made to minimize the occurrence of
sodium retention or depletion during long-term treatment
with an ACEI, because changes in salt and water balance can
exaggerate or attenuate the cardiovascular and renal effects of
treatment.274,277 Fluid retention can minimize the symptom-
atic benefits of ACE inhibition, whereas fluid loss increases
the risk of hypotension and azotemia. The use of an ACEI can
also minimize or eliminate the need for long-term potassiumsupplementation. Nonsteroidal anti-inflammatory drugs can
block the favorable effects and enhance the adverse effects of
ACEIs in patients with HF and should be avoided.190,252
Clinical experience in patients who are hemodynamically
or clinically unstable suggests that the hypotensive effects of
ACE inhibition may attenuate the natriuretic response to
diuretics and antagonize the pressor response to intravenous
vasoconstrictors.301,302 As a result, in such patients (particu-
larly those who are responding poorly to diuretic drugs), it
may be prudent to interrupt treatment with the ACEI tempo-
rarily until the clinical status of the patient stabilizes.
Retrospective analyses of large-scale clinical trials have sug-
gested that aspirin might interfere with the benefits of ACE
inhibition in patients with HF by inhibiting kinin-mediated
prostaglandin synthesis. In short-term hemodynamic and
maximal-exercise studies, aspirin can attenuate the hemody-
namic actions of ACEIs in patients with HF,303,304 an effect not
seen with nonaspirin antiplatelet agents (e.g., clopidogrel).305
In several multicenter trials, concomitant use of aspirin was
associated with a diminution of the effect of ACEIs on
survival and on cardiovascular morbidity.306,307 A recent
comprehensive systematic overview of 22 060 patients from
6 long-term randomized trials of ACEIs reevaluated the issue
of the potential detrimental effect of combining aspirin with
ACEI therapy. When all of these trials were considered
together, the effects of ACEIs were significantly beneficial in
patients with and without aspirin therapy. The composite risk
reduction was 20% for patients taking aspirin and 29% for
those not taking aspirin, a difference that did not reach
statistical significance.308 A second retrospective review sub-
sequently also reported no adverse effect of concomitant
aspirin use with ACEIs on long-term survival.309 Given these
retrospective results, many physicians believe the data justify
prescribing aspirin and ACEIs together when there is an
indication for use of aspirin. However, these large overviews
are subject to varying interpretation. Other physicians would
consider not combining aspirin with an ACEI because there
are no data to indicate that it can reduce the risk of ischemic
events in patients with HF,310,311 or they might consider the
use of an alternative antiplatelet agent such as clopidogrel,
which does not interact with ACEIs and which may have
superior effects in preventing ischemic events.312 However,
clopidogrel does not have an indication for the primary
prevention of ischemic events. There may be an important
interaction between aspirin and ACEIs, but there is contro-
versy regarding this point, and it requires further study.
PRACTICAL USE OF ACEIS. Risks of treatment. Most of the
adverse reactions of ACEIs can be attributed to the 2 principal
pharmacological actions of these drugs: those related to
angiotensin suppression and those related to kinin potentia-
tion. Other types of side effects may also occur (e.g., rash and
taste disturbances).
Adverse effects related to angiotensin suppression.
1. HYPOTENSION
The most common adverse effects of ACE inhibition in
patients with HF are hypotension and dizziness. Blood
pressure declines without symptoms in nearly every patient
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 treated with an ACEI, so hypotension is generally a concern
only if it is accompanied by postural symptoms, worsening
renal function, blurred vision, or syncope. Hypotension is
seen most frequently during the first few days of initiation of
increments in therapy, particularly in patients with hypovo-
lemia, a recent marked diuresis, or severe hyponatremia (serum
sodium concentration less than 130 mmol per liter).313
Should symptomatic hypotension occur with the first
doses, it may not recur with repeated administration of the
same doses of the drug. However, it is prudent under such
circumstances to reduce the activation of and dependence on
the renin-angiotensin system by reducing the dose of diuret-
ics, liberalizing salt intake, or both, provided the patient does
not have significant fluid retention. The doses of other
hypotensive agents (especially vasodilators) can be reduced
or staggered so their peak effect does not coincide with that of
the ACEI. Most patients who experience early symptomatic
hypotension remain excellent candidates for longterm ACE
inhibition if appropriate measures are taken to minimize
recurrent hypotensive reactions.
2. WORSENING RENAL FUNCTION
In states characterized by reduced renal perfusion (such as
HF), glomerular filtration is critically dependent on
angiotensin-mediated efferent arteriolar vasoconstriction,314
and ACE inhibition may cause functional renal insufficiency.274
Because the decline in glomerular filtration is related to the
withdrawal of the actions of angiotensin II, the risk of
azotemia is highest in patients who are most dependent on the
renin-angiotensin system for support of renal homeostasis
(i.e., class IV hyponatremic patients).315 A significant in-
crease in serum creatinine (e.g., greater than 0.3 mg per dL)
with the use of ACEIs is observed in 15% to 30% of patients
with severe HF,316 but in only 5% to 15% of patients with
mild to moderate symptoms.317 The risks are substantially
greater if patients have bilateral renal artery stenosis or are
taking nonsteroidal anti-inflammatory drugs.189,252,318 Renal
function usually improves after a reduction in the dose of
concomitantly administered diuretics, and thus, these patients
can generally be managed without the need to withdraw
treatment with the ACEI.274 However, if the dose of diuretic
cannot be reduced because the patient has fluid retention, the
physician and patient may need to tolerate mild to moderate
degrees of azotemia to maintain therapy with the ACEI.
3. POTASSIUM RETENTION
Hyperkalemia can occur during ACE inhibition in patients
with HF and may be sufficiently severe to cause cardiac
conduction disturbances. In general, hyperkalemia is seen in
patients whose renal function deteriorates or who are taking
oral potassium supplements or potassium-sparing diuretics, or
aldosterone antagonists, especially if they have diabetes
mellitus.319
Adverse effects related to kinin potentiation.
1. COUGH
Cough related to the use of ACEIs is the most common reason
for the withdrawal of long-term treatment with these drugs;320the frequency of cough is approximately 5% to 10% in white
patients of European descent and rises to nearly 50% in
Chinese patients.321 It is characteristically nonproductive, is
accompanied by a persistent and annoying “tickle” in the
back of the throat, usually appears within the first months of
therapy, disappears within 1 to 2 weeks of discontinuing
treatment, and recurs within days of rechallenge. Other
causes of cough, especially pulmonary congestion, should
always be considered, and the ACEI should be implicated
only after these have been excluded. Demonstration that the
cough disappears after drug withdrawal and recurs after
rechallenge with another ACEI strongly suggests that ACE
inhibition is the cause of the cough. In a number of studies of
ACEI cough, it was found that this symptom did not recur
with rechallenge and probably was a coincidental finding.
Because of the long-term benefits of ACEIs, physicians
should encourage patients to continue taking these drugs if
the cough is not severe. Only if the cough proves to be
persistent and troublesome should the physician consider
withdrawal of the ACEI and the use of alternative medica-
tions (e.g., an ARB).
2. ANGIOEDEMA
Angioedema occurs in fewer than 1% of patents taking an
ACEI but is more frequent in blacks. Because its occurrence
may be life-threatening, the clinical suspicion of this reaction
justifies subsequent avoidance of all ACEIs for the lifetime of
the patient.320 Angiotensin converting enzyme inhibitors
should not be initiated in any patient with a history of
angioedema. Although ARBs may be considered as alterna-
tive therapy for patients who have developed angioedema
while taking an ACEI, there are a number of patients who
have also developed angioedema with ARBs and extreme
caution is advised when substituting an ARB in a patient who
has had angioedema associated with ACEI use.177,322–324
4.3.1.2.2.2. ANGIOTENSIN RECEPTOR BLOCKERS. Agents that
block these receptors were developed on the rationale that
1) angiotensin II production continues in the presence of
ACE inhibition, driven through alternative enzyme path-
ways, and 2) interference with the renin-angiotensin sys-
tem without inhibition of kininase would produce all of the
benefits of ACEIs while minimizing the risk of their
adverse reactions.325 However, it is now known that some
of the benefits may be related to the accumulation of
kinins326 rather than to the suppression of angiotensin II
formation, whereas some of the side effects of ACEIs in
HF are related to the suppression of angiotensin II forma-
tion.293–295 Table 6 lists the inhibitors of the renin-
angiotensin-aldosterone system and beta blockers that are
commonly used for the treatment of patients with HF with
low ejection fraction.
Several ARBs (e.g., candesartan, eprosartan, irbesartan,
losartan, telmisartan, olmesartan, and valsartan) are available
for clinical use. Experience with these drugs in controlled
clinical trials of patients with HF is considerably less than
that with ACEIs. Nevertheless, in several placebo-controlled
studies, long-term therapy with ARBs produced hemody-
namic, neurohormonal, and clinical effects consistent with
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 those expected after interference with the renin angiotensin
system.178–183 In patients with evidence of LV dysfunction
early after MI, a recent trial demonstrated that ARBs had a
benefit that was not inferior to that of ACEIs without an
advantage in terms of tolerability.130 However, the addition of
an ARB to an ACEI did not improve outcomes and resulted
in more side effects.
For patients unable to tolerate ACEIs because of cough or
angioedema, the ARBs valsartan and candesartan177,184 have
demonstrated benefit by reducing hospitalizations and mor-
tality. The combination of an ACEI and ARBs may produce
more reduction of LV size than either agent alone.185 The
addition of ARBs to chronic ACEI therapy caused a modest
decrease in hospitalization in 2 studies, with a trend to
decreased total mortality in one and no impact on mortality in
another.184,185,327
Recommendations Concerning Angiotensin Receptor Block-
ers. Angiotensin converting enzyme inhibitors remain the first
choice for inhibition of the renin-angiotensin system in
Table 6. Inhibitors of the Renin-Angiotensin-Aldosterone
System and Beta Blockers Commonly Used for the Treatment
of Patients With HF With Low Ejection Fraction
Drug Initial Daily Dose(s) Maximum Doses(s)
ACE Inhibitors
Captopril 6.25 mg 3 times 50 mg 3 times
Enalapril 2.5 mg twice 10 to 20 mg twice
Fosinopril 5 to 10 mg once 40 mg once
Lisinopril 2.5 to 5 mg once 20 to 40 mg once
Perindopril 2 mg once 8 to 16 mg once
Quinapril 5 mg twice 20 mg twice
Ramipril 1.25 to 2.5 mg once 10 mg once
Trandolapril 1 mg once 4 mg once
Angiotensin Receptor
Blockers
Candesartan 4 to 8 mg once 32 mg once
Losartan 25 to 50 mg once 50 to 100 mg
once
Valsartan 20 to 40 mg twice 160 mg twice
Aldosterone
Antagonists
Spironolactone 12.5 to 25 mg once 25 mg once or
twice
Eplerenone 25 mg once 50 mg once
Beta Blockers
Bisoprolol 1.25 mg once 10 mg once
Carvedilol 3.125 mg twice 25 mg twice
50 mg twice for
patients 85 kg
Metoprolol
succinate
extended release
(metoprolol CR/
XL)
12.5 to 25 mg once 200 mg once
ACE indicates angiotensin converting enzyme; kg, kilograms, and mg,
milligrams.chronic HF, but ARBs can now be considered a reasonablealternative. Candesartan improved outcomes in patients with
preserved LVEF who were intolerant of ACEIs in the
Candesartan in Heart Failure Assessment of Reduction in
Mortality and Morbidity (CHARM) Alternative trial.177 An-
giotensin receptor blockers are as likely to produce hypoten-
sion, worsening renal function, and hyperkalemia as ACEIs.
Although angioedema is much less frequent with ARBs, there
are cases of patients who developed angioedema to both
ACEIs and later to ARBs.177 There is little information
available about the addition of ARBs to therapy with both
ACEIs and aldosterone antagonists, but risks of renal dys-
function and hyperkalemia would be further increased. Until
further information is available, the routine combined use of
all 3 inhibitors of the renin-angiotensin system cannot be
recommended.
PRACTICAL USE OF ARBS. Initiation and maintenance. When
used, angiotensin receptor antagonists should be initiated
with the starting doses shown in Table 6. Many of the
considerations with ARB are similar to those with initiation
of an ACEI, as discussed above. Blood pressure (including
postural blood pressure changes), renal function, and potas-
sium should be reassessed within 1 to 2 weeks after initiation
and followed closely after changes in dose. Patients with
systolic blood pressure below 80 mm Hg, low serum sodium,
diabetes mellitus, and impaired renal function merit particular
surveillance during therapy with inhibitors of the renin
angiotensin-aldosterone system. Titration is generally
achieved by doubling doses. For stable patients, it is reason-
able to add therapy with beta-blocking agents before full
target doses of either ACEIs or ARBs are reached.
The risks of treatment with ARBs are those attributed to
suppression of angiotensin stimulation, as discussed above
for ACEIs. These risks of hypotension, renal dysfunction,
and hyperkalemia are greater when combined with another
inhibitor of this axis, such as ACEIs or aldosterone
antagonists.
4.3.1.2.2.3. ALDOSTERONE ANTAGONISTS. Although short-term
therapy with both ACEIs and ARBs can lower circulating
levels of aldosterone, such suppression may not be sustained
during long-term treatment.328 The lack of long-term suppres-
sion may be important, because experimental data suggest
that aldosterone exerts adverse effects on the structure and
function of the heart, independently of and in addition to the
deleterious effects produced by angiotensin II.329–335
Spironolactone is the most widely used aldosterone antag-
onist. In a large-scale, long-term trial,256 low doses of
spironolactone (starting at 12.5 mg daily) were added to
ACEI therapy for patients with NYHA functional class IV HF
symptoms or class III symptoms and recent hospitalization.
The risk of death was reduced from 46% to 35% (30%
relative risk reduction) over 2 years, with a 35% reduction in
HF hospitalization and an improvement in functional class.
Initial creatinine levels were below 2.0 mg per dL in the
dose-ranging pilot trial and below 2.5 mg per dL in the main
trial. Potassium replacements were stopped at trial entry, and
serum potassium and renal function were followed very
closely.
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 A recent trial investigated the newer aldosterone antag-
onist eplerenone in patients with LVEF less than or equal
to 40% and clinical evidence of HF or diabetes mellitus
within 14 days of MI. Mortality was decreased from 13.6%
to 11.8% at 1 year. Hyperkalemia occurred in 5.5% of
patients treated with eplerenone compared with 3.9% of
those given placebo overall and in up to 10.1% versus
4.6% of patients with estimated creatinine clearance less
than 50 mL per minute.118
PRACTICAL USE OF ALDOSTERONE ANTAGONISTS. Selection of
patients. Decisions regarding the selection of patients for
aldosterone antagonists reflect the balance between potential
benefit to decrease death and hospitalization from HF and
potential risks of life-threatening hyperkalemia. Despite this,
patients who meet recommended criteria from formal trials
may need to be excluded in practice for a recent history of
renal dysfunction characterized by higher creatinine, mark-
edly elevated blood urea nitrogen, or hyperkalemia, particu-
larly in the presence of insulin-requiring diabetes mellitus.
Serum creatinine levels often underestimate renal dysfunc-
tion, particularly in the elderly, in whom estimated creatinine
clearance less than 50 mL per minute should trigger a
reduction of the initial dose of spironolactone to 12.5 mg
daily or of eplerenone to 25 mg daily, and aldosterone
antagonists should not be given when clearance is less than
30 mL per minute (Table 7). Patients chronically requiring
high doses of diuretics without potassium replacement should
be evaluated closely, because potassium handling may be
Table 7. Guidelines for Minimizing the Risk of Hyperkalemia in
Patients Treated With Aldosterone Antagonists
1. Impaired renal function is a risk factor for hyperkalemia during treatment
with aldosterone antagonists. The risk of hyperkalemia increases
progressively when serum creatinine exceeds 1.6 mg/dL.* In elderly
patients or others with low muscle mass in whom serum creatinine does
not accurately reflect glomerular filtration rate, determination that
glomerular filtration rate or creatinine clearance exceeds 30 ml per
minute is recommended.
2. Aldosterone antagonists should not be administered to patients with
baseline serum potassium in excess of 5.0 mEq per liter.
3. An initial dose of spironolactone of 12.5 mg or eplerenone 25 mg is
recommended, following which the dose may be increased to
spironolactone 25 mg or eplerenone 50 mg if appropriate.
4. The risk of hyperkalemia is increased with concomitant use of higher
doses of ACEIs (captopril greater than or equal to 75 mg daily; enalapril
or lisinopril greater than or equal to 10 mg daily.
5. Non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors
should be avoided.
6. Potassium supplements should be discontinued or reduced.
7. Close monitoring of serum potassium is required; potassium levels and
renal function should be checked in 3 days and at 1 week after initiating
therapy and at least monthly for the first 3 months.
8. Diarrhea or other causes of dehydration should be addressed emergently.
ACEI indicates angiotensin converting enzyme inhibitor.
*Although the entry criteria for the trials of aldosterone antagonists included
creatinine greater than 2.5 mg per dL, the majority of patients had creatinine
much lower; in 1 trial 335a 95% of patients had creatinine less than or equal
to 1.7 mg per dL.impaired.PRACTICAL USE OF ALDOSTERONE ANTAGONISTS. Risks of Aldo-
sterone Antagonists. The major risk of aldosterone antago-
nists is hyperkalemia due to inhibition of potassium
excretion. Renal dysfunction may be aggravated, which
further impairs potassium excretion. The positive results of
a recent trial led to wider use of spironolactone in HF
regimens. The subsequent incidence of hyperkalemia was
reported to be as high as 24% in one series,219 in which half
of the subjects with hyperkalemia had potassium levels in
excess of 6 mEq per liter. Similar results were reported
from Norway.221 Although this far exceeded the 2%
incidence in the large trial, it is comparable to the 13%
observed in the preceding pilot trial with a 25-mg dose and
20% with a 50-mg dose.
The potential impact on the overall HF population is
suggested by a population-based analysis in Ontario, Canada,
of more than 30 000 patients taking ACEIs after a hospital-
ization for HF. After publication of these trial results in 1999,
prescriptions for spironolactone in this geographic area more
than tripled, the rate of hospitalization for hyperkalemia
increased from 2.4 to 11 patients per thousand, and the
associated mortality increased from 0.3 to 2 per thousand.220
These observations lead to a strong recommendation for
caution in the selection and monitoring of patients to be given
aldosterone antagonists, because the observations make it
clear that clinical trial populations are highly selected, and
there is a great increase in evidence of toxicity when the trial
results are applied to the general population.
Although aldosterone antagonists usually have a relatively
weak diuretic effect, some patients may experience marked
potentiation of other diuretic therapy after the addition of
aldosterone antagonists. Fluid depletion can occur, which
further increases the risk of renal dysfunction and hyperka-
lemia. During chronic therapy after initial stabilization, hy-
perkalemia may occur in the setting of other conditions that
cause volume depletion, such as gastroenteritis. Gynecomas-
tia or other antiandrogen effects that can occur during therapy
with spironolactone are not generally seen with the newer
aldosterone antagonist eplerenone.118
PRACTICAL USE OF ALDOSTERONE ANTAGONISTS. Initiation and
Monitoring. Spironolactone should be initiated at a dose of
12.5 to 25 mg daily, or occasionally on alternate days.
Eplerenone was used after MI in one study118 at doses of 25
mg per day, increasing to 50 mg daily. Potassium supplemen-
tation is generally stopped after the initiation of aldosterone
antagonists, and patients should be counseled to avoid high
potassium–containing foods. However, patients who have
required large amounts of potassium supplementation may
need to continue receiving supplementation, albeit at a lower
dose, particularly when previous episodes of hypokalemia
have been associated with ventricular arrhythmias. On the
other hand, potassium supplementation required during vig-
orous therapy of fluid overload is often no longer necessary
once the goal is to maintain even fluid balance. Patients
should be cautioned to avoid the addition of nonsteroidal
anti-inflammatory agents and cyclo-oxygenase- 2 inhibitors,
which can lead to worsening renal function and hyperkale-
mia. Potassium levels and renal function should be rechecked
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 within 3 days and again at 1 week after initiation of an
aldosterone antagonist. Subsequent monitoring should be
dictated by the general clinical stability of renal function and
fluid status but should occur at least monthly for the first 3
months and every 3 months thereafter. The addition or an
increase in dosage of ACEIs or ARBs should trigger a new
cycle of monitoring. In view of the potential risk for hyper-
kalemia, the writing committee recommends that the routine
triple combination of ACEIs, ARBs, and an aldosterone
antagonist be avoided.
The development of potassium levels in excess of 5.5 mEq
per liter should generally trigger discontinuation or dose
reduction of the aldosterone antagonist unless patients have
been receiving potassium supplementation, which should
then be stopped. The development of worsening renal func-
tion should lead to careful evaluation of the entire medical
regimen and consideration for stopping the aldosterone an-
tagonist. Patients should be instructed specifically to stop the
aldosterone antagonist during an episode of diarrhea or while
loop diuretic therapy is interrupted.
4.3.1.2.3. Beta-Adrenergic Receptor Blockers. Beta blockers act
principally to inhibit the adverse effects of the sympathetic
nervous system in patients with HF, and these effects far
outweigh their well-known negative inotropic effects.
Whereas cardiac adrenergic drive initially supports the
performance of the failing heart, long-term activation of
the sympathetic nervous system exerts deleterious effects
that can be antagonized by the use of beta blockers.
Sympathetic activation can increase ventricular volumes
and pressure by causing peripheral vasoconstriction336 and
by impairing sodium excretion by the kidneys.337 Norepi-
nephrine can also induce cardiac hypertrophy but restrict
the ability of the coronary arteries to supply blood to the
thickened ventricular wall, leading to myocardial isch-
emia.316,338,339 Activation of the sympathetic nervous sys-
tem can also provoke arrhythmias by increasing the auto-
maticity of cardiac cells, increasing triggered activity in
the heart, and promoting the development of hypokale-
mia.253,340 –342 Norepinephrine can also increase heart rate
and potentiate the activity and actions of other neurohor-
monal systems. Finally, by stimulating growth and oxida-
tive stress in terminally differentiated cells, norepinephrine
can trigger programmed cell death or apoptosis.343 These
deleterious effects are mediated through actions on alpha-1–,
beta-1–, and beta-2–adrenergic receptors.253,316,336–343
Three beta blockers have been shown to be effective in
reducing the risk of death in patients with chronic HF:
bisoprolol158 and sustained-release metoprolol (succinate),159
which selectively block beta-1–receptors, and carve-
dilol,165,166 which blocks alpha-1–, beta-1–, and beta-2–
receptors. Positive findings with these 3 agents, however,
should not be considered indicative of a beta-blocker class
effect, as shown by the lack of effectiveness of bucindolol and
the lesser effectiveness of short-acting metoprolol in clinical
trials.160,161,344 Patients who have Stage C HF should be
treated with 1 of these 3 beta-blockers. The relative efficacy
among these 3 agents is not known, but available evidence
does suggest that beta-blockers can differ in their effects onsurvival.160 In one trial,161 carvedilol (target dose 25 mg twice
daily) was compared with immediate-release metoprolol tar-
trate (target dose 50 mg twice daily). In that trial, carvedilol
was associated with a significantly reduced mortality com-
pared with metoprolol tartrate. Although both the dose and
the formulation of metoprolol (metoprolol tartrate) used in
the above-referenced trial are commonly prescribed by phy-
sicians for the treatment of HF, they were neither the dose nor
the formulation used in the controlled trial159 that showed that
sustained-release metoprolol (metoprolol succinate) reduces
the risk of death.162 There have been no trials to explore
whether the survival benefits of carvedilol are greater than
those of sustained-released metoprolol when both are used at
the target doses.
Effect of Beta Blockers in the Management of HF. Beta
blockers have now been evaluated in more than 20 000
patients with HF who participated in more than 20 published
placebo-controlled clinical trials.89,93,158,162–164,166,167,345 All
trials enrolled patients with reduced LVEF (EF less than 35%
to 45%) who had already been treated with diuretics and an
ACEI, with or without digitalis. These trials recruited many
types of patients, including women and the elderly, as well as
patients with a wide range of causes and severity of LV
dysfunction, but patients with preserved systolic function,
low heart rates (less than 65 beats per min), or low systolic
blood pressure (less than 85 mm Hg) and those who were
hospitalized or who had class IV HF were not recruited or
represented a small proportion of the patients who partici-
pated in these published studies. An exception was one trial
with carvedilol that enrolled clinically stable patients with
NYHA functional class III and IV symptoms who were free
of edema. That trial also demonstrated a reduction in mortal-
ity similar to the trials of patients with less advanced
disease.345
This collective experience indicates that long-term treat-
ment with beta blockers can lessen the symptoms of HF,
improve the clinical status of patients, and enhance the
patient’s overall sense of well-being.168–175 In addition, like
ACEIs, beta blockers can reduce the risk of death and the
combined risk of death or hospitalization.158,162,164,176,346
These benefits of beta blockers were seen in patients with or
without coronary artery disease and in patients with or
without diabetes mellitus, as well as in women and black
patients. The favorable effects of beta blockers were also
observed in patients already taking ACEIs, which suggests
that combined blockade of the 2 neurohormonal systems can
produce additive effects.
PRACTICAL USE OF BETA BLOCKERS. Selection of patients. Beta
blockers should be prescribed to all patients with stable HF
due to reduced LVEF unless they have a contraindication to
their use or have been shown to be unable to tolerate
treatment with these drugs. Because of the favorable effects of
beta blockers on survival and disease progression, treatment
with a beta blocker should be initiated as soon as LV
dysfunction is diagnosed. Even when symptoms are mild or
have responded to other therapies, beta-blocker therapy is
important and should not be delayed until symptoms return or
disease progression is documented during treatment with
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 other drugs. Therefore, even if patients do not benefit symp-
tomatically because they have little disability, they should
receive treatment with a beta-blocker to reduce the risk of
disease progression, future clinical deterioration, and sudden
death.158,162,164,175,176
Patients need not be taking high doses of ACEIs before
being considered for treatment with a beta blocker, because
most patients enrolled in the beta-blocker trials were not
taking high doses of ACEIs. Furthermore, in patients taking a
low dose of an ACEI, the addition of a beta-blocker produces
a greater improvement in symptoms and reduction in the risk
of death than an increase in the dose of the ACEI, even to the
target doses used in clinical trials.298,347 In patients with
current or recent history of fluid retention, beta blockers
should not be prescribed without diuretics, because diuretics
are needed to maintain sodium and fluid balance and prevent
the exacerbation of fluid retention that can accompany the
initiation of beta-blocker therapy.348–350
Which patients are sufficiently stable to be considered for
treatment with a beta blocker? Regardless of the severity of
symptoms, patients should not be hospitalized in an intensive
care unit, should have no or minimal evidence of fluid
overload or volume depletion, and should not have required
recent treatment with an intravenous positive inotropic agent.
Those excluded from treatment for these reasons should first
receive intensified treatment with other drugs for HF (e.g.,
diuretics) and then be re-evaluated for beta-blockade after
clinical stability has been achieved. Beta-blockers may be
considered in patients who have reactive airway disease or
asymptomatic bradycardia but should be used with great
caution or not at all in patients with persistent symptoms of
either condition.
PRACTICAL USE OF BETA BLOCKERS. Initiation and mainte-
nance. Treatment with a beta blocker should be initiated at very
low doses (see Table 6), followed by gradual increments in dose
if lower doses have been well tolerated. Patients should be
monitored closely for changes in vital signs and symptoms
during this uptitration period. In addition, because initiation of
therapy with a beta-blocker can cause fluid alpha retention,348–
350 physicians should ask patients to weigh themselves daily and
to manage any increase in weight by immediately increasing the
dose of concomitantly administered diuretics until weight is
restored to pretreatment levels. Planned increments in the dose
of a beta blocker should be delayed until any side effects
observed with lower doses have disappeared. Using such a
cautious approach, most patients (approximately 85%) enrolled
in clinical trials with beta blockers were able to tolerate short-
and long-term treatment with these drugs and achieve the
maximum planned trial dose.158,162,164,165 Recent data show that
beta blockers can be safely started before discharge even in
patients hospitalized for HF, provided they do not require
intravenous therapy for HF.351
What dose of a beta blocker should physicians try to
achieve in patients with HF? As with ACEIs, the dose of beta
blockers in controlled clinical trials was not determined by a
patient’s therapeutic response but was increased until the
patient received a prespecified target dose. Low doses were
prescribed only if the target doses were not tolerated, andthus, most trials did not evaluate whether low doses would be
effective. Therefore, physicians, especially cardiologists and
primary care physicians, should make every effort to achieve
the target doses of the beta blockers shown to be effective in
major clinical trials.
Once the target dose has been achieved, patients can
generally continue long-term therapy with a beta blocker with
little difficulty. Patients should be advised that clinical re-
sponses to the drug are generally delayed and may require 2
to 3 months to become apparent.273 Even if symptoms do not
improve, long-term treatment should be maintained to reduce
the risk of major clinical events. Abrupt withdrawal of
treatment with a beta blocker can lead to clinical deterioration
and should be avoided.352
How should clinical deterioration be managed in patients
who have been taking a beta blocker for long periods of time
(more than 3 months)? Because long-term treatment with a
beta blocker reduces the risk of worsening HF, discontinua-
tion of long-term treatment with these drugs after an episode
of worsening HF will not diminish and may in fact increase
the subsequent risk of clinical decompensation. Conse-
quently, if patients develop fluid retention, with or without
mild symptoms, it is reasonable to continue the beta blocker
while the dose of diuretic is increased.353 However, if the
deterioration in clinical status is characterized by hypoperfu-
sion or requires the use of intravenous positive inotropic
drugs, it may be prudent to halt or significantly reduce
treatment with beta blockers temporarily until the status of
the patient stabilizes. In such patients, positive inotropic
agents whose effects are mediated independently of the beta
receptor (e.g., a phosphodiesterase inhibitor such as milri-
none) may be preferred. Once stabilized, the beta blocker
should be reintroduced to reduce the subsequent risk of
clinical deterioration.
PRACTICAL USE OF BETA BLOCKERS. Risks of treatment. Initia-
tion of treatment with a beta blocker has produced 4 types of
adverse reactions that require attention and management, as
discussed below.
1. FLUID RETENTION AND WORSENING HF
Initiation of therapy with a beta blocker can cause fluid
retention,348–350 which is usually asymptomatic and is de-
tected primarily by an increase in body weight but which may
become sufficiently marked to cause worsening symptoms of
HF.354 Patients with fluid retention before treatment are at
greatest risk of fluid retention during treatment, and thus,
physicians should ensure that patients are not volume over-
loaded before a beta blocker is initiated.
Furthermore, physicians should monitor patients closely
for increases in weight and for worsening signs and symp-
toms of HF and should augment the dose of diuretic if weight
increases whether or not other signs or symptoms of wors-
ening HF are present. The occurrence of fluid retention or
worsening HF is not generally a reason for the permanent
withdrawal of treatment. Such patients generally respond
favorably to intensification of conventional therapy, and once
treated, such patients remain excellent candidates for long-
term treatment with a beta blocker.
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 2. FATIGUE
Treatment with a beta blocker can be accompanied by
feelings of general fatigue or weakness. In many cases, the
sense of lassitude resolves spontaneously within several
weeks without treatment, but in some patients, it may be
severe enough to limit increments in dose or require the
withdrawal of treatment. Complaints of fatigue can generally
be managed by a reduction in the dose of the beta blocker (or
the accompanying diuretic), but treatment should be discon-
tinued if the syndrome of weakness is accompanied by
evidence of peripheral hypoperfusion. Reinitiation at a later
time or with a different effective beta blocker may be
successful.
3. BRADYCARDIA AND HEART BLOCK
The slowing of heart rate and cardiac conduction produced by
beta blockers is generally asymptomatic and thus generally
requires no treatment; however, if the bradycardia is accom-
panied by dizziness or lightheadedness or if second- or
third-degree heart block occurs, physicians should decrease
the dose of the beta blocker. Physicians should also consider
the possibility of drug interactions, because other drugs can
cause bradycardia or heart block and may be discontinued.
The role of pacemaker therapy with or without cardiac
resynchronization therapy (CRT) to permit the use of beta-
blocker therapy is entirely unknown.
4. HYPOTENSION
Beta blockers, especially those that also block alpha-1–
receptors, can produce hypotension, which is usually asymp-
tomatic but may produce dizziness, lightheadedness, or
blurred vision.164 For beta blockers that also block alpha
receptors, such as carvedilol, these vasodilatory side effects
are generally seen within 24 to 48 hours of the first dose or the
first increments in dose and usually subside with repeated
dosing without any change in dose. Physicians may minimize
the risk of hypotension by administering the beta blocker and
ACEI at different times during the day. If this is ineffective,
the occurrence of hypotension may require a temporary
reduction in the dose of the ACEI. Hypotensive symptoms
may also resolve after a decrease in the dose of diuretics in
patients who are volume depleted, but in the absence of such
depletion, relaxation of diuretic therapy may increase the risk
or consequences of fluid retention.348–350 If hypotension is
accompanied by other clinical evidence of hypoperfusion,
beta-blocker therapy should be decreased or discontinued
pending further patient evaluation.
4.3.1.2.4. Digitalis. The digitalis glycosides exert their ef-
fects in patients with HF by virtue of their ability to inhibit
sodium-potassium (Na-K) adenosine triphosphatase
(ATPase).355 Inhibition of this enzyme in cardiac cells results
in an increase in the contractile state of the heart, and for
many decades, the benefits of digitalis in HF were ascribed
exclusively to this positive inotropic action. However, recent
evidence suggests that the benefits of digitalis may be related
in part to enzyme inhibition in noncardiac tissues. Inhibition
of Na-K ATPase in vagal afferent fibers acts to sensitize
cardiac baroreceptors, which in turn reduces sympatheticoutflow from the central nervous system.356,357 In addition, by
inhibiting Na-K ATPase in the kidney, digitalis reduces
the renal tubular reabsorption of sodium358; the resulting
increase in the delivery of sodium to the distal tubules leads
to the suppression of renin secretion from the kidneys.359
These observations have led to the hypothesis that digitalis
acts in HF primarily by attenuating the activation of neuro-
hormonal systems and not as a positive inotropic drug.360
Although a variety of digitalis glycosides have been used in
the treatment of HF for the last 200 years, the most commonly
used preparation in the United States is digoxin.
EFFECT OF DIGITALIS IN THE TREATMENT OF HF. Several
placebo-controlled trials have shown that treatment with
digoxin for 1 to 3 months can improve symptoms, quality of
life, and exercise tolerance in patients with mild to moderate
HF.229–235 These benefits have been seen regardless of the
underlying rhythm (normal sinus rhythm or atrial fibrillation),
cause of HF (ischemic or nonischemic cardiomyopathy), or
concomitant therapy (with or without ACEIs). In a long-term
trial that enrolled patients who primarily had Class II or III
symptoms, treatment with digoxin for 2 to 5 years had no
effect on mortality but modestly reduced the combined risk of
death and hospitalization.134
PRACTICAL USE OF DIGITALIS IN HF. Selection of patients.
Physicians may consider adding digoxin in patients with
persistent symptoms of HF during therapy with diuretics,
an ACEI (or ARB), and a beta blocker.361,362 Digoxin may
also be added to the initial regimen in patients with severe
symptoms who have not yet responded symptomatically
during treatment with diuretics, an ACEI, and beta block-
ers. Alternatively, treatment with digoxin may be delayed
until the patient’s response to ACEIs and beta blockers has
been defined and be used only in patients who remain
symptomatic despite therapy with the neurohormonal an-
tagonists. Yet another strategy is to initiate aldosterone
antagonists in this type of symptomatic patient and delay
the addition of digoxin except in patients who do not
respond or who cannot tolerate aldosterone antagonists. If
a patient is taking digoxin but not an ACEI or a beta
blocker, treatment with digoxin should not be withdrawn,
but appropriate therapy with the neurohormonal antago-
nists should be instituted. Digoxin is prescribed routinely
in patients with HF and chronic atrial fibrillation, but beta
blockers are usually more effective when added to digoxin
in controlling the ventricular response, particularly during
exercise.363–366 Because beta blockers improve survival
and may be effective in controlling rate alone, digoxin
should be considered as an adjunctive agent for rate
control.
Digoxin is not indicated as primary therapy for the stabi-
lization of patients with an acute exacerbation of HF symp-
toms, including fluid retention or hypotension. Such patients
should first receive appropriate treatment for HF (usually
with intravenous medications); therapy with digoxin may be
initiated after stabilization as part of an effort to establish a
long-term treatment strategy.
Patients should not be given digoxin if they have signifi-
cant sinus or atrioventricular block, unless the block has been
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 addressed with a permanent pacemaker. The drug should be
used cautiously in patients taking other drugs that can depress
sinus or atrioventricular nodal function or affect digoxin
levels (e.g., amiodarone or a beta blocker), even though such
patients usually tolerate digoxin without difficulty.
PRACTICAL USE OF DIGITALIS IN HF. Initiation and mainte-
nance. Although a variety of glycosides have been utilized,
digoxin is the most commonly used, and it is the only
glycoside that has been evaluated in placebo-controlled trials.
There is little reason to prescribe other cardiac glycosides for
the management of HF.
Therapy with digoxin is commonly initiated and maintained
at a dose of 0.125 to 0.25 mg daily. Low doses (0.125 mg daily
or every other day) should be used initially if the patient is more
than 70 years old, has impaired renal function, or has a low lean
body mass.367 Higher doses (e.g., digoxin 0.375 to 0.50 mg
daily) are rarely used or needed in the management of patients
with HF. There is no reason to use loading doses of digoxin to
initiate therapy in patients with HF.
Doses of digoxin that achieve a concentration of drug in
plasma in the range of 0.5 to 1.0 ng per mL are suggested,
given the limited evidence currently available. There has been
no prospective, randomized evaluation of the relative efficacy
or safety of different plasma concentrations of digoxin.
Retrospective analysis of 2 studies of digoxin withdrawal
found that the prevention of worsening HF by digoxin at
lower concentrations in plasma (0.5 to 0.9 ng per mL) was as
great as that achieved at higher concentrations.368 In a
retrospective analysis of the Digitalis Investigation Group
trial, risk-adjusted mortality increased as the plasma concen-
trations exceeded 1.0 ng per mL.369 However, the likelihood
that reduced clearance of digoxin by renal and hepatic
P-glycoprotein transporters reflects HF severity provides an
alternate explanation of the relationship of higher plasma
levels with mortality, and the most conservative interpretation
is that levels of digoxin greater than 1.0 ng per mL were not
associated with a superior outcome.
PRACTICAL USE OF DIGITALIS IN HF. Risks of treatment. When
administered with attention to dose and to factors that alter its
disposition, digoxin is well tolerated by most patients with
HF.370 The principal adverse reactions occur primarily when
digoxin is administered in large doses, but large doses may
not be needed to produce clinical benefits.371–373 The major
side effects include cardiac arrhythmias (e.g., ectopic and
re-entrant cardiac rhythms and heart block), gastrointestinal
symptoms (e.g., anorexia, nausea, and vomiting), and neuro-
logical complaints (e.g., visual disturbances, disorientation,
and confusion). Overt digitalis toxicity is commonly associ-
ated with serum digoxin levels greater than 2 ng per mL.
However, toxicity may occur with lower digoxin levels,
especially if hypokalemia, hypomagnesemia, or hypothyroid-
ism coexists.374,375 The concomitant use of clarithromycin,
erythromycin, amiodarone, itraconazole, cyclosporine,
verapamil, or quinidine can increase serum digoxin concen-
trations and may increase the likelihood of digitalis
toxicity.219,376,377 The dose of digoxin should be reduced if
treatment with these drugs is initiated. Spironolactone does
not inhibit the disposition of digoxin378; cross-reactivity ofsome digoxin antibodies with spironolactone confounded
earlier attempts to assess the effect of spironolactone on
digoxin clearance. In addition, a low lean body mass and
impaired renal function can also elevate serum digoxin levels,
which may explain the increased risk of digitalis toxicity in
elderly patients. Of note, one analysis suggested that women
may not benefit from digoxin therapy and may be at increased
risk for death with such therapy.379
In addition to these established side effects, there is concern
that levels of digoxin that previously had been considered to
be in the therapeutic range (up to 2 ng per mL) may exert
deleterious cardiovascular effects in the long term, even
though such levels appear to be well tolerated in the short-
term. In one major long-term trial, serum digoxin concentra-
tions in the therapeutic range were associated with an
increased frequency of hospitalizations for cardiovascular
events other than HF and an increased risk of death due to
arrhythmias or MI.134 These effects neutralized any benefit on
survival that might otherwise have been seen as a result of the
favorable effect of the drug on HF. These observations have
raised the possibility that digoxin doses and serum digoxin
concentrations that are generally considered by physicians to
be safe may adversely affect the heart.380 Digoxin should be
used with caution or not used at all in post-MI patients,
particularly if they have ongoing ischemia.381
The writing committee has re-evaluated the evidence
pertinent to the value of digitalis therapy in patients with HF.
Although no new data or trials using digitalis have emerged
since publication of the 2001 guidelines, the writing commit-
tee believes that in terms of safety and efficacy, digitalis does
not compare favorably with such agents as the aldosterone
blockers, to which the writing committee has assigned a Class
IIa level of recommendation. If digitalis were a new drug with
clinical trials showing a very narrow risk/benefit ratio (espe-
cially for potential use in the aging population) and no
mortality benefit, it would clearly not be considered for a
Class I recommendation. The writing committee, therefore,
decided to change the level of recommendation for digitalis
glycosides from Class I to Class IIa in the current document.
4.3.1.2.5. Ventricular Arrhythmias and Prevention of Sudden
Death (Updated). Patients with LV dilation and reduced
LVEF frequently manifest ventricular tachyarrhythmias, both
nonsustained ventricular tachycardia (VT) and sustained VT.
The cardiac mortality of patients with all types of ventricular
tachyarrhythmias is high. The high mortality results from
progressive HF, as well as from sudden death. Sudden death
is often equated with a primary arrhythmic event, but multiple
causes of sudden death have been documented and include
ischemic events such as acute MI,382 electrolyte disturbances,
pulmonary or systemic emboli, or other vascular events.
Although ventricular tachyarrhythmias are the most common
rhythms associated with unexpected sudden death, bradycar-
dia and other pulseless supraventricular rhythms are common
in patients with advanced HF.383
Sudden death can be decreased meaningfully by the ther-
apies that decrease disease progression, as discussed else-
where in these guidelines. For instance, clinical trials with
beta blockers have shown a reduction in sudden death, as well
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 as in all-cause mortality, in both postinfarction patients and
patients with HF regardless of cause.124,125,158,162,164 Aldoste-
rone antagonists decrease sudden death and overall mortality
in HF early after MI and in advanced HF.118 Sudden unex-
pected death can be decreased further by the use of implanted
devices that terminate sustained arrhythmias.144,205 Even
when specific antiarrhythmic therapy is necessary to diminish
recurrent ventricular tachyarrhythmias and device firings, the
frequency and tolerance of arrhythmias may be improved
with appropriate therapy for HF. In some cases, definitive
therapy of myocardial ischemia or other reversible factors
may prevent recurrence of tachyarrhythmia, particularly poly-
morphic VT, ventricular fibrillation, and nonsustained VT.
Nonetheless, implantable defibrillators should be recom-
mended in all patients who have had a life-threatening
tachyarrhythmia and have an otherwise good prognosis.
The absolute frequency of sudden death is highest in
patients with severe symptoms, or Stage D HF. Many patients
with end-stage symptoms experience “sudden death” that is
nonetheless expected. Prevention of sudden death in this
population could potentially shift the mode of death from
sudden to that of progressive HF without decreasing total
mortality, as competing risks of death emerge. On the other
hand, prevention of sudden death in mild HF may allow many
years of meaningful survival. This makes it imperative for
physicians to not only assess an individual patient’s risk for
sudden death but also assess overall prognosis and functional
capacity before consideration of device implantation.
Secondary Prevention of Sudden Death. Patients with
previous cardiac arrest or documented sustained ventricular
arrhythmias have a high risk of recurrent events. Implantation
of an ICD has been shown to reduce mortality in cardiac
arrest survivors. An ICD is indicated for secondary preven-
tion of death from ventricular tachyarrhythmias in patients
with otherwise good clinical function and prognosis, for
whom prolongation of survival is a goal. Patients with
chronic HF and a low EF who experience syncope of unclear
origin have a high rate of subsequent sudden death and should
also be considered for placement of an ICD.198 However,
when ventricular tachyarrhythmias occur in a patient with a
progressive and irreversible downward spiral of clinical HF
decompensation, placement of an ICD is not indicated to
prevent recurrence of sudden death, because death is likely
imminent regardless of mode. An exception may exist for the
small minority of patients for whom definitive therapy such
as cardiac transplantation is planned.
Primary Prevention of Sudden Death. Patients with low EF
without prior history of cardiac arrest, spontaneous VT, or
inducible VT (positive programmed electrical stimulation
study) have a risk of sudden death that is lower than for those
who have experienced previous events, but it remains signif-
icant. Within this group, it has not yet been possible to
identify those patients at highest risk, especially in the
absence of prior MI. Approximately 50% to 70% of patients
with low EF and symptomatic HF have episodes of nonsus-
tained VT on routine ambulatory electrocardiographic mon-
itoring; however, it is not clear whether the occurrence of
complex ventricular arrhythmias in these patients with HF
contributes to the high frequency of sudden death or, alter-natively, simply reflects the underlying disease process.384–386
Antiarrhythmic drugs to suppress premature ventricular de-
polarizations and nonsustained ventricular arrhythmias have
not improved survival,191,192 although nonsustained VT may
play a role in triggering ventricular tachyarrhythmias. Fur-
thermore, most antiarrhythmic drugs have negative inotropic
effects and can increase the risk of serious arrhythmia; these
adverse cardiovascular effects are particularly pronounced in
patients with low EF.193,247,387 This risk is especially high
with the use of Class IA agents (quinidine and procainamide),
Class IC agents (flecainide and propafenone), and some Class
III agents (d-sotalol),191,192,388,389 which have increased mor-
tality in post-MI trials.390
Amiodarone is a Class III antiarrhythmic agent but differs
from other drugs in this Class in having a sympatholytic effect
on the heart.391 Amiodarone has been associated with overall
neutral effects on survival when administered to patients with
low EF and HF.196,392–394 Amiodarone therapy may also act
through mechanisms other than antiarrhythmic effects, be-
cause amiodarone has been shown in some trials to increase
LVEF and decrease the incidence of worsening HF.393,394
Side effects of amiodarone have included thyroid abnormal-
ities, pulmonary toxicity, hepatotoxicity, neuropathy, insom-
nia, and numerous other reactions. Therefore, amiodarone
should not be considered as part of the routine treatment of
patients with HF, with or without frequent premature ventric-
ular depolarizations or asymptomatic nonsustained VT; how-
ever, it remains the agent most likely to be safe and effective
when antiarrhythmic therapy is necessary to prevent recurrent
atrial fibrillation or symptomatic ventricular arrhythmias.
Other pharmacological antiarrhythmic therapies, apart from
beta blockers, are rarely indicated in HF but may occasionally
be used to suppress recurrent ICD shocks when amiodarone
has been ineffective or discontinued owing to toxicity.
The role of ICDs in the primary prevention of sudden death
in patients without prior history of symptomatic arrhythmias
has been explored recently in a number of trials. If sustained
ventricular tachyarrhythmias can be induced in the electro-
physiology laboratory in patients with previous MI or chronic
ischemic heart disease, the risk of sudden death in these
patients is in the range of 5% to 6% per year and can be
improved by ICD implantation.199
The role of ICD implantation for the primary prevention of
sudden death in patients with HF and low EF and no history
of spontaneous or inducible VT has been addressed by
several large trials that used only readily available clinical
data as entry criteria.196,200,201 The first of these demonstrated
that ICDs, compared with standard medical therapy, de-
creased the occurrence of total mortality for patients with EF
of 30% or less after remote MI.200 Absolute mortality was
decreased in the ICD arm by 5.6%, a relative decrease of 31%
over 20 months. In a second trial, a survival benefit was not
demonstrated with devices implanted within 6 to 40 days
after an acute MI in patients who at that time had an EF less
than 35% and abnormal heart rate variability. Although
sudden deaths were decreased, there was an increase in other
events, and ICD implantation did not confer any survival
benefit in this setting.201 A third trial examining the benefit of
ICD implantation for patients with EF less than 35% and
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 NYHA functional class II to III symptoms of HF included
both ischemic and nonischemic causes of HF; absolute
mortality was decreased by 7.2% over a 5-year period in the
arm that received a simple “shock-box” ICD with backup
pacing at a rate of 40 bpm. This represented a relative
mortality decrease of 23%, which was a survival increase of
11%.196 There was no improvement in survival during the
first year, with a 1.8% absolute survival benefit per year
averaged over the next 4 years. The DEFINITE (Defibrilla-
tors in Non-Ischemic Cardiomyopathy Treatment Evaluation)
trial compared medical therapy alone with medical therapy
plus an ICD in patients with nonischemic cardiomyopathy,
NYHA functional class I to III HF, and an LVEF less than
36%.395 The ICD was associated with a reduction in all-cause
mortality that did not reach statistical significance but was
consistent in terms of magnitude of effect (30%) with the
findings of the MADIT II (Multicenter Automatic Defibril-
lator Implantation II)200 and the SCD-HeFT (Sudden Cardiac
Death in Heart Failure: Trial of prophylactic amiodarone
versus implantable defibrillator therapy).196
There is an intrinsic variability in measurement of EF
particularly shortly after recovery from an acute coronary
syndrome event. Moreover, as reviewed earlier, the pivotal
primary prevention trials used a variable inclusion EF,
ranging below 30% or 36%. Given the totality of the data
demonstrating the efficacy of an ICD in reducing overall
mortality in a population with dilated cardiomyopathy of
either ischemic or nonischemic origins, the current recom-
mendation is to include all such patients with an LVEF of less
than or equal to 35%.
ICDs are highly effective in preventing death due to
ventricular tachyarrhythmias; however, frequent shocks from
an ICD can lead to a reduced quality of life, whether triggered
appropriately by life-threatening rhythms or inappropriately
by sinus or other supraventricular tachycardia. For symptoms
from recurrent discharges triggered by ventricular arrhyth-
mias or atrial fibrillation, antiarrhythmic therapy, most often
amiodarone, may be added. For recurrent ICD discharges
from VT despite antiarrhythmic therapy, catheter ablation
may be effective.396
It is important to recognize that ICDs have the potential to
aggravate HF and have been associated with an increase in
HF hospitalizations.200,202 This may result from right ventric-
ular pacing that produces dyssynchronous cardiac contrac-
tion; however, the occurrence of excess nonsudden events
with ICDs placed early after MI suggests that other factors
may also limit the overall benefit from ICDs. Careful atten-
tion to the details of ICD implantation, programming, and
pacing function is important for all patients with low EF who
are treated with an ICD. The ACC/AHA/HRS 2008 Guide-
lines for Device-Based Therapy of Cardiac Rhythm Abnor-
malities144 provides further discussion of the potential prob-
lem of worsening HF and LV function in all patients with right
ventricular pacing.
The decision regarding the balance of potential risks and
benefits of ICD implantation for an individual patient thus
remains a complex one. A decrease in incidence of sudden
death does not necessarily translate into decreased total
mortality, and decreased total mortality does not guarantee aprolongation of survival with meaningful quality of life. This
concept is particularly important in patients with limited
prognosis owing to advanced HF or other serious comorbidi-
ties, because there was no survival benefit observed from ICD
implantation until after the first year in 2 of the major
trials.196,200 Furthermore, the average age of patients with HF
and low EF is over 70 years, a population not well repre-
sented in any of the ICD trials. Comorbidities common in the
elderly population, such as prior stroke, chronic pulmonary
disease, and crippling arthritic conditions, as well as nursing
home residence, should be factored into discussions regarding
ICD. Atrial fibrillation, a common trigger for inappropriate
shocks, is more prevalent in the elderly population. The gap
between community and trial populations is particularly
important for a device therapy that may prolong survival but
has no positive impact on function or quality of life. Some
patients may suffer a diminished quality of life because of
device-site complications, such as bleeding, hematoma, or
infections, or after ICD discharges, particularly those that are
inappropriate.
Consideration of ICD implantation is thus recommended in
patients with EF less than or equal to 35% and mild to
moderate symptoms of HF and in whom survival with good
functional capacity is otherwise anticipated to extend beyond
1 year. Because medical therapy may substantially improve
EF, consideration of ICD implants should follow documen-
tation of sustained reduction of EF despite a course of beta
blockers and ACEIs or ARBs; however, ICDs are not
warranted in patients with refractory symptoms of HF (Stage
D) or in patients with concomitant diseases that would
shorten their life expectancy independent of HF. Before
implantation, patients should be fully informed of their
cardiac prognosis, including the risk of both sudden and
nonsudden mortality; the efficacy, safety, and risks of an ICD;
and the morbidity associated with an ICD shock. Patients and
families should clearly understand that the ICD does not
improve clinical function or delay HF progression. Most
important, the possible reasons and process for potential
future deactivation of defibrillator features should be dis-
cussed long before functional capacity or outlook for survival
is severely reduced.
4.3.1.3. Interventions to Be Considered for Use in Selected
Patients
Controlled clinical trials have shown some interventions to be
useful in limited cohorts of patients with HF. Several of these
interventions are undergoing active investigation in large-
scale trials to determine whether their role in the management
of HF might be justifiably expanded, and others have already
been validated as useful in specific cohorts.
4.3.1.3.1. Isosorbide Dinitrate. Isosorbide dinitrate was one of
the first vasodilator agents reported to be useful for chronic
therapy of HF. Nitrate therapy may decrease symptoms of
dyspnea at night and during exercise and may improve
exercise tolerance in patients who have persistent limitations
despite optimization of other therapies.397 Most experience
relates to the oral dinitrate and more recently the mononitrate
preparations, with little information available about topical
nitrate therapy in this population. Recent evidence suggests
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 that nitrates can inhibit abnormal myocardial and vascular
growth398,399 and may thereby attenuate the process of ven-
tricular remodeling400 and improve symptoms.
The only common side effects of nitrate therapy are
headaches and hypotension. In clinical use, nitrates are
frequently prescribed to patients with persistent congestive
symptoms. Although the only large trial of nitrates in HF239
used a combination of nitrates and hydralazine, nitrates
predominantly are potent venodilators that also have effects
on arterial tone when used alone, particularly when systemic
vascular resistance is severely elevated. Because they act
through cyclic guanosine monophosphate, there is a theoret-
ical reason that they may be titrated up to facilitate weaning
of intravenous infusions that act through the same pathway.
There is extensive literature regarding the development of
nitrate tolerance. This appears to be minimized by prescrip-
tion of a “nitrate-free interval” of at least 10 hours and by
combination with ACEIs or hydralazine.
4.3.1.3.2. Hydralazine. Hydralazine is an arterial vasodilator
with relatively little effect on venous tone and cardiac filling
pressures. The rationale for its combined use with nitrates
was to achieve both venous and arterial vasodilation.401,402 In
addition to its direct vascular actions, hydralazine in theory
may interfere with the biochemical and molecular mecha-
nisms responsible for the progression of HF403,404 and the
development of nitrate tolerance.405–408 There are limited data
regarding the use of hydralazine alone in HF.
4.3.1.3.3. Hydralazine and Isosorbide Dinitrate (Updated).
In a large-scale trial that compared the vasodilator combina-
tion with placebo, the use of hydralazine and isosorbide
dinitrate reduced mortality but not hospitalizations in patients
with HF treated with digoxin and diuretics but not an ACEI
or beta blocker.238,239 However, in another large-scale trial
that compared the vasodilator combination with an ACEI, the
ACEI produced more favorable effects on survival,156 a
benefit not evident in the subgroup of patients with class III
to IV HF. In both trials, the use of hydralazine and isosorbide
dinitrate produced frequent adverse reactions (primarily
headache and gastrointestinal complaints), and many patients
could not continue treatment at target doses.
Of note, a post hoc retrospective analysis of both vasodi-
lator trials demonstrated particular efficacy of isosorbide
dinitrate and hydralazine in the African American cohort.222
A confirmatory trial has been done. In that trial, which was
limited to the patients self-described as African American, the
addition of hydralazine and isosorbide dinitrate to standard
therapy with an ACEI and/or a beta blocker was shown to be
of significant benefit.223 The benefit was presumed to be
related to enhanced nitric oxide bioavailability. Accordingly,
this combination is recommended for African Americans who
remain symptomatic despite optimal medical therapy.
Whether this benefit is evident in other patients with HF
remains to be investigated. The combination of hydralazine
and isosorbide dinitrate should not be used for the treatment
of HF in patients who have no prior use of an ACEI and
should not be substituted for ACEI in patients who are
tolerating ACEIs without difficulty.Despite the lack of data with the vasodilator combination
in patients who are intolerant of ACEIs, the combined use of
hydralazine and isosorbide dinitrate may be considered as a
therapeutic option in such patients. However, compliance
with this combination has generally been poor because of the
large number of tablets required and the high incidence of
adverse reactions.156,238 For patients with more severe HF
symptoms and ACEI intolerance, the combination of hydral-
azine and nitrates is used frequently, particularly when ACEI
therapy is limited by hypotension or renal insufficiency.
There are, however, no trials addressing the use of isosorbide
dinitrate and hydralazine specifically in the population of
patients who have persistent symptoms and intolerance to
inhibitors of the renin-angiotensin system.
4.3.1.3.4. Cardiac Resynchronization Therapy (Updated).
Approximately one-third of patients with low EF and class III
to IV symptoms of HF manifest a QRS duration greater than
0.12 seconds.409–411 This electrocardiographic representation
of abnormal cardiac conduction has been used to identify
patients with dyssynchronous ventricular contraction. While
imperfect, no other consensus definition of cardiac dyssyn-
chrony exists as yet, although several echocardiographic
measures appear promising. The mechanical consequences of
dyssynchrony include suboptimal ventricular filling, a reduc-
tion in LV dP/dt (rate of rise of ventricular contractile force
or pressure), prolonged duration (and therefore greater sever-
ity) of mitral regurgitation, and paradoxical septal wall
motion.412–414 Ventricular dyssynchrony has also been asso-
ciated with increased mortality in HF patients.206–208 Dyssyn-
chronous contraction can be addressed by electrically activat-
ing the right and left ventricles in a synchronized manner with
a biventricular pacemaker device. This approach to HF
therapy, commonly called cardiac resynchronization therapy
(CRT), may enhance ventricular contraction and reduce the
degree of secondary mitral regurgitation.209–211 In addition,
the short-term use of CRT has been associated with improve-
ments in cardiac function and hemodynamics without an
accompanying increase in oxygen use,212 as well as adaptive
changes in the biochemistry of the failing heart.210
To date, more than 4000 HF patients with ventricular
dyssynchrony have been evaluated in randomized controlled
trials of optimal medical therapy alone versus optimal med-
ical therapy plus CRT with or without an ICD. CRT, when
added to optimal medical therapy in persistently symptomatic
patients, has resulted in significant improvements in quality
of life, functional class, exercise capacity (by peak oxygen
uptake) and exercise distance during a 6-minute walk test,
and EF in patients randomized to CRT213 or to the combination
of CRT and ICD.205,214,215 In a meta-analysis of several CRT
trials, HF hospitalizations were reduced by 32% and all-cause
mortality by 25%.215 The effect on mortality in this meta-
analysis became apparent after approximately 3 months of
therapy.215 In 1 study, subjects were randomized to optimal
pharmacological therapy alone, optimal medical therapy plus
CRT alone, or optimal medical therapy plus the combination
of CRT and an ICD. Compared with optimal medical therapy
alone, both device arms significantly decreased the combined
risk of all-cause hospitalization and all-cause mortality by
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 approximately 20%, whereas the combination of a CRT and
an ICD decreased all-cause mortality significantly by 36%.216
More recently, in a randomized controlled trial comparing
optimal medical therapy alone with optimal medical therapy
plus CRT alone (without a defibrillator), CRT significantly
reduced the combined risk of death of any cause or unplanned
hospital admission for a major cardiovascular event (analyzed
as time to first event) by 37%.204 In that trial, all-cause
mortality was significantly reduced by 36% and HF hospital-
izations by 52% with the addition of CRT.
Thus, there is strong evidence to support the use of CRT to
improve symptoms, exercise capacity, quality of life, LVEF,
and survival and to decrease hospitalizations in patients with
persistently symptomatic HF undergoing optimal medical
therapy who have cardiac dyssynchrony (as evidenced by a
prolonged QRS duration). The use of an ICD in combination
with CRT should be based on the indications for ICD therapy.
With few exceptions, resynchronization trials have en-
rolled patients in normal sinus rhythm. Although the entry
criteria specified QRS duration only longer than 0.12 sec-
onds, the average QRS duration in the large trials was longer
than 0.15 seconds, with less information demonstrating ben-
efit in patients with lesser prolongation of QRS. Two small
studies, one randomized217 and the other observational,218
evaluated the potential benefit of CRT in HF patients with
ventricular dyssynchrony and atrial fibrillation. Although
both studies demonstrated the benefit of CRT in these
patients, the total number of patients examined (fewer than
100) precludes a recommendation for CRT in otherwise
eligible patients with atrial fibrillation. To date, only a small
number of patients with “pure” right bundle-branch block
have been enrolled in CRT trials. Similarly, the prolonged
QRS duration associated with right ventricular pacing has
also been associated with ventricular dyssynchrony that may
be improved by CRT, but no published studies have ad-
dressed this situation as yet. Recommendations regarding
CRT for patients with LVEF of less than or equal to 35%,
NYHA functional class III, and ambulatory class IV symptoms
or dependence on ventricular pacing have been updated to be
consistent with the ACC/AHA/HRS 2008 Guidelines for
Device-Based Therapy of Cardiac Rhythm Abnormalities.144
Ten studies have reported on CRT peri-implant morbidity
and mortality. There were 13 deaths in 3113 patients (0.4%).
From a pooled assessment of 3475 patients in 17 studies, the
success rate of implantation was approximately 90%.215
Device-related problems during the first 6 months after
implantation reported in 13 studies included lead malfunction
or dislodgement in 8.5%, pacemaker problems in 6.7%, and
infection in 1.4% of cases. These morbidity and mortality
data are derived from trials that used expert centers. Results
in individual clinical centers may vary considerably and are
subject to a significant learning curve for each center;
however, as implantation techniques evolve and equipment
improves, complication rates may also decline.215
4.3.1.3.5. Exercise Training. In the past, patients with HF
were advised to avoid physical exertion in the hope that bed
rest might minimize symptoms415 and in the belief that
physical activity might accelerate the progression of LVdysfunction416–418; however, it is now understood that a
reduction in physical activity (produced by the symptoms of
HF or prescribed by physicians treating HF) leads to a state of
physical deconditioning that contributes to the symptoms and
exercise intolerance of patients with chronic HF.243,246 Lim-
itations of activity not only may impair exercise capacity but
also may produce adverse psychological effects and impair
peripheral vasodilatory responses.245,419 These findings have
led to the hypothesis that exercise training might improve the
clinical status of patients with chronic HF.243,420
Several controlled trials have shown that exercise training
can lessen symptoms, increase exercise capacity, and im-
prove the quality of life of patients with chronic HF.421–430
The improvement was comparable to that achieved with
pharmacological interventions,420 was in addition to the
benefits of ACEIs and beta blockers,422,423 and was associated
with an enhancement of endothelium-dependent peripheral
vasodilation and skeletal muscle metabolism.422,431 In these
studies, physical conditioning was generally accomplished in
the context of a formal program, which required patients to
gradually achieve workloads of 40% to 70% of maximal effort
for 20 to 45 minutes 3 to 5 times per week for periods of 8 to 12
weeks.429
The long-term effects of exercise training have not been
completely defined. In short-term studies, exercise training
has been accompanied by a reduction in the activation of
neurohormonal systems and attenuation of the process of
ventricular remodeling.424,432,433 In the experimental setting,
exercise appears to attenuate the rate of progression of
HF.434,435 These observations suggest that exercise training
might have a favorable effect on the natural history of HF.
Only 1 study has evaluated the long-term effect of physical
conditioning in patients with HF,430 and in that trial, exercise
training was associated with a reduction in the risk of
hospitalization and death. Little work has been conducted to
identify patients most likely to respond favorably to training
and to define optimal exercise protocols.
Recommendations Concerning Exercise Training. Exercise
training should be considered for all stable outpatients with
chronic HF who are able to participate in the protocols needed
to produce physical conditioning. Exercise training should be
used in conjunction with drug therapy.
4.3.1.4. Drugs and Interventions Under Active
Investigation
Several drugs and other interventions are undergoing active
evaluation in long-term, large-scale trials because they
showed promise in pilot studies that involved small numbers
of patients. Until the results of definitive trials are available,
none of these interventions can be recommended for use in
patients with HF. Several drugs that showed promise in pilot
studies and were included in this section in the 2001 guide-
lines failed to live up to their promise in long-term, large-
scale trials and are no longer included as “promising” in this
update. Several remain under or have begun active investi-
gation. Investigational drug therapies currently in phase III
evaluation for the treatment of chronic HF include vasopres-
sin receptor antagonists, intermittent nesiritide infusions, and
oral phosphodiesterase III inhibitors. In addition, newer
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 devices and technologies, such as implantable hemodynamic
monitors and internal cardiac support devices, external coun-
terpulsation, treatment for sleep-disordered breathing, myo-
cardial growth factors and stem cell transplantation, and
devices to achieve intravascular volume reduction, as well as
novel surgical approaches, including surgical ventricular
restoration, are under active investigation. Several of these
are discussed below.
4.3.1.4.1. Techniques for Respiratory Support. Patients with
HF frequently exhibit abnormal respiratory patterns, includ-
ing Cheyne-Stokes breathing and sleep-disordered breath-
ing.436 In the Sleep Heart Health Study, the presence of
sleep-disturbed breathing was associated with a 2.38 relative
risk of HF independent of other known risk factors.437 This
risk of HF exceeded that for all other cardiovascular disease
syndromes evaluated, including hypertension, stroke, and
coronary artery disease. The use of nocturnal oxygen and
devices that provide continuous positive airway pressure has
been reported to produce symptomatic improvement.438,439
Although there is no direct evidence that treatment of
sleep-disturbed breathing prevents incident HF, treatment of
established LV dysfunction with continuous positive airway
pressure breathing has been shown to improve LV structure
and function in patients with either obstructive or central
sleep apnea disturbed-breathing syndrome.440 Additional
studies are in progress to evaluate the efficacy of these
interventions. It is hoped that such studies will provide
information about the efficacy and safety of this approach and
help identify patients most likely to benefit from treatment.
4.3.1.4.2. External Counterpulsation. The technique of ex-
ternal counterpulsation involves the use of a device with
inflatable cuffs that surround the lower limbs and inflate and
deflate in synchronization with the cardiac cycle. The device
is designed to reduce loading conditions in systole while
increasing coronary perfusion pressures in diastole.441 Exter-
nal counterpulsation has been shown to reduce the frequency
and severity of anginal attacks in patients with symptomatic
coronary artery disease.442 A possible mechanism of action
for this observed clinical effect may be an improvement in
endothelial function of the coronary vascular bed.443,444 Early
trials of this therapy in patients with HF and low EF have
been encouraging, and a randomized trial has been completed
recently.445,446 Until more data are available, routine use of
this therapy cannot be recommended for the management of
patients with symptomatic reduced LVEF.
4.3.1.4.3. Vasopressin Receptor Antagonists. Arginine vaso-
pressin is a peptide hormone with significant cardiovascular
and renal effects. These effects are mediated through at least
2 receptor subtypes: the V1A receptor, which is found on
vascular smooth muscle cells and in the myocardium, and the
V2 receptors, which are found in the kidney. Vasopressin
levels are often elevated in patients with HF and LV dysfunc-
tion, and they appear to be associated with adverse outcomes
in the setting of low EF after MI.447
Early studies with 2 different vasopressin receptor antago-
nists have shown favorable changes in hemodynamics and
urine output without a significant change in blood pressure orheart rate. The drugs appear to reduce body weight and
edema, and they normalized serum sodium in patients with
hyponatremia, but the duration and significance of these
clinical effects are not clear.448,449 Currently, longer-term
clinical trials are under way to determine the role, if any, of
these vasopressin antagonists in patients with chronic
HF.450,451
4.3.1.4.4. Implantable Hemodynamic Monitors. Several im-
plantable systems are in development for the chronic, remote,
outpatient monitoring of ventricular filling pressures and
other hemodynamic and clinical variables in HF patients. One
such system has completed phase I and II study and is
currently being evaluated in a phase III randomized outcomes
trial. The hypothesis underlying this approach suggests that
changes in therapy to optimize LV filling pressure may
improve outcomes in HF patients.452,453
4.3.1.4.5. Cardiac Support Devices. There is developing
experience with surgical devices that are designed to alter
physical stresses on the LV; theoretically, the devices may
improve performance or attenuate further ventricular dilata-
tion. One such device now being evaluated clinically is a
cardiac wrapping device made from a bidirectional woven
polyester that allows for shortening but resists circumferential
expansion beyond the limits of the wrap.454 Clinical trials in
Europe455 and the United States are currently under way to
evaluate the safety and efficacy of this device in patients.
Other ventricular constraint or support devices are also under
investigation in Europe and the United States.
4.3.1.4.6. Surgical Approaches Under Investigation. A
number of surgical approaches have emerged as potentially
beneficial in patients with ischemic HF. The goals of such
procedures generally include revascularization, reduction in
“geometric” or functional mitral regurgitation, and restoration
of a more normal LV geometry and function. In this context,
the so-called surgical ventricular restoration procedure is one
of the most extensively studied and applied techniques for
reshaping or excluding anteroapical and septal regions of
asynergy.456–458 The surgical ventricular restoration proce-
dure, although extensively applied to the treatment of LV
asynergy, is now being studied prospectively in a randomized
trial comparing standard medical therapy versus surgical
therapy (coronary artery bypass grafting) alone versus surgi-
cal ventricular restoration plus coronary artery bypass graft-
ing in patients with ischemic HF. The National Heart, Lung,
and Blood Institute’s multicenter, international, randomized
STICH (Surgical Treatment for Ischemic Heart Failure) trial
began enrolling patients with coronary artery disease and HF
in the spring of 2002. The goal of this study is to determine
whether a benefit over medical therapy can be found for
coronary revascularization and whether this benefit can be
enhanced by ventricular restoration surgery.
4.3.1.4.7. Nesiritide. Natriuretic peptides are novel com-
pounds that promote diuresis and natriuresis, have vasodila-
tory properties, lead to an indirect increase in cardiac output,
and suppress neurohormonal activation; they have been
approved for use in the management of acute HF.459–461 In
this setting, nesiritide has been shown to improve symptoms
Hunt et al 2009 ACCF/AHA Heart Failure Guidelines e429
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 of acute HF, but the effect on morbidity and mortality has not
been clear from available clinical trials.462,463
They are currently under investigation as adjunctive ther-
apy, administered on an intermittent outpatient basis, for
advanced chronic HF. Unless a definitive study does demon-
strate safety and efficacy, intermittent or continuous outpa-
tient infusion of nesiritide and other natriuretic peptides is not
recommended.
4.3.1.5. Drugs and Interventions of Unproved Value and
Not Recommended
4.3.1.5.1. Nutritional Supplements and Hormonal Thera-
pies. Patients with HF, particularly those treated with diuret-
ics, may become deficient in vitamins and micronutrients.
Several nutritional supplements (e.g., coenzyme Q10, carni-
tine, taurine, and antioxidants) and hormonal therapies (e.g.,
growth hormone or thyroid hormone) have been proposed for
the treatment of HF.464–469 Aside from replenishment of
documented deficiencies, randomized trials have failed to
demonstrate benefit for routine vitamin, nutritional, or hor-
monal supplementation.470
In most data or other literature regarding nutraceuticals,
there are issues, including outcomes analyses, adverse effects,
and drug-nutraceutical interactions, that remain unresolved.
No clinical trials have demonstrated improved survival in
users of nutritional or hormonal therapy. Some studies have
suggested a possible effect for coenzyme Q10 in reduced
hospitalization rates, dyspnea, and edema in patients with HF,
but these benefits have not been seen uniformly.471–474 Be-
cause of possible adverse effects and drug interactions of
nutritional supplements and their widespread use, physicians
caring for patients with HF should routinely inquire about
their use. Until more data are available, nutritional supple-
ments or hormonal therapies are not recommended for the
treatment of HF. The ACCF Clinical Expert Consensus
Document on Integrating Complementary Medicine Into
Cardiovascular Medicine475 will provide more details regard-
ing cardiovascular issues with alternative and complementary
medicine.
Most patients with HF due to reduced LVEF respond
favorably to pharmacological and nonpharmacological treat-
ments and enjoy a good quality of life and enhanced survival;
however, some patients do not improve or experience rapid
recurrence of symptoms despite optimal medical therapy.
Such patients characteristically have symptoms at rest or on
minimal exertion, including profound fatigue; cannot perform
most activities of daily living; frequently have evidence of
cardiac cachexia; and typically require repeated and/or pro-
longed hospitalizations for intensive management. These
individuals represent the most advanced stage of HF and
should be considered for specialized treatment strategies,
such as mechanical circulatory support, continuous intrave-
nous positive inotropic therapy, referral for cardiac transplan-
tation, or hospice care.
Before a patient is considered to have refractory HF,
physicians should confirm the accuracy of the diagnosis,
identify any contributing conditions, and ensure that all
conventional medical strategies have been optimally em-
ployed. Measures listed as Class I recommendations forpatients in stages A, B, and C are also appropriate for patients
in end-stage HF (also see Section 5). When no further
therapies are appropriate, careful discussion of the prognosis
and options for end-of life care should be initiated (see
Section 7).
4.3.1.5.2. Intermittent Intravenous Positive Inotropic Therapy
(Updated). Although positive inotropic agents can improve
cardiac performance during short- and long-term therapy,476,477
long-term oral therapy with these drugs has not improved
symptoms or clinical status233,478–488 and has been associated
with a significant increase in mortality, especially in patients
with advanced HF.486,489–494 Despite these data, some physi-
cians have proposed that the regularly scheduled intermittent
use of intravenous positive inotropic drugs (e.g., dobutamine
or milrinone) in a supervised outpatient setting might be
associated with some clinical benefits.59–61
However, there has been little experience with intermittent
home infusions of positive inotropic agents in controlled
clinical trials. Nearly all of the available data are derived from
open-label and uncontrolled studies or from trials that have
compared one inotropic agent with another, without a placebo
group.59–61,495 Most trials have been small and short in
duration and thus have not been able to provide reliable
information about the effect of treatment on the risk of serious
cardiac events. Much, if not all, of the benefit seen in these
uncontrolled reports may have been related to the increased
surveillance of the patient’s status and intensification of
concomitant therapy and not to the use of positive inotropic
agents. Only 1 placebo-controlled trial of intermittent intra-
venous positive inotropic therapy has been published,496 and
its findings are consistent with the results of long-term studies
with continuous oral positive inotropic therapy in HF (e.g.,
with milrinone), which showed little efficacy and were
terminated early because of an increased risk of death.
Given the lack of evidence to support their efficacy and
concerns about their toxicity, intermittent infusions of posi-
tive inotropic agents (whether at home, in an outpatient clinic,
or in a short-stay unit) should not be used in the long-term
treatment of HF, even in its advanced stages. The use of
continuous infusions of positive inotropic agents as palliative
therapy in patients with end-stage disease (Stage D) is
discussed later in this document.226,227
4.3.2. Patients With Heart Failure and Normal Left
Ventricular Ejection Fraction
Recommendations
Class I
1. Physicians should control systolic and diastolic hyper-
tension in patients with HF and normal LVEF, in
accordance with published guidelines. (Level of Evi-
dence: A)
2. Physicians should control ventricular rate in patients
with HF and normal LVEF and atrial fibrillation.
(Level of Evidence: C)
3. Physicians should use diuretics to control pulmonary
congestion and peripheral edema in patients with HF
and normal LVEF. (Level of Evidence: C)
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 Class IIa
1. Coronary revascularization is reasonable in patients
with HF and normal LVEF and coronary artery
disease in whom symptomatic or demonstrable myo-
cardial ischemia is judged to be having an adverse
effect on cardiac function. (Level of Evidence: C)
Class IIb
1. Restoration and maintenance of sinus rhythm in pa-
tients with atrial fibrillation and HF and normal LVEF
might be useful to improve symptoms. (Level of Evi-
dence: C)
2. The use of beta-adrenergic blocking agents, ACEIs,
ARBs, or calcium antagonists in patients with HF and
normal LVEF and controlled hypertension might be
effective to minimize symptoms of HF. (Level of Evi-
dence: C)
3. The usefulness of digitalis to minimize symptoms of HF
in patients with HF and normal LVEF is not well
established. (Level of Evidence: C)
Table 8 summarizes the recommendations for treatment of
patients with HF and normal LVEF.
4.3.2.1. Identification of Patients
For many years, the syndrome of HF was considered to be
synonymous with diminished contractility of the LV, or
reduced LVEF. Over the past few years, however, there has
Table 8. Recommendations for Treatment of Patients With
Heart Failure and Normal Left Ventricular Ejection Fraction
Recommendation Class
Level of
Evidence
Physicians should control systolic and diastolic
hypertension, in accordance with published
guidelines.
I A
Physicians should control ventricular rate in
patients with atrial fibrillation.
I C
Physicians should use diuretics to control
pulmonary congestion and peripheral
edema.
I C
Physicians might recommend coronary
revascularization in patients with coronary
artery disease in whom symptomatic or
demonstrable myocardial ischemia is judged
to be having an adverse effect on cardiac
function.
IIa C
Restoration and maintenance of sinus rhythm
in patients with atrial fibrillation might be
useful to improve symptoms.
IIb C
The use of beta-adrenergic blocking agents,
angiotensin converting enzyme inhibitors,
angiotensin receptor blockers, or calcium
antagonists in patients with controlled
hypertension might be effective to minimize
symptoms of heart failure.
IIb C
The use of digitalis to minimize symptoms of
heart failure might be considered.
IIb Cbeen a growing appreciation that a large number of patientswith HF have a relatively normal EF, or preserved EF. The
pathophysiology of this type of HF has been reviewed in
depth,497 and a large, randomized study that enrolled patients
with HF and normal EF has been completed.327 Currently, a
number of investigators are seeking to clarify the epidemiol-
ogy, clinical characteristics, and prognosis of patients with
HF and a normal LVEF.498
Depending on the criteria used to delineate HF and the
accepted threshold for defining preserved LVEF, it is esti-
mated that as many as 20% to 60% of patients with HF have
a relatively (or near) normal LVEF and, in the absence of
valvular disease, are believed to have reduced ventricular
compliance as a major contributor to the clinical syn-
drome.499–503 Some investigators have found that in a signif-
icant number of patients, a tendency to fluid retention and
reduced vascular compliance, rather than myocardial stiff-
ness, represent the principal abnormalities.504 Regardless,
abnormal renal sodium handling and arterial stiffness, in
addition to myocardial stiffness, are likely to play important
pathophysiologic roles in many patients. Diastole is that
period in the cardiac cycle during which the myocardium
loses its ability to generate force and shorten and returns to an
unstressed length and force, and diastolic dysfunction occurs
when these events are prolonged, slowed, or are incom-
plete.497 It should also be recognized that diastolic function is
abnormal in patients with HF and reduced LVEF, as well as
those with preserved LVEF. Several recognized myocardial
disorders are associated with HF and a normal LVEF,
including restrictive cardiomyopathy, obstructive and nonob-
structive hypertrophic cardiomyopathy, and infiltrative car-
diomyopathies. The vast majority of patients with HF and
relatively preserved LVEF have a history of hypertension,
and many, if not most, of these patients have evidence of
LVH on echocardiography. However, some patients who
present with HF and relatively preserved LVEF have no
identifiable myocardial pathology. Because these patients
usually present with symptoms typical of HF, they should be
classified as Stage C. Indeed, most patients will have some
detectable structural abnormality of the heart, including LVH,
atrial dilation, mitral annular calcification, aortic sclerosis, or
myocardial scar.
Heart failure associated with relatively preserved LVEF is
most prevalent among elderly women, most of whom have
hypertension, diabetes mellitus, or both and often coronary
artery disease or atrial fibrillation as well.500 This observation
may be related to the fact that aging has a greater impact on
ventricular filling characteristics than on EF.505 Aging is
associated with decreases in the elastic properties of the heart
and great vessels, which leads to an increase in systolic blood
pressure and an increase in myocardial stiffness. The rate of
ventricular filling decreases in part because of structural
changes in the heart (due to fibrosis) and because of a decline
in relaxation and compliance. These deleterious effects on
diastolic function are exacerbated by a decrease in beta-
adrenergic receptor density and a decline in peripheral vaso-
dilator capacity, both of which are characteristic of elderly
patients. In addition, elderly patients commonly have associ-
ated disorders (e.g., coronary artery disease, diabetes melli-
tus, aortic stenosis, atrial fibrillation, or obesity), which can
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 adversely affect the diastolic properties of the heart or
decrease the time available for ventricular filling. There may
also be sex-specific responses to hypertension and diabetes
mellitus that make women more susceptible than men to the
cumulative effects of aging on diastolic function.506
A number of recent investigations have focused on the
differences between HF with preserved EF and that with low
LVEF.48,49,498 Myocardial infarction or other evidence of
atherosclerotic disease appears to be less common in HF with
normal LVEF, but hypertension is at least as common in this
subgroup. The morbidity and mortality associated with HF
and a relatively preserved LVEF may be nearly as profound
as that with low LVEF; frequent and repeated hospitalizations
characterize the patient with HF and a normal LVEF.507,508
Most, but not all, series of patients with HF and relatively
preserved LVEF have shown better survival than is seen in
patients with HF and reduced LVEF; however, these com-
parisons are difficult to interpret, because it is difficult to be
certain that such series do not contain at least some patients
in whom the diagnosis of HF is erroneous.
4.3.2.2. Diagnosis
There have been several proposed criteria by which clini-
cians and investigators may define HF with a relatively
preserved LVEF.509 –512 In general, a definitive diagnosis
can be made when the rate of ventricular relaxation is
slowed; this physiological abnormality is characteristically
associated with the finding of an elevated LV filling
pressure in a patient with normal LV volumes and con-
tractility. In practice, the diagnosis is generally based on
the finding of typical symptoms and signs of HF in a
patient who is shown to have a normal LVEF and no
valvular abnormalities (aortic stenosis or mitral regurgita-
tion, for example) on echocardiography. Every effort should
be made to exclude other possible explanations or disorders that
Table 9. Differential Diagnosis in a Patient With Heart Failure
and Normal Left Ventricular Ejection Fraction
Incorrect diagnosis of HF
Inaccurate measurement of LVEF
Primary valvular disease
Restrictive (infiltrative) cardiomyopathies
Amyloidosis, sarcoidosis, hemochromatosis
Pericardial constriction
Episodic or reversible LV systolic dysfunction
Severe hypertension, myocardial ischemia
HF associated with high metabolic demand (high output states)
Anemia, thyrotoxicosis, arteriovenous fistulae
Chronic pulmonary disease with right HF
Pulmonary hypertension associated with pulmonary vascular disorders
Atrial myxoma
Diastolic dysfunction of uncertain origin
Obesity
HF indicates heart failure; LV, left ventricular; and LVEF, left ventricular
ejection fraction.may present in a similar manner503,513 (Table 9).Noninvasive methods (especially those that rely on Dopp-
ler echocardiography) have been developed to assist in the
diagnosis of HF with normal LVEF, but these tests have
significant limitations, because cardiac filling patterns are
readily altered by nonspecific and transient changes in load-
ing conditions in the heart and by aging, changes in heart rate,
or the presence of mitral regurgitation.514–520 The analysis of
BNP levels in association with echocardiographic filling
patterns can improve diagnostic accuracy. For example, a
normal BNP level along with completely normal diastolic
end-filling parameters makes HF much less likely; however,
HF does remain a strictly clinical diagnosis.521
4.3.2.3. Principles of Treatment
In contrast to the treatment of HF due to reduced LVEF, few
clinical trials are available to guide the management of
patients with HF and relatively preserved LVEF. Although
controlled studies have been performed with digitalis, ACEIs,
ARBs, beta blockers, and calcium channel blockers in pa-
tients with HF who had a relatively preserved LVEF, for the
most part, these trials have been small or have produced
inconclusive results.134,241,522–524 Nevertheless, many patients
with HF and normal LVEF are treated with these drugs
because of the presence of comorbid conditions (i.e., atrial
fibrillation, hypertension, diabetes mellitus, and coronary
artery disease). A large, randomized trial recently completed
included patients with HF and normal LVEF, which demon-
strates that studies in such patients can be accomplished.327 In
that trial, the addition of candesartan to the treatment regimen
for patients with symptomatic HF and relatively preserved
LVEF significantly reduced morbidity but did not reach the
primary endpoint.
In the absence of other controlled clinical trials, the
management of these patients is based on the control of
physiological factors (blood pressure, heart rate, blood vol-
ume, and myocardial ischemia) that are known to exert
important effects on ventricular relaxation.503 Likewise, dis-
eases that are known to cause HF with normal LVEF should
be treated, such as coronary artery disease, hypertension, or
aortic stenosis. Clinically, it seems reasonable to target
symptom reduction, principally by reducing cardiac filling
pressures at rest and during exertion.497 Recommendations
regarding the use of anticoagulation and antiarrhythmic
agents apply to all patients with HF, irrespective of LVEF.
POTENTIAL TREATMENT STRATEGIES. Hypertension exerts a del-
eterious effect on ventricular function by causing both struc-
tural and functional changes in the heart. Increases in systolic
blood pressure have been shown to slow myocardial relax-
ation,525 and the resulting hypertrophy may adversely affect
passive chamber stiffness. Physicians should make every
effort to control both systolic and diastolic hypertension with
effective antihypertensive therapy in accordance with pub-
lished guidelines.78 Consideration should at least be given to
achieving target levels of blood pressure lower than those
recommended for patients with uncomplicated hypertension
(e.g., less than 130 mm Hg systolic and less than 80 mm Hg
diastolic).78,524,526 Because myocardial ischemia can impair
ventricular relaxation, coronary revascularization should be
considered in patients with coronary artery disease in whom
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 symptomatic or demonstrable myocardial ischemia is be-
lieved to be exerting a deleterious effect on cardiac function
(for more information, see the ACC/AHA 2004 Guideline
Update for Coronary Artery Bypass Graft Surgery).16
Because tachycardia can shorten the time available for
ventricular filling and coronary perfusion, drugs that slow the
heart rate or the ventricular response to atrial arrhythmias
(e.g., beta blockers, digoxin, and some calcium channel
blockers) can provide symptomatic relief in patients with HF
and normal LVEF. Similarly, patients with HF and preserved
LVEF may be particularly sensitive to loss of atrial kick,
which supports a potential benefit for restoration of sinus
rhythm in patients with atrial fibrillation. The benefits of
restoring sinus rhythm in these individuals are less clear, and
the large trials of rhythm versus rate control in atrial fibril-
lation published recently have excluded patients with HF.
Moreover, the presence of systolic or diastolic dysfunction
may diminish the efficacy and enhance the toxicity of drugs
used to achieve and maintain sinus rhythm.
Circulating blood volume is a major determinant of ven-
tricular filling pressure, and the use of diuretics may improve
breathlessness in patients with HF and normal LVEF as well
as those with reduced LVEF. Other possible agents used to
reduce diastolic filling pressures are nitrates or agents that
block neurohumoral activation. Hypotension may be a sig-
nificant problem in this population, especially in the very
elderly, because they can be quite sensitive to preload
reduction.
4.4. Patients With Refractory End-Stage Heart
Failure (Stage D) (UPDATED)
The role of intermittent infusions as effective treatment for
advanced HF has been further clarified by an additional
multicenter trial (Table 4).
Recommendations
Class I
1. Meticulous identification and control of fluid retention
is recommended in patients with refractory end-stage
HF.279,282,527–532 (Level of Evidence: B)
2. Referral for cardiac transplantation in potentially eli-
gible patients is recommended for patients with refrac-
tory end-stage HF.533 (Level of Evidence: B)
3. Referral of patients with refractory end-stage HF to a
HF program with expertise in the management of
refractory HF is useful.534–537 (Level of Evidence: A)
4. Options for end-of-life care should be discussed with
the patient and family when severe symptoms in
patients with refractory end-stage HF persist despite
application of all recommended therapies. (Level of
Evidence: C)
5. Patients with refractory end-stage HF and implantable
defibrillators should receive information about the
option to inactivate the defibrillator. (Level of Evi-
dence: C)Class IIa
1. Consideration of an LV assist device as permanent or
“destination” therapy is reasonable in highly selected
patients with refractory end-stage HF and an esti-
mated 1-year mortality over 50% with medical thera-
py.538,539 (Level of Evidence: B)
Class IIb
1. Pulmonary artery catheter placement may be reason-
able to guide therapy in patients with refractory
end-stage HF and persistently severe symptoms.533,540
(Level of Evidence: C)
2. The effectiveness of mitral valve repair or replacement
is not well established for severe secondary mitral
regurgitation in refractory end-stage HF.141,541,542
(Level of Evidence: C)
3. Continuous intravenous infusion of a positive inotropic
agent may be considered for palliation of symptoms in
patients with refractory end-stage HF.543,544 (Level of
Evidence: C)
Class III
1. Partial left ventriculectomy is not recommended in
patients with nonischemic cardiomyopathy and refrac-
tory end-stage HF. (Level of Evidence: C)
2. Routine intermittent infusions of vasoactive and
positive inotropic agents are not recommended for
patients with refractory end-stage HF545,546 (Level of
Evidence: A)
Most patients with HF due to reduced LVEF respond
favorably to pharmacological and nonpharmacological treat-
ments and enjoy a good quality of life and enhanced survival;
however, some patients do not improve or experience rapid
recurrence of symptoms despite optimal medical therapy.
Such patients characteristically have symptoms at rest or on
minimal exertion, including profound fatigue; cannot perform
most activities of daily living; frequently have evidence of
cardiac cachexia; and typically require repeated and/or pro-
longed hospitalizations for intensive management. These
individuals represent the most advanced stage of HF and
should be considered for specialized treatment strategies,
such as mechanical circulatory support, continuous intrave-
nous positive inotropic therapy, referral for cardiac transplan-
tation, or hospice care.
Before a patient is considered to have refractory HF,
physicians should confirm the accuracy of the diagnosis,
identify any contributing conditions, and ensure that all
conventional medical strategies have been optimally em-
ployed. Measures listed as Class I recommendations for
patients in stages A, B, and C are also appropriate for patients
in end-stage HF (see also Section 5). When no further
therapies are appropriate, careful discussion of the prognosis
and options for end-of-life care should be initiated (see
Section 7).
4.4.1. Management of Fluid Status
Many patients with advanced HF have symptoms that are
related to the retention of salt and water and thus will respond
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 favorably to interventions designed to restore sodium bal-
ance. Hence, a critical step in the successful management of
end-stage HF is the recognition and meticulous control of
fluid retention.
In most patients with chronic HF, volume overload can be
treated adequately with low doses of a loop diuretic combined
with moderate dietary sodium restriction; however, as HF
advances, the accompanying decline in renal perfusion can limit
the ability of the kidneys to respond to diuretic therapy.263,275
In such patients, the control of fluid retention may require
progressive increments in the dose of a loop diuretic and
frequently the addition of a second diuretic that has a
complementary mode of action (e.g., metolazone).283,285 If the
patient continues to exhibit evidence of volume overload
despite these measures, hospitalization is generally required
for further adjustment of therapy,282,527 possibly including
intravenous dopamine or dobutamine. This strategy can elicit
a marked increase in urine volume, but such a diuresis is
frequently accompanied by worsening azotemia, especially if
patients are also being treated with an ACEI. Provided that
renal function stabilizes, small or moderate elevations of
blood urea nitrogen and serum creatinine should not lead to
efforts to minimize the intensity of therapy; however, if the
degree of renal dysfunction is severe or if the edema becomes
resistant to treatment, ultrafiltration or hemofiltration may be
needed to achieve adequate control of fluid retention.547,548
The use of such mechanical methods of fluid removal can
produce meaningful clinical bene fits in patients with
diuretic-resistant HF and may restore responsiveness to con-
ventional doses of loop diuretics.
In general, patients should not be discharged from the
hospital until a stable and effective diuretic regimen is
established, and ideally, not until euvolemia is achieved.
Patients who are sent home before these goals are reached are
at high risk of recurrence of fluid retention and early
readmission,549 because unresolved edema may itself attenu-
ate the response to diuretics.278 –280 Once euvolemia is
achieved, the patient’s dry weight can be defined and used as
a continuing target for the adjustment of diuretic doses. Many
patients are able to modify their own diuretic regimen in
response to changes in weight that exceed a predefined range.
The restriction of dietary sodium (to 2 g daily or less) can
greatly assist in the maintenance of volume balance.
Patients with persistent or recurrent fluid retention despite
sodium restriction and high-dose diuretic use may benefit
from review of fluid intake and restriction to 2 liters daily.
The ongoing control of fluid retention may be enhanced by
enrollment in an HF program, which can provide the close
surveillance and education needed for the early recognition
and treatment of volume overload.258–261
4.4.2. Utilization of Neurohormonal Inhibitors
Controlled trials suggest that patients with advanced HF
respond favorably to treatment with both ACEIs and beta
blockers in a manner similar to those with mild to moderate
disease.155,158,162–165,297,298,300 –302,305,310 –321,336 –343,550 How-
ever, because neurohormonal mechanisms play an important
role in the support of circulatory homeostasis as HF
progresses, neurohormonal antagonism may be less welltolerated by patients with severe symptoms than by patients
with mild symptoms. Patients who are at the end stage of their
disease are at particular risk of developing hypotension and
renal insufficiency after the administration of an ACEI and of
experiencing worsening HF after treatment with a beta
blocker. As a result, patients with refractory HF may tolerate
only small doses of these neurohormonal antagonists or may
not tolerate them at all.
Consequently, physicians should exercise great care when
considering the use of both ACEIs and beta blockers in
patients with refractory HF. Treatment with either type of
drug should not be initiated in patients who have systolic
blood pressures less than 80 mm Hg or who have signs of
peripheral hypoperfusion. In addition, patients should not be
started on a beta blocker if they have significant fluid
retention or if they recently required treatment with an
intravenous positive inotropic agent. Treatment with an ACEI
or beta blocker should be initiated in very low doses, and
patients should be monitored closely for signs or symptoms
of intolerance. If low doses are tolerated, further dosage
increments may be considered but may not be tolerated.
However, clinical trials with lisinopril and carvedilol suggest
that even low doses of these drugs may provide important
benefits.174,551
Alternative pharmacological treatments may be considered
for patients who cannot tolerate ACEIs or beta-blockers. A
combination of nitrates and hydralazine has been reported to
have favorable effects on survival in patients with mild to
moderate symptoms who were not taking an ACEI or a beta
blocker,238 but the utility of this vasodilator combination in
patients with end-stage disease who are being given these
neurohormonal antagonists remains unknown. In addition,
many patients experience headaches or gastrointestinal dis-
tress with these direct-acting vasodilators, which can prevent
patients from undergoing long-term treatment. Spironolac-
tone has been reported to prolong life and reduce the risk of
hospitalization for HF in patients with advanced disease256;
however, the evidence supporting the use of the drug has been
derived in patients who have preserved renal function, and the
drug can produce dangerous hyperkalemia in patients with
impaired renal function. Finally, although ARBs325 are fre-
quently considered as alternatives to ACEIs because of the
low incidence of cough and angioedema with these medica-
tions, it is not clear that ARBs are as effective as ACEIs, and
they are as likely as ACEIs to produce hypotension or renal
insufficiency.297,552
4.4.3. Intravenous Peripheral Vasodilators and
Positive Inotropic Agents (UPDATED)
Patients with refractory HF are hospitalized frequently for
clinical deterioration, and during such admissions, they com-
monly receive infusions of both positive inotropic agents
(dobutamine, dopamine, or milrinone) and vasodilator drugs
(nitroglycerin, nitroprusside, or nesiritide) in an effort to
improve cardiac performance, facilitate diuresis, and promote
clinical stability. Some physicians have advocated the place-
ment of pulmonary artery catheters in patients with refractory
HF, with the goal of obtaining hemodynamic measurements
that might be used to guide the selection and titration of
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 therapeutic agents.540 However, the logic of this approach has
been questioned, because many useful drugs for HF produce
benefits by mechanisms that cannot be evaluated by measur-
ing their short-term hemodynamic effects.352,553 Regardless of
whether invasive hemodynamic monitoring is used, once the
clinical status of the patient has stabilized, every effort
should be made to devise an oral regimen that can maintain
symptomatic improvement and reduce the subsequent risk
of deterioration. Assessment of the adequacy and tolera-
bility of orally based strategies may necessitate observa-
tion in the hospital for at least 48 hours after the infusions
are discontinued.554
Patients who cannot be weaned from intravenous to oral
therapy despite repeated attempts may require placement of
an indwelling intravenous catheter to allow for the continuous
infusion of dobutamine or milrinone or, as has been used
more recently, nesiritide. Such a strategy is commonly used
in patients who are awaiting cardiac transplantation, but it
may also be used in the outpatient setting in patients who
otherwise cannot be discharged from the hospital. The deci-
sion to continue intravenous infusions at home should not be
made until all alternative attempts to achieve stability have
failed repeatedly, because such an approach can present a
major burden to the family and health services and may
ultimately increase the risk of death. However, continuous
intravenous support may provide palliation of symptoms as
part of an overall plan to allow the patient to die with comfort
at home.543,544 The use of continuous intravenous support to
allow hospital discharge should be distinguished from the
intermittent administration of infusions of such agents to
patients who have been successfully weaned from inotropic
support.536 Intermittent outpatient infusions of either vasoac-
tive drugs such as nesiritide or positive inotropic drugs have
not shown to improve symptoms or survival in patients with
advanced HF.536,545,546
4.4.4. Mechanical and Surgical Strategies
Cardiac transplantation is currently the only established
surgical approach to the treatment of refractory HF, but it is
available to fewer than 2500 patients in the United States
each year.555,556 Current indications for cardiac transplanta-
tion focus on the identification of patients with severe
functional impairment or dependence on intravenous inotro-
pic agents (Table 10). Less common indications for cardiac
transplantation include recurrent life-threatening ventricular
arrhythmias or angina that is refractory to all currently
available treatments.557
Alternative surgical and mechanical approaches for the
treatment of end-stage HF are under development. Clinical
improvement has been reported after mitral valve repair or
replacement in patients who have a clinically important
degree of mitral regurgitation that is secondary to LV
dilatation.141 However, no controlled studies have evaluated
the effects of this procedure on ventricular function, clinical
status, or survival. One recent single-center report of a
nonrandomized series of patients considered appropriate can-
didates for mitral valve repair did not demonstrate a survival
advantage.541Although both cardiomyoplasty and left ventriculectomy
(Batista procedure) at one time generated considerable ex-
citement as potential surgical approaches to the treatment of
refractory HF,558,559 these procedures failed to result in
clinical improvement and were associated with a high risk of
death.560 A variant of the aneurysmectomy procedure is now
being developed for the management of patients with isch-
emic cardiomyopathy,458 but its role in the management of
HF remains to be defined. None of the current surgical
reconstruction techniques offer “rescue therapy” to patients
with critical hemodynamic compromise.
The use of mechanical circulatory assist devices in
endstage HF is an area of intense investigation. Extracor-
poreal devices can be used for short-term circulatory
support in patients who are expected to recover from a
major cardiac insult (e.g., myocardial ischemia, postcar-
diotomy shock, or fulminant myocarditis). Left ventricular
assist devices provide similar degrees of hemodynamic
support; many are implantable and thus allow for long-
term support, patient ambulation, and hospital dis-
charge.561 Most clinical experience with these devices has
been derived from their use in patients being “bridged” to
transplant. The completion of the Randomized Evaluation
of Mechanical Assistance for the Treatment of Congestive
Heart Failure (REMATCH) trial investigated the use of
these devices as permanent or “destination” therapy in
selected non–transplant-eligible patients.
This trial enrolled 129 patients, for whom 2-year survival
was 23% in the 68 patients treated with the device and 8% in
the 61 patients who received medical therapy.562 Device-
Table 10. Indications for Cardiac Transplantation
Absolute Indications in Appropriate Patients
For hemodynamic compromise due to HF
● Refractory cardiogenic shock
● Documented dependence on IV inotropic support to maintain adequate
organ perfusion
● Peak VO2 less than 10 mL per kg per minute with achievement of
anaerobic metabolism
Severe symptoms of ischemia that consistently limit routine activity and are
not amenable to coronary artery bypass surgery or percutaneous
coronary intervention
Recurrent symptomatic ventricular arrhythmias refractory to all therapeutic
modalities
Relative Indications
Peak VO2 11 to 14 mL per kg per minute (or 55% predicted) and major
limitation of the patient’s daily activities
Recurrent unstable ischemia not amenable to other intervention
Recurrent instability of fluid balance/renal function not due to patient
noncompliance with medical regimen
Insufficient Indications
Low left ventricular ejection fraction
History of functional class III or IV symptoms of HF
Peak VO2 greater than 15 mL per kg per minute (and greater than 55%
predicted) without other indications
HF indicates heart failure; IV, intravenous; and VO2, oxygen consumption per
unit time.related adverse events were numerous and included bleeding,
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 infection, thromboembolic events, and device failure. This
trial established the efficacy of device therapy for end-stage
HF. Improvements in newer generations of devices will
hopefully permit even further prolongation of survival. Pres-
ently, destination device therapy is anticipated to benefit
those patients predicted to have a 1-year survival of less than
50%. One such group could be the population of non–
transplant-eligible patients requiring continuous intravenous
inotropic infusions. Some reports have suggested that pro-
longed mechanical decompression of the failing heart may
occasionally be followed by sufficient recovery of myocardial
function to allow explantation of the device.563 Improvements
in ventricular mechanics, myocardial energetics, histology,
and cell signaling have been reported with LV assist device
support. However, the frequency and duration of myocardial
recovery have been variable,564 and sufficient recovery to
permit device explantation is rare except in a few patients
with acute onset of HF and the absence of coronary artery
disease. Coupling of device therapy with cell transplantation
and a variety of angiogenesis or myocardial growth factors
are approaches planned for future investigation.
Many patients with HF are members of subpopulations
who are likely to exhibit unique responses that accelerate the
development or progression of HF or complicate the man-
agement of HF.
4.5. The Hospitalized Patient (NEW)
Recommendations
Class I
1. The diagnosis of HF is primarily based on signs and
symptoms derived from a thorough history and phys-
ical examination. Clinicians should determine the fol-
lowing:
a. adequacy of systemic perfusion;
b. volume status;
c. the contribution of precipitating factors and/or
comorbidities;
d. if the heart failure is new onset or an exacerbation
of chronic disease; and
e. whether it is associated with preserved ejection
fraction.
Chest radiographs, electrocardiogram, and echocardi-
ography are key tests in this assessment. (Level of
Evidence: C)
2. Concentrations of B-type natriuretic peptide (BNP)
or N-terminal pro-B-type natriuretic peptide (NT-
proBNP) should be measured in patients being eval-
uated for dyspnea in which the contribution of HF is
not known. Final diagnosis requires interpreting these
results in the context of all available clinical data and
ought not to be considered a stand-alone test.565,566 (Level
of Evidence: A)
3. Acute coronary syndrome precipitating HF hospital-
ization should be promptly identified by electrocardio-
gram and cardiac troponin testing, and treated as
appropriate to the overall condition and prognosis of
the patient. (Level of Evidence: C)4. It is recommended that the following common poten-
tial precipitating factors for acute HF be identified as
recognition of these comorbidities is critical to guide
therapy:
a. acute coronary syndromes/coronary ischemia;
b. severe hypertension;
c. atrial and ventricular arrhythmias;
d. infections;
e. pulmonary emboli;
f. renal failure; and
g. medical or dietary noncompliance. (Level of Evi-
dence: C)
5. Oxygen therapy should be administered to relieve
symptoms related to hypoxemia. (Level of Evidence: C)
6. Whether the diagnosis of HF is new or chronic, pa-
tients who present with rapid decompensation and
hypoperfusion associated with decreasing urine output
and other manifestations of shock are critically ill and
rapid intervention should be used to improve systemic
perfusion. (Level of Evidence: C)
7. Patients admitted with HF and with evidence of
significant fluid overload should be treated with
intravenous loop diuretics. Therapy should begin in
the emergency department or outpatient clinic with-
out delay, as early intervention may be associated
with better outcomes for patients hospitalized with
decompensated HF.32,567,568 (Level of Evidence: B) If
patients are already receiving loop diuretic therapy,
the initial intravenous dose should equal or exceed
their chronic oral daily dose. Urine output and signs
and symptoms of congestion should be serially as-
sessed, and diuretic dose should be titrated accord-
ingly to relieve symptoms and to reduce extracellu-
lar fluid volume excess. (Level of Evidence: C)
8. Effect of HF treatment should be monitored with
careful measurement of fluid intake and output; vital
signs; body weight, determined at the same time each
day; clinical signs (supine and standing) and symptoms
of systemic perfusion and congestion. Daily serum
electrolytes, urea nitrogen, and creatinine concentra-
tions should be measured during the use of IV diuretics
or active titration of HF medications. (Level of Evi-
dence: C)
9. When diuresis is inadequate to relieve congestion, as
evidenced by clinical evaluation, the diuretic regimen
should be intensified using either:
a. higher doses of loop diuretics;
b. addition of a second diuretic (such as metolazone,
spironolactone, or intravenous chlorothiazide); or
c. continuous infusion of a loop diuretic. (Level of
Evidence: C)
10. In patients with clinical evidence of hypotension
associated with hypoperfusion and obvious evidence
of elevated cardiac filling pressures (e.g., elevated
jugular venous pressure; elevated pulmonary artery
wedge pressure), intravenous inotropic or vasopres-
sor drugs should be administered to maintain sys-
temic perfusion and preserve end-organ performance
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 while more definitive therapy is considered. (Level of
Evidence: C)
11. Invasive hemodynamic monitoring should be per-
formed to guide therapy in patients who are in
respiratory distress or with clinical evidence of im-
paired perfusion in whom the adequacy or excess of
intracardiac filling pressures cannot be determined
from clinical assessment. (Level of Evidence: C)
12. Medications should be reconciled in every patient and
adjusted as appropriate on admission to and dis-
charge from the hospital. (Level of Evidence: C)
13. In patients with reduced ejection fraction experienc-
ing a symptomatic exacerbation of HF requiring
hospitalization during chronic maintenance treat-
ment with oral therapies known to improve outcomes,
particularly ACEIs or ARBs and beta-blocker ther-
apy, it is recommended that these therapies be con-
tinued in most patients in the absence of hemody-
namic instability or contraindications. (Level of
Evidence: C)
14. In patients hospitalized with HF with reduced ejec-
tion fraction not treated with oral therapies known to
improve outcomes, particularly ACEIs or ARBs and
beta-blocker therapy, initiation of these therapies is
recommended in stable patients prior to hospital
discharge.569,570 (Level of Evidence: B)
15. Initiation of beta-blocker therapy is recommended
after optimization of volume status and successful
discontinuation of intravenous diuretics, vasodila-
tors, and inotropic agents. Beta-blocker therapy
should be initiated at a low dose and only in stable
patients. Particular caution should be used when
initiating beta blockers in patients who have re-
quired inotropes during their hospital course.569,570
(Level of Evidence: B)
16. In all patients hospitalized with HF, both with pre-
served (see Section 4.3.2, Patients With Heart Failure
and Normal Left Ventricular Ejection Fraction) and
low EF, transition should be made from intravenous
to oral diuretic therapy with careful attention to oral
diuretic dosing and monitoring of electrolytes. With
all medication changes, the patient should be moni-
tored for supine and upright hypotension, and wors-
ening renal function and HF signs/symptoms. (Level
of Evidence: C)
17. Comprehensive written discharge instructions for all
patients with a hospitalization for HF and their
caregivers is strongly recommended, with special
emphasis on the following 6 aspects of care: diet;
discharge medications, with a special focus on adher-
ence, persistence, and uptitration to recommended
doses of ACEI/ARB and beta-blocker medication;
activity level; follow-up appointments; daily weight
monitoring; and what to do if HF symptoms worsen.
(Level of Evidence: C)
18. Postdischarge systems of care, if available, should be
used to facilitate the transition to effective outpatient
care for patients hospitalized with HF.215,571–577 (Level
of Evidence: B)Class IIa
1. When patients present with acute HF and known or
suspected acute myocardial ischemia due to occlusive
coronary disease, especially when there are signs and
symptoms of inadequate systemic perfusion, urgent
cardiac catheterization and revascularization is rea-
sonable where it is likely to prolong meaningful sur-
vival. (Level of Evidence: C)
2. In patients with evidence of severely symptomatic fluid
overload in the absence of systemic hypotension, vaso-
dilators such as intravenous nitroglycerin, nitroprus-
side or nesiritide can be beneficial when added to
diuretics and/or in those who do not respond to diuret-
ics alone. (Level of Evidence: C)
3. Invasive hemodynamic monitoring can be useful for
carefully selected patients with acute HF who have
persistent symptoms despite empiric adjustment of
standard therapies, and
a. whose fluid status, perfusion, or systemic or pulmo-
nary vascular resistances are uncertain;
b. whose systolic pressure remains low, or is associated
with symptoms, despite initial therapy;
c. whose renal function is worsening with therapy;
d. who require parenteral vasoactive agents; or
e. who may need consideration for advanced device
therapy or transplantation. (Level of Evidence: C)
4. Ultrafiltration is reasonable for patients with refrac-
tory congestion not responding to medical therapy.578
(Level of Evidence: B)
Class IIb
1. Intravenous inotropic drugs such as dopamine, dobut-
amine or milrinone might be reasonable for those
patients presenting with documented severe systolic dys-
function, low blood pressure and evidence of low cardiac
output, with or without congestion, to maintain systemic
perfusion and preserve end-organ performance. (Level of
Evidence: C)
Class III
1. Use of parenteral inotropes in normotensive patients
with acute decompensated HF without evidence of
decreased organ perfusion is not recommended.579
(Level of Evidence: B)
2. Routine use of invasive hemodynamic monitoring in
normotensive patients with acute decompensated HF
and congestion with symptomatic response to diuret-
ics and vasodilators is not recommended.580 (Level of
Evidence: B)
A patient may develop acute or progressive symptoms of
HF and require hospitalization. In general, there are 3 clinical
profiles that describe the hospitalized patient with HF: 1) the
patient with volume overload, manifested by pulmonary
and/or systemic congestion, frequently precipitated by an
acute increase in chronic hypertension; 2) the patient with
profound depression of cardiac output manifested by hypo-
tension, renal insufficiency, and/or a shock syndrome, and 3)
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 the patient with signs and symptoms of both fluid overload
and shock. Irrespective of the presenting clinical picture,
there have been a confusing variety of terms in the literature
used to describe these patients, including acute HF syndrome,
acute decompensated HF, or cardiogenic shock. However
different these 3 groups of patients may be in outcome, they
can all be characterized as having a change in HF signs and
symptoms resulting in a need for urgent therapy. Patients with
HF and preserved LVEF (see Section 4.3.2, Patients With
Heart Failure and Normal Left Ventricular Ejection Fraction)
are just as likely to be admitted to hospital as those with HF
and low LVEF.581 Admission with HF is often triggered by a
concomitant cardiovascular event such as a symptomatic
tachyarrhythmia, unstable coronary syndrome, or a cerebro-
vascular event; often the admission is related to medical or
dietary noncompliance. The threshold for admission may also
be lowered when HF exacerbation is accompanied with a
noncardiac condition such as pneumonia or newly diagnosed
anemia. Indeed, it is important to note that concurrent
conditions and comorbidities such as coronary artery disease,
hypertension, valvular heart disease, arrhythmias, renal dys-
function, diabetes, thromboembolism, and anemia are often
present, more so than has usually been described in clinical
trials, and may precipitate or contribute to the pathophysiol-
ogy of the syndrome. Unfortunately, the precipitating event
leading to hospitalization is not always readily apparent.
Common Factors That Precipitate Hospitalization for
Heart Failure
• Noncompliance with medical regimen, sodium and/or fluid
restriction
• Acute myocardial ischemia
• Uncorrected high blood pressure
• Atrial fibrillation and other arrhythmias
• Recent addition of negative inotropic drugs (e.g., vera-
pamil, nifedipine, diltiazem, beta blockers)
• Pulmonary embolus
• Nonsteroidal anti-inflammatory drugs
• Excessive alcohol or illicit drug use
• Endocrine abnormalities (e.g., diabetes mellitus, hyperthy-
roidism, hypothyroidism)
• Concurrent infections (e.g., pneumonia, viral illnesses)
HF hospitalizations account for a substantial portion of the
overall costs of caring for patients with HF and may be
associated with a staggering degree of morbidity and
mortality, particularly in the elderly population. It is
evident that the prognosis after an index hospitalization for
HF is ominous, with a 50% rate of readmission at 6 months
and a 25% to 35% incidence of death at 12 months.582–586
Indeed, many HF trials now incorporate the need for
hospitalization as an important endpoint with which to
evaluate a new therapy; government agencies and insur-
ance companies are increasingly interested in understand-
ing the frequency of repeat HF hospitalizations. Thus, it is
important to outline what should occur in the hospital for
the HF patient requiring therapy. The scope of these
recommendations are based on evidence from the few
available randomized trials evaluating management strat-egies in the acute decompensated HF patient,461,578 –580,587
analyses of large registries, and consensus opinion. Addi-
tional and more comprehensive information on this subject
may be found in the guidelines from the Heart Failure
Society of America and the European Society of
Cardiology.588,589,589a
4.5.1. Diagnostic Strategies
The diagnosis of HF in the hospitalized patient should be
based primarily on signs and symptoms, as discussed in
Section 3.1., Initial Evaluation of Patients. Clinicians need to
determine as accurately and as quickly as possible 1) the
volume status of the patient, 2) the adequacy of circulatory
support or perfusion, and 3) the role or presence of precipi-
tating factors and/or comorbidities. In the patient with previ-
ously established HF, efforts should likewise be directed
toward understanding what has caused the apparent acute
worsening of clinical symptoms. Many of the steps in this
investigation are identical to those used in the initial evalua-
tion of HF (see Sections 3.1.3, Evaluation of the Cause of
Heart Failure and 3.2, Ongoing Evaluation of Patients). When
the diagnosis of HF is uncertain, determination of plasma
BNP or NT-proBNP concentration should be considered in
patients being evaluated for dyspnea who have signs and
symptoms compatible with HF. The natriuretic peptide con-
centration should not be interpreted in isolation but in the
context of all available clinical data bearing on the diagnosis
of HF.
An important cause of worsening HF, and for new-onset
HF, is an acute MI. Because many patients admitted with
acute HF have coronary artery disease, troponins are
typically evaluated at admission for acute exacerbation.
Actual criteria for an acute coronary event that may
indicate the need for further intervention may be present in
up to 20% of patients.590,591 However, many other patients
may have low levels of detectable troponins not meeting
criteria for an acute ischemic event but typical of chronic HF
with an acute exacerbation.592 Registry data have suggested
that the use of coronary angiography is low for patients
hospitalized with decompensated HF and opportunities to
diagnose important coronary artery disease may be missed.
Symptoms of HF or cardiogenic shock associated with an
ischemic event are covered in other guidelines10,593 and are
beyond the scope of this update. For the patient with newly
discovered HF, clinicians should be aware of the important
role of coronary artery disease in causing HF and should be
certain that coronary structure and function are well delin-
eated (see Section 3.1.2, Identification of a Structural and
Functional Abnormality) while simultaneously beginning
treatment. Coronary visualization may be an important part of
the evaluation of patients hospitalized with HF.
Often, patients with chronic HF are admitted with acute
decompensation from a number of possible precipitating
causes. Clinicians should carefully review the patient’s main-
tenance HF medications and decide whether adjustments
should be made as a result of the hospitalization. The large
majority of patients with HF admitted to the hospital, espe-
cially those with concomitant hypertension, should have their
oral therapy continued, or even uptitrated, during hospitaliza-
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 tion. It is important to note that it has been shown that
continuation of beta blockers for most patients is well
tolerated and results in better outcomes.569,570 Withholding of
or reduction in beta-blocker therapy should be considered
only in patients hospitalized after recent initiation or increase
in beta-blocker therapy or with marked volume overload.
Patients admitted with worsening azotemia should be consid-
ered for a reduction in or temporary discontinuation of their
ACEIs, ARBs, and/or aldosterone antagonists until renal
function improves. Patients with marked volume overload
will require intravenous diuretic therapy with uptitration of
diuretic dose and/or addition of synergistic diuretic agents. It
should be noted that uptitration of ACEIs or beta blockers
during decompensation may reduce the efficacy of the acute
interventions to relieve congestion. Although it is important
to ensure that evidence-based medications are instituted prior
to the patient leaving the hospital, it is equally as critical to
reassess medications on admission and to adjust their admin-
istration in light of the worsening HF.
4.5.2. Treatment in the Hospital
4.5.2.1. Diuretics: The Patient With Volume Overload
Patients admitted with evidence of significant fluid overload
should initially be treated with loop diuretics, usually given
intravenously. Therapy for this compelling presentation of
HF should begin in the emergency department and should be
initiated without delay. Early intervention has been associated
with better outcomes for patients hospitalized with decom-
pensated HF.594,595 After admission to the hospital, patients
should be carefully monitored in accordance with the severity
of their symptoms and the results of initial findings on the
physical examination and laboratory assessment. Careful and
frequent serial evaluation of the patient is important primarily
to assess volume status (see Section 3.2.2, Assessment of
Volume Status) and adequacy of circulatory support. Labo-
ratory parameters are likewise necessary to judge efficacy of
treatment (see Sections 3.1.3.2, Laboratory Testing, and
3.2.3, Laboratory Assessment). Monitoring of daily weight,
supine and standing vital signs, fluid input, and output is a
necessary part of daily management; assessment of daily
electrolytes and renal function should be done while intrave-
nous diuretics or active HF medication titration is being
undertaken.
Intravenous loop diuretics have the potential to reduce
glomerular filtration rate (GFR), further worsen neurohu-
moral activation, and produce electrolyte disturbances. Thus,
although the use of diuretics may result in the effective relief
of symptoms, their impact on mortality has not been well
studied. Diuretics should be administered at doses sufficient
to produce a rate of diuresis that will optimize volume status
and relieve signs and symptoms of congestion without induc-
ing an excessively rapid reduction in intravascular volume,
which could result in hypotension, renal dysfunction, or both
(see Sections 4.3.1.2.1, Diuretics, and 4.4.1, Management of
Fluid Status). Because loop diuretics have a relatively short
half-life, sodium reabsorption in the tubules will occur once
the tubular concentration of the diuretics declines. Therefore,
strictly limiting sodium intake and dosing the diuretic multi-
ple times per day will enhance effectiveness of the diure-sis.275–279,596–598 Some patients may present with congestion
and moderate to severe renal dysfunction. The response to
diuretics may be significantly blunted, requiring higher initial
doses. In many cases, reduction of fluid overload may
improve not only congestion but also renal dysfunction,
particularly if significant venous congestion is reduced.599
Clinical experience suggests it is difficult to determine
whether congestion has been adequately treated in many
patients, and registry data have confirmed that patients are
frequently discharged after a net weight loss of only a few
pounds. Although patients may rapidly improve symptomat-
ically, they may remain hemodynamically compromised.
Unfortunately, the routine use of serial natriuretic peptide
measurement (BNP or NT-proBNP) or even a Swan-Ganz
catheter to monitor hemodynamics has not been shown to be
helpful in improving the outcomes of the hospitalized patient
with HF. Nevertheless, careful evaluation of all physical
findings, laboratory parameters, weight change, and net fluid
change should be considered before discharge planning is
commenced.
When a patient with congestion fails to respond to initial
doses of intravenous diuretics, several options may be con-
sidered. Efforts should be taken to make certain that, indeed,
congestion persists and that another hemodynamic profile or
perhaps another disease process is not evident. This is
particularly important for the patient with progressive renal
insufficiency. If there is substantial doubt about the fluid
status of the patient, HF experts suggest that it is an
appropriate time for a formal hemodynamic assessment of
ventricular filling pressures and cardiac output, typically done
with a right heart catheterization. If volume overload is
confirmed, the dose of the loop diuretic should be initially
increased to ensure that adequate drug levels reach the
kidney. If this is inadequate, a second type of diuretic,
typically a thiazide (metolazone or intravenous chlorothia-
zide) or spironolactone, can be added to improve diuretic
responsiveness. As a third strategy, continuous infusion of the
loop diuretic may be considered. By continuous delivery of
the diuretic to the nephron, rebound resorption occurring
during the time blood levels of diuretic are low is avoided and
ototoxicity risk may actually be reduced (see Sections
4.3.1.2.1, Diuretics, and 4.4.1, Management of Fluid Sta-
tus).279,280,282–286,598,600,601 If all diuretic strategies are unsuc-
cessful, ultrafiltration or another renal replacement strategy
may be reasonable. Ultrafiltration moves water and small- to
medium-weight solutes across a semipermeable membrane to
reduce volume overload. Because the electrolyte concentra-
tion is similar to plasma, relatively more sodium can be
removed than by diuretics.529,578,602–604 Consultation with a
kidney specialist may be appropriate before opting for any
mechanical strategy to affect diuresis.
4.5.2.2. Vasodilators
There are a number of clinical scenarios whereby the addition
of vasodilators to the HF regimen of the hospitalized patient
might be appropriate. For patients with adequate blood
pressure and ongoing congestion not sufficiently responsive
to diuretics and standard oral therapy (e.g., maintenance of
prior HF medications, if applicable), intravenous vasodilators
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 such as nitroprusside, nitroglycerin, or nesiritide may be
added to the treatment regimen. Regardless of the agent used,
the clinician should make certain that intravascular volume is,
in fact, expanded and that the patient’s blood pressure can
tolerate the addition of the vasodilating drug.
Intravenous nitroglycerin, primarily through venodilation
effects, lowers preload and may help to more rapidly reduce
pulmonary congestion. Patients with HF and hypertension,
coronary ischemia, or significant mitral regurgitation are
often cited as ideal candidates for the use of intravenous
nitroglycerin. However, tachyphylaxis to nitroglycerin may
develop rather quickly and up to 20% of those with HF may
develop resistance to even high doses.605–607 Sodium nitro-
prusside is a balanced preload-reducing venodilator and
afterload-reducing arteriodilator that also dilates the pulmo-
nary vasculature. Data demonstrating efficacy are limited, and
invasive hemodynamic blood pressure monitoring is typically
required. Nitroprusside has the potential for producing
marked hypotension and is usually used in the intensive care
setting as well; longer infusions of the drug have been
associated with thiocyanate toxicity, particularly in the setting
of renal insufficiency. Nitroprusside is potentially of value in
severely congested patients with hypertension or severe
mitral valve regurgitation complicating LV dysfunction. Ne-
siritide (human BNP) reduces LV filling pressure but has
variable effects on cardiac output, urinary output, and sodium
excretion. The severity of dyspnea is reduced more rapidly
compared to diuretics alone. Because nesiritide has a longer
effective half-life than nitroglycerin or nitroprusside, side
effects such as hypotension may persist longer. Conservative
dosing of the drug (i.e., no bolus) and use of only the recom-
mended doses may reduce complications. Adverse renal
consequences with nesiritide have been suggested; careful
monitoring of renal function is mandatory.459,461–463,608–610
The effects of nesiritide on mortality remain uncertain and
active clinical investigation is ongoing.
The role of intravenous vasodilators for the patient hospi-
talized with HF can not be generalized. The goals of HF
therapy with vasodilators, in the absence of more definitive
data, include a more rapid resolution of congestive symp-
toms; relief of anginal symptoms while awaiting coronary
intervention; control of hypertension complicating HF;
and, in conjunction with ongoing hemodynamic monitoring
while the intravenous drug is administered, improvement of
hemodynamic abnormalities prior to instituting oral HF
medications.
4.5.2.3. Inotropes
Patients presenting with either predominantly low output
syndrome (e.g., symptomatic hypotension) or combined con-
gestion and low output may be considered for intravenous
inotropes such as dopamine, dobutamine, and milrinone.
These agents may help relieve symptoms due to poor perfu-
sion and preserve end-organ function in patients with severe
systolic dysfunction and dilated cardiomyopathy. Inotropic
agents are of greatest value in patients with relative hypoten-
sion and intolerance or no response to vasodilators and
diuretics. Clinicians should be cautioned again that the use of
these drugs portends a very poor prognosis for their patients;a thorough hemodynamic assessment must be undertaken to
ensure that the low output syndrome is responsible for the
presenting clinical signs and symptoms. Likewise, clinicians
should not use a specific blood pressure value that might or
might not mean hypotension, to dictate the use of inotropic
agents. Rather, a depressed blood pressure associated with
signs of poor cardiac output or hypoperfusion (e.g., cold
clammy skin, cool extremities, decreased urine output, altered
mentation) should prompt a consideration for more aggres-
sive intravenous therapy. Dobutamine requires the beta-
receptor for its inotropic effects, while milrinone does not.
This may be a significant consideration for patients already
maintained on beta-blocking drugs. Furthermore, milrinone
has vasodilating properties for both the systemic circulation
and the pulmonary circulation. Despite these considerations,
there is no evidence of benefit for routine use of inotropic
support in patients presenting with acute HF due to conges-
tion only.579,611–613 Indeed, data from several studies suggest
an increase in adverse outcomes when inotropes are used.
Thus, inotropes should be confined to carefully selected
patients with low blood pressure and reduced cardiac output
who can have blood pressure and heart rhythm monitored
closely (see Section 4.4.3, Intravenous Peripheral Vasodila-
tors and Positive Inotropic Agents).
Routine invasive hemodynamic monitoring is not indicated
for most patients hospitalized with symptoms of worsening
HF. Recent evaluations of the use of right heart catheteriza-
tion to improve outcomes have been essentially neutral with
regard to overall benefit.580,614 However, hemodynamic mon-
itoring should be strongly considered in patients whose
volume and filling pressures are uncertain or who are refrac-
tory to initial therapy, particularly in those whose filling
pressures and cardiac output are unclear. Patients with clini-
cally significant hypotension (systolic blood pressure typi-
cally less than 90 mm Hg or symptomatic low systolic blood
pressure) and/or worsening renal function during initial ther-
apy might also benefit. Patients being considered for cardiac
transplantation or placement of a mechanical circulatory
support device are also candidates for complete right heart
catheterization, a necessary part of the initial evaluation (see
Section 4.4.4, Mechanical and Surgical Strategies). Invasive
hemodynamic monitoring should be performed in patients with
1) presumed cardiogenic shock requiring escalating pressor
therapy and consideration of mechanical support; 2) severe
clinical decompensation in which therapy is limited by uncer-
tainty regarding relative contributions of elevated filling pres-
sures, hypoperfusion, and vascular tone; 3) apparent dependence
on intravenous inotropic infusions after initial clinical improve-
ment; or 4) persistent severe symptoms despite adjustment of
recommended therapies. This reinforces the concept that right
heart catheterization is best reserved for those situations where a
specific clinical or therapeutic question needs to be addressed.
4.5.2.4. Other Considerations
Other treatment or diagnostic strategies may be necessary for
individual patients after stabilization, particularly related to
the underlying cause of the acute event. Considerations are
similar to those previously discussed in Section 3.1.3, Eval-
uation of the Cause of Heart Failure. The patient hospitalized
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 with HF is at increased risk for thromboembolic complica-
tions and deep venous thrombosis and should receive pro-
phylactic anticoagulation with either intravenous unfraction-
ated heparin or subcutaneous preparations of unfractionated
or low-molecular-weight heparin, unless contraindicated.615
As the hospitalized patient becomes more clinically stable
and volume status normalizes, oral HF therapy should be
initiated or reintroduced (see Sections 4.3.1, Patients With
Reduced Left Ventricular Ejection Fraction, and 4.3.2, Pa-
tients With Heart Failure and Normal Left Ventricular Ejec-
tion Fraction). Particular caution should be used when initi-
ating beta blockers in patients who have required inotropes
during their hospital course or when initiating ACEIs in those
patients who have experienced marked azotemia. During
additional hospital days, the patient should be fully transi-
tioned off all intravenous therapy, and oral therapy should be
adjusted and maximized. The clinical team should provide
further education about HF to both the patient and family.
The treating clinicians should also reassess overall prognosis
once current functional status and precipitating causes of the
hospitalization have been determined. The appropriateness of
discussion about advanced therapy or end-of-life preferences
should also be considered (see Sections 3.2.4, Assessment of
Prognosis, and 7, End-of-Life Considerations). On discharge,
the patient, the family, and the patient’s primary physician
should be aware and supportive of the follow-up plans.
4.5.3. The Hospital Discharge
To ensure safe, high-quality, and efficient care for patients
following hospitalization for HF, the consistent use of clinical
practice guidelines developed by the ACCF, the AHA, and
the Heart Failure Society of America should be promoted
during and after the hospital stay. One critical performance
measure for care coordination and transition is that of written
discharge instructions or educational material given to patient
and/or caregiver at discharge to home or during the hospital
stay addressing all of the following: activity level, diet,
discharge medications, follow-up appointment, weight mon-
itoring, and what to do if symptoms worsen.616 Education of
HF patients and their families is critical and often complex.
Failure of these patients to understand how best to comply
with physician’s and other healthcare providers’ instructions
is often a cause of HF exacerbation leading to subsequent
hospital readmission.
Large registries of hospitalized HF patients suggest that
many patients are discharged before optimal volume status is
achieved, or sent home without the benefit of life-saving
therapies such as ACE/ARB and beta-blocker medications.
Among hospitals providing care for patients with HF, there is
significant individual variability in conformity to quality-of-
care indicators and clinical outcomes and a substantial gap in
overall performance.617 Patients are discharged without ade-
quate control of their blood pressure or the ventricular
response to atrial fibrillation. Often, the treating clinician fails
to appreciate the severity of the HF process or delays
diagnostic testing until the patient is seen as an outpatient.
These problems, and others, may account for the high rate of
HF rehospitalizations seen in the United States.It is, therefore, incumbent on healthcare professionals to be
certain that patients and their families have an understanding
of the causes of HF, prognosis, therapy, dietary restrictions,
activity, importance of compliance, and signs and symptoms
of recurrent HF. Thorough discharge planning that includes a
special emphasis on ensuring compliance with an evidence-
based medication regimen571 is associated with improved
patient outcomes.572,618,619
Several studies have examined the effect of providing more
intensive delivery of discharge instructions coupled tightly
with subsequent well-coordinated follow-up care for patients
hospitalized with HF, many with positive results.215,573–575
Comprehensive discharge planning plus postdischarge sup-
port for older patients with HF can significantly reduce
readmission rates and may improve health outcomes such as
survival and quality of life without increasing costs. A
meta-analysis576 of 18 studies representing data from 8
countries randomized 3304 older inpatients with HF to
comprehensive discharge planning plus postdischarge sup-
port or usual care. During a mean observation period of 8
months, fewer intervention patients were readmitted com-
pared with controls. Analysis of studies reporting secondary
outcomes found a trend toward lower all-cause mortality,
length of stay, hospital costs, and improvement in quality-of-
life scores for patients assigned to an intervention compared
with usual care. One other important study577 focusing on
hospital discharge for patients with HF demonstrated that the
addition of a 1-hour, nurse educator–delivered teaching
session at the time of hospital discharge using standardized
instructions resulted in improved clinical outcomes, increased
self-care measure adherence, and reduced cost of care.
Patients receiving the education intervention had a lower risk
of rehospitalization or death and lower costs of care.
The importance of patient safety for all patients hospital-
ized with HF cannot be overemphasized. Meaningful evi-
dence has facilitated a much better understanding of the
systems changes necessary to achieve safer care. This in-
cludes the adoption by all U.S. hospitals of a standardized set
of 30 “Safe Practices” endorsed by the National Quality
Forum,620 which overlap in many ways with the National
Patient Safety Goals espoused by The Joint Commission.621
Improved communication between physicians and nurses,
medication reconciliation, transitions between care settings,
and consistent documentation are examples of patient safety
standards that should be ensured for patients discharged from
the hospital with HF. Care information, especially changes in
orders and new diagnostic information, must be transmitted in
a timely and clearly understandable form to all of the patient’s
current healthcare providers who need that information to
provide follow-up care.
Hospitalization is in and of itself an independent risk
factor for shortened survival in patients with chronic HF.
Hence, appropriate levels of symptomatic relief, support,
and palliative care for patients with chronic HF should be
addressed as an ongoing key component of their plan of
care, especially when hospitalized with acute decompen-
sation.622 Fortunately, most US hospitals today have direct
access to palliative care services.623 Good evidence exists
for the critical importance of delivering comprehensive
Hunt et al 2009 ACCF/AHA Heart Failure Guidelines e441
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 supportive care to these patients, including the assessment
and treatment of dyspnea and physiological issues includ-
ing anxiety and depression.624,625,625a,625b
5. Treatment of Special Populations
(UPDATED)
The recommendations for hydralazine/isosorbide dinitrate in
a specific population have been clarified in this section and in
a previous section,223,236 based on a recent multicenter trial
(Table 6).
Recommendations
Class I
1. The combination of a fixed dose of isosorbide dinitrate
and hydralazine to a standard medical regimen for HF,
including ACEIs and beta blockers, is recommended in
order to improve outcomes for patients self-described
as African Americans, with NYHA functional class III
or IV HF. Others may benefit similarly, but this has not
yet been tested.223,236 (Level of Evidence: A)
2. Groups of patients including (a) high-risk ethnic mi-
nority groups (e.g., blacks), (b) groups underrepre-
sented in clinical trials, and (c) any groups believed to
be underserved should, in the absence of specific
evidence to direct otherwise, have clinical screening
and therapy in a manner identical to that applied to the
broader population.626,627 (Level of Evidence: B)
3. It is recommended that evidence-based therapy for HF
be used in the elderly patient, with individualized
consideration of the elderly patient’s altered ability to
metabolize or tolerate standard medications. (Level of
Evidence: C)
5.1. Women and Men
Many physicians regard HF primarily as a disease of men,
because coronary risk factors are common in men and
primarily men are enrolled in clinical trials of treatments for
HF; however, the majority of patients with HF in the general
population are women (particularly elderly women), who
frequently have HF associated with a normal LVEF.48 Even
HF due to reduced LVEF may be different in women than in
men. Yet, most large, multicenter trials have not included
sufficient numbers of women to allow conclusions about the
efficacy and safety of their treatment. Several studies have
documented a lower use of ACEIs in women with HF than in
men,628 and another study reported that women are given
fewer cardiovascular medications after an MI than
men.564,629,630 These findings may explain why women have
been noted to rate their quality of inpatient care lower than
men and why they have less improvement in physical health
status after an episode of HF.564 Some analyses have sug-
gested that women with HF, particularly with asymptomatic
reduced LVEF, may not show survival benefits from ACE
inhibition.631,632 Women may also have a different safety
profile than men, as evidenced by their higher risk of
ACEI-induced cough.633 The conflicting data regarding the
efficacy of digoxin in women suggests that if it is prescribed,
particular attention should be paid to dosing and renalfunction.379 Currently, great efforts are being made (and
mandated) to include a higher proportion of women in
government-sponsored trials.
Because HF is frequently accompanied by erectile dys-
function, men may express interest in the use of a phospho-
diesterase type 5 inhibitor (e.g., sildenafil) as a means of
enhancing sexual performance. Few patients with HF were
enrolled in controlled trials with sildenafil, and thus, the
efficacy and safety of this drug in patients with HF are not
known. Nevertheless, recent studies suggest that sildenafil
may produce hemodynamic benefits in patients with coronary
artery disease and may act to improve some of the peripheral
vascular abnormalities that characterize patients with HF.634
Although patients with HF appear to tolerate short-term
administration of the drug without difficulty, sildenafil should
not be given to patients taking nitrates, who may experience
profound hypotension due to its ability to potentiate the
systemic vasodilator effects of drugs that increase intracellu-
lar levels of cyclic guanosine monophosphate.635
5.2. Ethnic Considerations
Race is an imprecise concept that has largely become a social
and political construct, with more limited biological signifi-
cance.636 The concept of racial “minorities” may be relevant
to large populations, especially those in clinical trials, but is
clearly not a concept applicable in many demographic areas
and clinical practices. However, it is useful to review epide-
miological and clinical trial evidence to raise awareness of
potential areas of concern and guide socioeconomic and
clinical remedies. This has become especially pertinent in the
evaluation of HF as it affects blacks, although much more
information is also needed about the effects of current and
new therapies in the Hispanic population. Heart failure is a
major public health problem in blacks. Heart failure is more
common in the black population, affecting approximately 3%
of all black adults. This reflects a 50% higher incidence of HF
in the black population than is seen in the general population.
Black patients develop symptoms of HF at an earlier
average age than nonblacks, possibly because black patients
are more likely to have hypertension and diabetes mellitus
than nonblacks and because they more frequently exhibit
sodium retention, ventricular hypertrophy, and vascular in-
jury. Once the diagnosis is made, HF progresses more rapidly
in black than in white patients, as evidenced by a higher risk
of initial and recurrent hospitalizations.637–639 This risk can-
not be explained by the presence of epicardial coronary artery
disease or documented MI, both of which are less common in
black than in nonblack patients with HF. The data are not
clear as to whether a definitive increase in mortality risk
exists.637–639
The literature is mixed on whether blacks with HF more
frequently receive suboptimal inpatient care for their HF.640,641
However, deficiencies in cardiovascular risk factor evaluation
and disease detection and treatment as well as in access to
quality outpatient care may contribute to the increased inci-
dence and morbidity of blacks with HF.642–644
Blacks and other racial minorities with HF are underrep-
resented in most clinical trials of HF, which compromises the
extrapolation of results from major clinical trials to ethnic
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 subgroup populations. To date, there are no data to suggest
that any significant treatment variance from standard care for
HF should be acceptable in any particular group. Clinical
experience suggests that Asian patients have a higher than
average risk of cough during treatment with an ACEI.
Retrospective analysis of subgroup data has suggested that, as
in the treatment of hypertension, black patients with HF may
experience less efficacy than nonblacks from the use of
ACEIs.222 A recent analysis of a large ACEI HF trial that used
a matched-cohort design confirmed that black patients had a
greater number of hospitalizations for HF than matched white
patients.645 However, rates of death in that trial were similar
between black and nonblack patients with HF.645 Interest-
ingly, the results of 2 trials evaluating the effects of different
beta blockers in black patients have been discordant: bucin-
dolol caused a nonsignificant increase in the risk of a serious
clinical event in black patients, but it reduced deaths and
hospitalizations in nonblack patients.646 Thus, bucindolol
may represent a decidedly different beta blocker than those
already approved for the treatment of HF. Conversely, the
benefit of carvedilol in a separate series of trials was apparent
and of a similar magnitude in both black and nonblack
patients with HF.647 There may be race-based differences in
the outcome of cardiac transplantation as well.648 Further
study is needed to clarify these issues.
The emerging field of genomic medicine has begun to
suggest that important variances in the expression of certain
high-risk, single-nucleotide polymorphisms may be evident
along racial lines and may provide a physiological basis for
differences in the natural history of HF and differences in drug
responsiveness.649–652 Data from these early investigations
are not yet definitive; racial groupings are necessarily heter-
ogenous, and data will need to be interpreted cautiously.
A prospective, double-blind randomized trial conducted
specifically in blacks with NYHA class III/IV HF has been
completed.223 The patient population was characterized by a
much higher likelihood of a nonischemic cause of HF and of
a history of hypertension and obesity. In this trial, the
adjunctive use of a proprietary formulation of isosorbide
dinitrate and hydralazine along with a standard HF regimen
resulted in a 43% decrease in total mortality, which led to
premature termination of the trial. Additionally, time to first
hospitalization and quality of life were both improved. The
mechanism of benefit of this regimen may be related to an
improvement in nitric oxide bioavailability, but this regimen
had a small (but significant) effect on blood pressure lower-
ing. The effect of this combination of isosorbide dinitrate and
hydralazine in other patients with HF who are undergoing
standard therapy is not known because the population studied
was limited to blacks, but there is no reason to believe that
this benefit is limited to blacks.223
5.3. Elderly Patients
Heart failure is particularly common in elderly patients. The
prevalence of HF rises from 2% to 3% at age 65 to more than
80% in persons over 80 years of age,653 and HF is the most
common reason for hospitalization in elderly patients.654–657
The high prevalence of HF in the elderly may be associated
with age-related changes in ventricular function (particularlydiastolic function) and to the cumulative effects of hyperten-
sion and other chronic risk factors.658–662 In addition, risk
factors for HF (e.g., hypertension, diabetes mellitus, and
hyperlipidemia) are generally not treated aggressively in the
elderly, yet elderly patients commonly take medications that
can exacerbate the syndrome of HF (e.g., nonsteroidal anti-
inflammatory drugs).187
Heart failure in elderly patients is inadequately recognized
and treated.662 Both patients and physicians frequently at-
tribute the symptoms of HF to aging, and noninvasive cardiac
imaging commonly fails to reveal impaired systolic function
because HF with a preserved LVEF is frequently found in the
elderly. In addition, some reports suggest that elderly patients
may have diminished responses to diuretics, ACEIs, and
positive inotropic agents663–665 compared with younger pa-
tients and may experience a higher risk of adverse effects
attributable to treatment.630,666–670 Uncertainties regarding the
relation of risk to benefit are exacerbated by the fact that very
old individuals are poorly represented in large-scale clinical
trials designed to evaluate the efficacy and safety of new
treatments for HF.
Some multidisciplinary HF programs have been successful
in decreasing the rate of readmission and associated morbid-
ity in elderly patients.258,671 Managed care organizations
continue to struggle to find improved ways to implement
these pathways.672,673
6. Patients With Heart Failure Who Have
Concomitant Disorders (UPDATED)
Recommendations
Class I
1. All other recommendations should apply to patients
with concomitant disorders unless there are specific
exceptions. (Level of Evidence: C)
2. Physicians should control systolic and diastolic hyper-
tension and diabetes mellitus in patients with HF in
accordance with recommended guidelines. (Level of Evi-
dence: C)
3. Physicians should use nitrates and beta blockers for
the treatment of angina in patients with HF. (Level of
Evidence: B)
4. Physicians should recommend coronary revasculariza-
tion according to recommended guidelines in patients
who have both HF and angina. (Level of Evidence: A)
5. Physicians should prescribe anticoagulants in patients
with HF who have paroxysmal or persistent atrial
fibrillation or a previous thromboembolic event. (Level
of Evidence: A)
6. Physicians should control the ventricular response rate
in patients with HF and atrial fibrillation with a beta
blocker (or amiodarone, if the beta blocker is contra-
indicated or not tolerated). (Level of Evidence: A)
7. Patients with coronary artery disease and HF should
be treated in accordance with recommended guidelines
for chronic stable angina. (Level of Evidence: C)
8. Physicians should prescribe antiplatelet agents for
prevention of MI and death in patients with HF who
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 have underlying coronary artery disease. (Level of
Evidence: B)
Class IIa
1. It is reasonable to prescribe digitalis to control the
ventricular response rate in patients with HF and
atrial fibrillation. (Level of Evidence: A)
2. It is reasonable to prescribe amiodarone to decrease
recurrence of atrial arrhythmias and to decrease re-
currence of ICD discharge for ventricular arrhyth-
mias. (Level of Evidence: C)
Class IIb
1. The usefulness of current strategies to restore and
maintain sinus rhythm in patients with HF and
atrial fibrillation is not well established. (Level of
Evidence: C)
2. The usefulness of anticoagulation is not well estab-
lished in patients with HF who do not have atrial
fibrillation or a previous thromboembolic event. (Level
of Evidence: B)
3. The benefit of enhancing erythropoiesis in patients
with HF and anemia is not established. (Level of
Evidence: C)
Class III
1. Class I or III antiarrhythmic drugs are not recom-
mended in patients with HF for the prevention of
ventricular arrhythmias. (Level of Evidence: A)
2. The use of antiarrhythmic medication is not indicated
as primary treatment for asymptomatic ventricular
arrhythmias or to improve survival in patients with
HF. (Level of Evidence: A)
Patients with reduced LVEF frequently have associated
cardiovascular and noncardiovascular disorders, the course or
treatment of which may exacerbate the syndrome of HF. In
many patients, appropriate management of these concomitant
illnesses may produce symptomatic and prognostic benefits
that may be as important as the treatment of the HF condition
itself.
6.1. Cardiovascular Disorders
6.1.1. Hypertension, Hyperlipidemia, and
Diabetes Mellitus
Approximately two thirds of patients with HF have a past or
current history of hypertension, and approximately one third
have diabetes mellitus.674 Both disorders can contribute to the
development of systolic or diastolic dysfunction,675,676 either
directly or by contributing (together with hyperlipidemia) to
the development of coronary artery disease.677,678 Long-term
treatment of both hypertension and hyperlipidemia decreases
the risk of developing HF.72,73,679,680 In a large-scale trial, the
administration of a lipid-lowering agent to patients with
hypercholesterolemia and a history of MI reduced all-cause
mortality and the risk of developing HF.679 In 2 large-scale
multicenter studies, the treatment of hypertension reduced
both the risk of death and the risk of HF; this was true
regardless of whether the elevation of blood pressure wasprimarily systolic or diastolic.72,73,680 The benefits of lowering
blood pressure may be particularly marked in patients with
diabetes mellitus.80,82,681
Heart failure may complicate the management of both
hypertension and diabetes mellitus. Some antihypertensive
agents should be avoided in patients with HF because of their
ability to depress cardiac function or to lead to salt and water
retention. In addition, HF itself is associated with resistance to
the actions of insulin,682,683 and the resulting hyperinsulinemia
may promote both cardiac and vascular hypertrophy684–686 and
thus may hasten the progression of HF. These mechanisms may
compound the deleterious effects of accelerated atherosclero-
sis and altered energy metabolism on cardiac function and
may help to explain why diabetic patients with HF have a
worse prognosis than their nondiabetic counterparts.92
Thiazolidinediones have been associated with increased
peripheral edema and symptomatic HF in patients with
underlying risk factors or known cardiovascular disease. The
risk of developing edema with thiazolidinediones is dose
related and is higher in diabetic patients who are taking
concomitant insulin therapy. However, the incidence of
thiazolidinedione-related fluid retention is low in patients
with NYHA functional class I to II symptoms, in whom these
drugs can be administered safely with careful monitoring for
fluid retention. Initiation of these drugs is not recommended
in patients with NYHA functional class III to IV symptoms of
HF. Clinical experience has shown that one side effect of
newer oral agents of the thiazolidinedione class is weight
gain, which is due in part to fluid retention. This effect may
have the potential to precipitate or exacerbate HF in patients
with reduced cardiac reserve. Thiazolidinediones probably
should be used with caution in such patients.687,688
Recommendations Concerning Management. Little is
known about the benefits of treating hypertension, hypercho-
lesterolemia, or diabetes mellitus in patients with established
reduced LVEF and symptoms of HF. The lack of such data is
noteworthy, both because the progression of HF is frequently
associated with decreases in blood pressure (due to deterio-
ration of cardiac performance) and decreases in serum lipids
(due to development of cardiac cachexia)679 and because the
benefits of drugs used to lower blood pressure or blood lipids
may be seen only during prolonged periods of treatment (i.e.,
those that exceed the expected life span of many patients with
HF).72,73,679,680 Nevertheless, it is prudent to manage hyper-
tension, hypercholesterolemia, and diabetes mellitus in pa-
tients with HF as if the patients did not have HF. This may be
particularly true in patients with HF and preserved LVEF,
whose symptoms may respond particularly well to treatments
that lower blood pressure.689,690 Renal artery stenosis should
be considered in patients with hypertension and HF, because
renal artery stenting can treat both conditions.
Drugs that can both control blood pressure and treat HF
should be preferred in patients with both conditions; this
includes the use of diuretics, ACEIs, and beta blockers. In
contrast, physicians should avoid the use of most calcium
channel blockers, because of their cardiodepressant effects, or
potent direct-acting vasodilators such as minoxidil, because
of their sodium-retaining effects.
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 The drugs routinely used in the management of HF in
nondiabetic patients should be administered to those with
diabetes mellitus. Angiotensin converting enzyme inhibitors
and beta blockers prevent the progression of HF in diabetic
and nondiabetic patients157,162,691. Physicians should not
avoid the use of beta blockers in diabetic patients despite
fears that these drugs may mask symptoms of hypoglycemia
produced by antidiabetic therapy or may exacerbate glucose
intolerance or insulin resistance.
6.1.2. Coronary Artery Disease
Approximately two thirds of patients with HF have underly-
ing coronary artery disease, which may limit exercise toler-
ance by causing angina pectoris or may lead to further
myocardial injury by causing an MI. Therefore, physicians
should manage both the symptomatic and prognostic conse-
quences of the patient’s underlying coronary artery disease in
accordance with contemporary guidelines.
Recommendations Concerning Management of Patients
With Angina Pectoris. In general, patients who have both
angina pectoris and HF should be given drugs that relieve
angina along with drugs that are appropriate in the manage-
ment of HF.692 Both nitrates and beta blockers can improve
anginal symptoms and may produce hemodynamic and clin-
ical benefits in patients with reduced LVEF, and thus, they
are preferred if these conditions coexist.158,162,164,693,694 Yet,
the combination of the 2 drugs may produce little improve-
ment in anginal pain unless fluid retention is adequately
controlled with diuretics. It is therefore noteworthy that the
decrease in ventricular volume and pressures produced by
diuretics may exert independent antianginal effects.695
Some have suggested that the systemic and coronary
vasodilator actions of calcium channel blockers might im-
prove cardiac performance and relieve myocardial ischemia,
but these theoretical advantages have not been translated into
clinical benefits in controlled clinical trials in HF.696–698
These drugs have not improved symptoms of HF or enhanced
exercise tolerance,695–699 and short- and long-term treatment
with these drugs (even the use of sustained-release or vaso-
selective preparations) has increased the risk of worsening
HF and death in patients with LV dysfunction.135,700–708
Therefore, most calcium channel blockers should be avoided
in patients with HF, even when used for the treatment of
angina or hypertension. Of available agents, only amlodipine
has been shown not to adversely affect survival, although
experience with the drug exists largely in patients who are not
taking beta blockers.242
In patients with both HF and angina pectoris, strong
consideration should be given to the use of coronary revas-
cularization. Coronary revascularization can relieve symp-
toms of myocardial ischemia,709,710 and coronary artery by-
pass surgery has been shown to lessen angina and reduce the
risk of death in patients who have multivessel disease,
reduced LVEF, and stable angina711 (see the ACC/AHA/
ACPASIM Guidelines for the Management of Patients With
Chronic Stable Angina712 or the ACC/AHA 2004 Guideline
Update for Coronary Artery Bypass Graft Surgery).16
Recommendations Concerning Management of Patients
Without Angina. In patients with a prior MI but without HF orangina, 4 types of interventions have been used to reduce the
risk of reinfarction and death: neurohormonal antagonists
such as ACEIs and beta blockers83,123,124,129; drugs to address
dyslipidemia, such as statins; antiplatelet drugs such as
aspirin and clopidogrel310,312; and coronary revasculariza-
tion.709 In patients who have had an MI and who have HF but
not angina, the use of ACEIs and beta blockers can also
decrease the risk of reinfarction and death,126–128,713,714 but it
is less clear whether such patients benefit from the use of
aspirin or revascularization.
Aspirin has been shown to reduce the risk of major
ischemic events in patients without HF. The role of aspirin in
patients with HF has not been established,709 and concerns
have been raised that it may attenuate the hemodynamic and
survival benefits of ACEIs.303,306,307 For these reasons, the
role of aspirin in preventing ischemic events in patients with
chronic HF is controversial (see Section 4.3.1.2.2.1). Alter-
native antiplatelet agents (e.g., clopidogrel) may not interact
adversely with ACEIs305 and may have superior effects in
preventing clinical events,312 but their ability to favorably
affect outcomes in HF has not been demonstrated (see Section
4.3.1.2.2.1).
Surgical revascularization has been recommended for a
certain subset of patients in other guidelines.715 Some
physicians recommend the use of coronary revasculariza-
tion in patients with HF and coronary artery disease who
do not have symptoms of angina. Advocates of this ap-
proach have suggested that surgical reperfusion can improve
cardiac function and relieve symptoms of HF in patients with
myocardium that appears on imaging to be viable but not
contracting normally716–718 and may also reduce the risk of a
fatal coronary occlusion in patients with established multives-
sel disease.717 Despite these theoretical possibilities, how-
ever, coronary revascularization has not been shown to
improve cardiac function or symptoms or to prevent reinfarc-
tion or death in patients with HF and no angina.15,719
6.1.3. Supraventricular Arrhythmias (UPDATED)
There have been additional trials investigating the appropriate
management of atrial fibrillation in patients with HF. The text
has been modified to reflect the lessons learned from these
trials (see Section 4.3.1, Patients With Reduced Left Ventric-
ular Ejection Fraction). There is also an ACC/AHA/ESC
guideline on the management of atrial fibrillation.720
The course of patients with HF is frequently complicated
by supraventricular tachyarrhythmias, which may occur when
the myocardial disease process affects the atria or when the
atria are distended as a result of pressure or volume overload
of the right or left ventricles. The most common treatable
atrial arrhythmia is atrial fibrillation, which affects 10%
to 30% of patients with chronic HF and is associated with
a reduction in exercise capacity and a worse long-term
prognosis.721–723
Supraventricular tachyarrhythmias may exert adverse ef-
fects via 4 different mechanisms: 1) the loss of atrial enhance-
ment of ventricular filling may compromise cardiac output; 2)
the rapid heart rate may increase demand and decrease
coronary perfusion (by shortening ventricular filling time); 3)
the rapidity of ventricular response may diminish both car-
Hunt et al 2009 ACCF/AHA Heart Failure Guidelines e445
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 diac contraction (by aggravating abnormalities of the force-
frequency relation)724,725 and cardiac relaxation726,727; and 4)
the stasis of blood in the fibrillating atria may predispose
patients to pulmonary or systemic emboli. In most patients
with an ischemic or nonischemic dilated cardiomyopathy, the
rapidity of ventricular response is more important than the
loss of atrial support, because restoration of sinus rhythm
does not result in predictable clinical benefits.728 Rapid
supraventricular arrhythmias may actually cause a cardiomy-
opathy (even in patients without an underlying contractile
abnormality) or may exacerbate a cardiomyopathy caused by
another disorder.136,137 Hence, the control of ventricular rate
and the prevention of thromboembolic events are essential
elements of treatment of HF in patients with an underlying
supraventricular arrhythmia.729,730 Specific care and initially
low doses should be used when beta blockers are instituted to
control heart rate in patients with clinical evidence of HF
decompensation. The agent previously used in clinical prac-
tice to slow the ventricular response in patients with HF and
atrial fibrillation is digoxin, but the cardiac glycoside slows
atrioventricular conduction more effectively at rest than
during exercise.365,731 Hence, digitalis does not block the
excessive exercise-induced tachycardia that may limit the
functional capacity of patients with HF.363–365,731 Beta block-
ers are more effective than digoxin during exercise363,365 and
are preferred because of their favorable effects on the natural
history of HF.158,162,164 The combination of digoxin and beta
blockers may be more effective than beta blockers alone for
rate control. Although both verapamil and diltiazem can also
suppress the ventricular response during exercise, they can
depress myocardial function and increase the risk of worsen-
ing HF, especially in patients with HF and low EF, in whom
these drugs should be avoided.703,705 If beta blockers are
ineffective or contraindicated in patients with atrial fibrilla-
tion and HF, amiodarone may be a useful alternative.732
Atrioventricular nodal ablation may be needed if tachycardia
persists despite pharmacological therapy.387 Catheter ablation
for pulmonary vein isolation has been most effective in
patients without structural heart disease; the benefit for
patients with established HF is not known.733–735 Regardless
of the intervention used, every effort should be made to
reduce the ventricular response to less than 80 to 90 bpm at
rest and less than 110 to 130 bpm during moderate exercise.
Anticoagulation should be maintained in all patients with HF
and a history of atrial fibrillation, regardless of whether sinus
rhythm is achieved, because of the high rate of silent
recurrence of atrial fibrillation with its attendant embolic risk,
unless a contraindication exists.730
Should patients with HF and atrial fibrillation be converted
to and maintained in sinus rhythm? The efficacy and safety of
restoring and maintaining sinus rhythm in patients with atrial
fibrillation were evaluated in a total of 5032 patients in 4
separate trials.736 Both strategies for the management of atrial
fibrillation, either to restore and maintain sinus rhythm by
electrical or pharmacologic conversion, or to control ventric-
ular rate in atrial fibrillation, have been shown to have
equivalent outcomes. These results were confirmed in 2007
with the conclusion of a large trial of patients with both atrial
fibrillation and HF.226,227,730 Most patients revert to atrialfibrillation within a short time unless they are treated with a
Class I or III antiarrhythmic drug.721 However, patients with
HF are not likely to respond favorably to Class I drugs and
may be particularly predisposed to their cardiodepressant and
proarrhythmic effects,193,247 which can increase the risk of
death.191,192,388 Class III antiarrhythmic agents (e.g., sotalol,
dofetilide, and amiodarone) can maintain sinus rhythm in
some patients, but treatment with these drugs is associated
with an increased risk of organ toxicity (amiodarone)737,738
and proarrhythmia (dofetilide).248 Most patients who had
thromboembolic events, regardless of the strategy used, were
in atrial fibrillation at the time of the event and either were not
undergoing anticoagulation therapy or were undergoing ther-
apy at subtherapeutic levels. Thus, it is reasonable to treat HF
patients with atrial fibrillation with a strategy of either
scrupulous rate control or an attempt at rhythm control.
6.1.4. Prevention of Thromboembolic Events
Patients with chronic HF are at increased risk of thromboem-
bolic events due to stasis of blood in dilated hypokinetic
cardiac chambers and in peripheral blood vessels739,740 and
perhaps due to increased activity of procoagulant factors.741
However, in large-scale studies, the risk of thromboembolism
in clinically stable patients has been low (1% to 3% per year),
even in those with very depressed EFs and echocardiographic
evidence of intracardiac thrombi.742–746 These rates are suffi-
ciently low to limit the detectable benefit of anticoagulation
in these patients.
In several retrospective analyses, the risk of thromboem-
bolic events was not lower in patients with HF taking
warfarin than in patients not treated with antithrombotic
drugs.742,744,745 The use of warfarin was associated with a
reduction in major cardiovascular events and death in patients
with HF in one retrospective analysis but not in another.747–749
A randomized trial comparing the outcome of patients with
HF and low EF assigned to aspirin, warfarin, or clopidogrel
was completed recently.
Unfortunately, low enrollment in the trial precluded
definitive conclusions about efficacy, but no therapy ap-
peared to be superior. Another trial is currently under way
comparing aspirin with warfarin in patients with reduced
LVEF and may provide more definitive data upon which to
base recommendations.
Recommendations Concerning Management. In the ab-
sence of definitive trials, it is not clear how anticoagulants
should be prescribed in patients with HF. Despite the lack of
supportive data, some physicians prescribe anticoagulants to
all patients with markedly depressed EFs and dilated
hearts.739 Others would advocate the use of warfarin in
patients who are known to harbor a cardiac thrombus,740 even
though many thrombi detected by echocardiography do not
embolize and many embolic events are probably related to
thrombi that are not visualized.293,750 Anticoagulation with
warfarin is most justified in patients with HF who have
experienced a previous embolic event or who have paroxys-
mal or persistent atrial fibrillation.730 Anticoagulation should
also be considered in patients with underlying disorders that
may be associated with an increased thromboembolic risk
(e.g., amyloidosis or LV noncompaction) and in patients with
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 familial dilated cardiomyopathy and a history of thromboem-
bolism in first-degree relatives.
6.2. Noncardiovascular Disorders
6.2.1. Patients With Renal Insufficiency
Patients with HF frequently have impaired renal function as a
result of poor renal perfusion, intrinsic renal disease, or drugs
used to treat HF. Patients with renal hypoperfusion or
intrinsic renal disease show an impaired response to diuretics
and ACEIs275,751 and are at increased risk of adverse effects
during treatment with digitalis.370 Renal function may worsen
during treatment with diuretics or ACEIs,274,527 although the
changes produced by these drugs are frequently short-lived,
generally asymptomatic, and reversible. Persistent or progres-
sive renal functional impairment often reflects deterioration
of the underlying renal disease process and is associated with
a poor prognosis.41,752 The symptoms of HF in patients with
end-stage renal disease may be exacerbated by an increase in
loading conditions produced both by anemia753 and by fistulas
implanted to permit dialysis. In addition, toxic metabolites
and abnormalities of phosphate, thyroid, and parathyroid
metabolism associated with chronic renal insufficiency can
depress myocardial function.
Despite the potential for these adverse interactions, most
patients with HF tolerate mild to moderate degrees of
functional renal impairment without difficulty. In these indi-
viduals, changes in blood urea nitrogen and serum creatinine
are generally clinically insignificant and can usually be
managed without the withdrawal of drugs needed to slow the
progression of HF. However, if the serum creatinine increases
to more than 3 mg per dL, the presence of renal insufficiency
can severely limit the efficacy and enhance the toxicity of
established treatments.275,370,751 In patients with a serum
creatinine greater than 5 mg per dL, hemofiltration or dialysis
may be needed to control fluid retention, minimize the risk of
uremia, and allow the patient to respond to and tolerate the
drugs routinely used for the management of HF.548,754
6.2.2. Patients With Pulmonary Disease
Because dyspnea is the key symptom in both HF and
pulmonary disease, it is important to distinguish the 2
diseases and to quantify the relative contribution of cardiac
and pulmonary components to the disability of the patient
when these disorders coexist. Exercise testing with simulta-
neous gas exchange or blood gas measurements may be
helpful in this regard, particularly when used in conjunction
with right heart catheterization.755
Some drugs used to treat HF can produce or exacerbate
pulmonary symptoms. Angiotensin converting enzyme inhib-
itors can cause a persistent nonproductive cough that can be
confused with a respiratory infection, and conversely, ACEIs
may be inappropriately stopped in patients with pulmonary
causes of cough. Therefore, physicians should seek a pulmo-
nary cause in all patients with HF who complain of cough,
whether or not they are taking an ACEI. The cough should be
attributed to the ACEI only if respiratory disorders have been
excluded and the cough disappears after cessation of ACEI
therapy and recurs after reinstitution of treatment. Because
the ACEI-related cough does not represent any seriouspathology, many patients can be encouraged to tolerate it in
view of the important beneficial effects of ACEIs.
Beta blockers can aggravate bronchospastic symptoms in
patients with asthma; however, many patients with asymp-
tomatic or mild reactive airways disease tolerate beta-
blockers well. Also, most patients with chronic obstructive
pulmonary disease do not have a bronchospastic component
to their illness and remain reasonable candidates for beta-
blockade.756 Of note, both metoprolol tartrate and bisoprolol
may lose their beta-1 selectivity when prescribed in doses that
have been associated with an improvement in survival in
patients with HF.
6.2.3. Patients With Cancer
Patients with cancer are particularly predisposed to the
development of HF as a result of the cardiotoxic effects of
many cancer chemotherapeutic agents, especially the anthra-
cyclines,757 high-dose cyclophosphamide,758–762 and trastu-
zumab.763 Trastuzumab is a monoclonal antibody recently
approved for therapy of metastatic breast cancer764 that has a
significant potential to cause HF, especially when combined
with anthracyclines. Mediastinal radiation can also cause
acute and chronic injury to the pericardium, myocardium,
cardiac valves, and coronary arteries, particularly when used
in conjunction with cardiotoxic chemotherapy.765
Patients undergoing potentially cardiotoxic treatments for
cancer should be monitored closely for the development of
cardiac dysfunction. Heart failure may appear many years
after anthracycline exposure, particularly in association with
another stress, such as tachycardia. Although noninvasive
assessments of LV function and endomyocardial biopsy have
been advocated by some investigators,766 many cases escape
early detection despite close surveillance.
Dexrazoxane may confer some cardioprotection in patients
undergoing anthracycline-based chemotherapy and may al-
low for higher doses of the chemotherapy to be given.767,768
Heart failure due to chemotherapeutic agents is managed
similarly to HF due to other causes, although it is not clear
whether patients with cancer respond similarly to patients
with other causes of HF. Nevertheless, because most patients
with anthracycline-induced cardiomyopathy have striking
degrees of tachycardia, many experts believe that beta block-
ers play a particularly important role in the management of
these patients. Although once thought to progress inexorably,
HF related to chemotherapy often improves in response to
therapy, even when it appears late after exposure.
6.2.4. Patients With Thyroid Disease
Patients with both hyperthyroidism and hypothyroidism are
prone to develop HF. Special vigilance is required for patients
who are taking amiodarone, who may develop either hyper-
thyroidism or hypothyroidism. New atrial fibrillation or
exacerbation of ventricular arrhythmias should trigger reeval-
uation of thyroid status.
6.2.5. Patients With Hepatitis C and Human
Immunodeficiency Virus
Hepatitis C viral infection can be a cause of cardiomyopathy and
myocarditis. It appears that the virus can cause both dilated
cardiomyopathy and hypertrophic cardiomyopathy.514,515 The
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 relatively high prevalence of this virus in Japanese popula-
tions compared with those in North America and Europe
suggests that there may be a genetic predisposition to this
type of viral myocarditis.516,769 A small study showed that
hepatitis C virus myocarditis might respond favorably to
immunosuppressive therapy with prednisone and azathio-
prine.770,771 Preliminary data also suggest that this type of
myocarditis might respond well to interferon therapy,515
although there is concern that interferon can also depress
myocardial function.
Human immunodeficiency virus has been recognized as a
probable occasional cause of dilated cardiomyopathy. The
presence of reduced LVEF in patients with HIV infection
appears to correlate with decreased survival.772 Reduced
LVEF is often seen in association with a significantly reduced
CD4 count, although progression of cardiomyopathy does not
appear to be related to falling CD4 levels.773 Drug therapy for
HIV with zidovudine has also been implicated as a cause of
cardiomyopathy, possibly through its effect on cardiac myo-
cyte mitochondrial function.774 Heart failure in patients with
HIV infection may also be caused or exacerbated by pericar-
dial effusion or pulmonary hypertension. Interferon-alpha
therapy for HIV-related Kaposi’s sarcoma has also been
associated with reversible reduction in LVEF. Because of the
occurrence of complex opportunistic infections, autoimmune
responses to the viral infection, and drug cardiotoxicity, it is
difficult to determine how therapies influence the develop-
ment and control of cardiomyopathy with HIV.775
6.2.6. Patients With Anemia
Anemia is seldom the cause of HF in the absence of
underlying cardiac disease. To be the sole cause of high-
output HF, anemia must be severe (e.g., hemoglobin levels
less than 5 g per deciliter). On the other hand, patients with
HF frequently have anemia for a variety of reasons. The
severity of anemia may contribute to the increasing severity
of HF. Several studies have demonstrated worse outcomes in
patients with HF and anemia.776,777 It is unclear whether
anemia is the cause of decreased survival or a result of more
severe disease.
Several small studies have suggested benefit from use
of erythropoietin and iron for treatment of mild anemia in
HF.778–780 There is concern, however, that thromboembolic
events may be increased. This therapy is undergoing further
investigation.
7. End-of-Life Considerations
Recommendations
Class I
1. Ongoing patient and family education regarding prog-
nosis for functional capacity and survival is recom-
mended for patients with HF at the end of life. (Level of
Evidence: C)
2. Patient and family education about options for for-
mulating and implementing advance directives and
the role of palliative and hospice care services with
reevaluation for changing clinical status is recom-mended for patients with HF at the end of life. (Level
of Evidence: C)
3. Discussion is recommended regarding the option of
inactivating ICDs for patients with HF at the end of life.
(Level of Evidence: C)
4. It is important to ensure continuity of medical care
between inpatient and outpatient settings for patients
with HF at the end of life. (Level of Evidence: C)
5. Components of hospice care that are appropriate to
the relief of suffering, including opiates, are recom-
mended and do not preclude the options for use of
inotropes and intravenous diuretics for symptom
palliation for patients with HF at the end of life.
(Level of Evidence: C)
6. All professionals working with HF patients should
examine current end-of-life processes and work toward
improvement in approaches to palliation and end-of-life
care. (Level of Evidence: C)
Class III
1. Aggressive procedures performed within the final days
of life (including intubation and implantation of a
cardioverter-defibrillator in patients with NYHA func-
tional class IV symptoms who are not anticipated to
experience clinical improvement from available treat-
ments) are not appropriate. (Level of Evidence: C)
Although issues surrounding end-of-life care deserve at-
tention for all chronic terminal diseases, several general
principles merit particular discussion in the context of chronic
HF. Education of both patient and family regarding the
expected or anticipated course of illness, final treatment
options, and planning should be undertaken before the patient
becomes too ill to participate in decisions. Discussions
regarding treatment preferences, living wills, and advance
directives should encompass a variety of likely contingencies
that include responses to a potentially reversible exacerbation
of HF, a cardiac arrest, a sudden catastrophic event such as a
severe cerebrovascular accident, and worsening of major
coexisting noncardiac conditions. In reviewing these issues
with families, short-term intervention in anticipation of rapid
recovery should be distinguished from prolonged life support
without reasonable expectation of a return to good functional
capacity.
Most patients hospitalized with severe HF indicate a
preference that resuscitation be performed in the event of a
cardiopulmonary arrest. In the largest study of patients
hospitalized with HF, only 23% stated they did not wish
resuscitation, and 40% of these patients subsequently
changed their minds after the hospitalization.781 These fre-
quencies are higher than those seen in other chronic diseas-
es,782 perhaps because patients with HF are more likely to
experience extended periods of stability with good quality of
life after hospitalization for intensive care. Hospitals in the
United States are required by the Patient Self-Determination
Act783 to seek and record information regarding advance
directives at the time of admission. Yet, when these have not
been addressed in advance, forced contemplation of resusci-
tation options at the time of admission for worsening HF may
e448 Circulation April 14, 2009
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 heighten patient and family anxiety without revealing true
preferences.784 The majority of patients with HF who had not
discussed resuscitation during hospitalization indicated that
they had not desired such an interaction.781 Furthermore, in
one study, the impact of resuscitation preferences on in-
hospital outcome was minimal even for patients with HF in
intensive care, of whom only 4% experienced unexpected
cardiac arrests compared with more than 25% of patients in
intensive care units who had other chronic illnesses.785
When the limitations imposed by HF alone or in combi-
nation with other severe conditions become intolerable,
however, resuscitation may no longer be desired by the
patient. At this time, it is important to understand which
aspects of further care the patient wishes to forego. In some
cases, the patient may want full supportive care while
conscious, other than actual resuscitation; in other circum-
stances, hospitalization may no longer be desired for any
intervention. Any decision to forego resuscitation should lead
to possible deactivation of the life-saving function of an
implanted defibrillation device; the poor functional status of
any patient should also influence the decision regarding
implantation of such a device in the first place.786 To observe
both the intent and the directives of the patient and family, it
is highly desirable that outpatient, inpatient, and crisis man-
agement be supervised by the same team to diminish the
hazards of fragmented care during this period. The patient
should be encouraged to choose in advance a person to
assume legal authority (i.e., designated power of attorney or
healthcare proxy) for healthcare matters when the patient
cannot be involved in decisions. That individual should serve
as the contact point for the team. Rapid communications with
this team will reduce the conflicts and uncertainties that may
arise when patients are first seen in an emergent setting by
physicians not normally involved in their care. The standing-
care plans for each patient need to be quickly accessible to all
personnel likely to be involved in the patient’s care. Profes-
sionals caring for patients with advanced HF should have
realistic expectations for survival and communicate those
accurately to patients and families. Also, the professionals
should provide realistic recommendations for procedures
being done within the final days of life that do not add to the
hope of recovery or improvement in life quality. Finally,
greater attention and research need to be devoted to the
provision of comfort measures in the final days of life,
including relief of pain and dyspnea. Hospice services have
only recently been extended to patients dying of HF. Origi-
nally developed for patients with end-stage cancer, the focus
of hospice care has now been expanded to include the relief
of symptoms other than pain.787 This is appropriate because
the suffering of patients with HF is characteristically linked to
symptoms of breathlessness, and thus, compassionate care
may require the frequent administration of intravenous diuret-
ics and, in some cases, the continuous infusion of positive
inotropic agents rather than only the use of potent analgesics.
However, many patients dying of HF do describe pain during
the final days.622,788 Physicians caring for these patients
should become familiar with the prescription of anxiolytics,
sleeping medications, and narcotics to ease distress during the
last days.Traditionally, the utilization of hospice care has required a
prediction by a physician of death within 6 months, but this
operational policy may be difficult to apply, because health-
care providers are generally unable to accurately predict the
end of life in patients with HF. In a large US study on the
experience of patients hospitalized in intensive care units
with terminal stages of disease, the majority of patients who
were identified by broad criteria for hospice care survived the
next 6 months despite a prediction to the contrary.789 This
discrepancy between predicted and actual survival may be
particularly great for patients with HF, which more often than
other chronic illnesses is characterized by periods of good
quality of life despite the approaching end and which is likely
to be terminated by sudden death despite a recent remission
of symptoms. Current guidelines and policies790 are being
revised to allow patients with HF to benefit from the type of
care that can be provided through hospice services.
Ultimately, the decisions regarding when end of life is
nearing reflect a complex interaction between objective in-
formation and subjective information, emotions, and patient
and family readiness. Ideally, these decisions would be made
in conjunction with the individual or team most experienced
in caring for advanced HF or in collaboration and/or consul-
tation with such an expert. In reality, however, this does not
occur often. The writing committee recommends that all
those involved with HF care make it a priority to improve
recognition of end-stage disease and provide care to patients
and families approaching this stage. As we become more
familiar with the steps in progression to endstage HF in this
era, the current abrupt transition from aggressive intervention
to comfort and bereavement care will be softened by a
gradual and progressive emphasis on palliation until it dom-
inates the final days of care.788
8. Implementation of Practice Guidelines
Recommendations
Class I
1. Academic detailing or educational outreach visits are
useful to facilitate the implementation of practice
guidelines. (Level of Evidence: A)
2. Multidisciplinary disease-management programs for
patients at high risk for hospital admission or clin-
ical deterioration are recommended to facilitate the
implementation of practice guidelines, to attack dif-
ferent barriers to behavioral change, and to reduce
the risk of subsequent hospitalization for HF. (Level
of Evidence: A)
Class IIa
1. Chart audit and feedback of results can be effective to
facilitate implementation of practice guidelines. (Level
of Evidence: A)
2. The use of reminder systems can be effective to
facilitate implementation of practice guidelines.
(Level of Evidence: A)
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 3. The use of performance measures based on practice
guidelines may be useful to improve quality of care.
(Level of Evidence: B)
4. Statements by and support of local opinion leaders can
be helpful to facilitate implementation of practice
guidelines. (Level of Evidence: A)
Class IIb
1. Multidisciplinary disease-management programs for
patients at low risk for hospital admission or clinical
deterioration may be considered to facilitate imple-
mentation of practice guidelines. (Level of Evidence: B)
Class III
1. Dissemination of guidelines without more intensive
behavioral change efforts is not useful to facilitate
implementation of practice guidelines. (Level of Evi-
dence: A)
2. Basic provider education alone is not useful to
facilitate implementation of practice guidelines.
(Level of Evidence: A)
Despite the publication of evidence-based guidelines,262,791
the current care of patients with HF remains suboptimal.
Numerous studies document underutilization of key processes of
care, such as use of ACEIs in patients with decreased systolic
function and the measurement of LVEF.630,792,793 The overall
quality of inpatient care for HF as judged by both explicit and
implicit standards is variable, with lower quality associated with
higher readmission rates and mortality.549,794,795 Many HF
admissions may be prevented with good outpatient care.796
The literature on implementing practice guidelines for
patients with HF can be divided into 3 areas: isolated
provider interventions, disease management systems, and
use of performance measures.
8.1. Isolated Provider Interventions
A controlled trial has shown that the simple dissemination of
an HF guideline followed by written and verbal reminders
about recommended actions was unable to change the treat-
ment of HF in the intensive care unit.797 Indeed, an extensive
literature has documented how difficult it is to produce
appropriate changes in physician behavior.798–800 Basic phy-
sician education and passive dissemination of guidelines
alone are generally insufficient to sustain quality improve-
ment. Chart audit and feedback of results, reminder systems
to consider use of specific medicines or tests, and the use of
local opinion leaders have had variable results. Multifactorial
interventions that simultaneously attack different barriers to
change tend to be more successful than isolated efforts. For
example, academic detailing, which involves intensive
educational outreach visits that incorporate communica-
tion and behavioral change techniques, has been effective
and is commonly used by pharmaceutical companies.801
Thus, dissemination of a practice guideline must be ac-
companied by more intensive educational and behavioral
interventions to maximize the chances of improving phy-
sician practice patterns.8.2. Disease-Management Systems
The disease-management approach views HF as a chronic
illness that spans the home as well as outpatient and
inpatient settings. Most patients have multiple medical,
social, and behavioral challenges, and effective care re-
quires a multidisciplinary systems approach that addresses
these various difficulties. Heart failure disease-
management programs vary in their content, but in general,
they include intensive patient education, encouragement of
patients to be more aggressive participants in their care,
close monitoring of patients through telephone follow-up
or home nursing, careful review of medications to improve
adherence to evidence-based guidelines, and multidisci-
plinary care with nurse case management directed by a
physician. High-risk patients have usually been chosen for
such programs.
Observational studies and randomized controlled trials
have shown that disease-management programs can reduce
the frequency of hospitalization and can improve quality of
life and functional status.261,802 Patients at high risk for clinical
deterioration or hospitalization are likely to benefit from disease-
management programs and represent those for whom such
interventions are most likely to be cost-effective.803 The largest
successful randomized controlled trial of disease management
targeted elderly patients who had been hospitalized for HF, had
a prior history of HF, had 4 or more hospitalizations within 5
years, or had an HF exacerbation caused by an acute MI or
uncontrolled hypertension.258 Patients randomized to the
disease-management program had significantly fewer hospital-
izations and a reduced cost of care compared with patients in the
control group. However, it is not clear which elements of
disease-management programs are crucial for success. In addi-
tion, it is not known whether such interventions are feasible in
settings with limited resources and personnel and among diverse
patient populations.
8.3. Performance Measures
Performance measures are standards of care for a particular
illness or condition that are designed to assess and subse-
quently improve the quality of medical care. Performance
measures are chosen on the basis of the knowledge or
assumption that the particular item is linked to improved
patient outcomes. In the field of HF, such measures might
include documentation of the level of LV function, medica-
tions used, or patient education measures. These measures
can be used either internally within an organization or
publicly to compare the performance of providers, hospitals,
and healthcare organizations. In theory, performance mea-
sures could improve care by encouraging providers to com-
pete on the basis of quality as opposed to cost, empowering
consumers to make informed choices in the marketplace,
providing incentives to providers to concentrate on certain
diseases or processes of care, and supplying information to
aid with internal quality improvement. The evidence is
mixed, but some studies indicate that performance measures
can improve health outcomes.804
The ACCF and AHA are collaborating with a variety of
organizations to develop and implement performance mea-
sures. ACCF/AHA practice guidelines are useful starting
e450 Circulation April 14, 2009
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 points for performance measures, but several considerations
apply: 1) ACCF/AHA practice guidelines are designed for
improving the care of individual patients. Performance mea-
sures are generally used for improving the care of populations
of patients. Although significant overlap exists in these goals,
performance measures need to take into account additional
factors, such as ease of data collection, simplicity of stan-
dards, calculation of sufficient numbers of patients for whom
the measure would apply, and provision of flexibility for
clinically diverse situations. 2) In general, most performance
measures should be chosen from Class I and Class III practice
guideline recommendations; however, given the additional
factors involved in improving the care of populations of
patients, Class IIa recommendations may be suitable in
selected situations. 3) Opportunities should be given for
clinicians to describe why a particular performance measures
may not be appropriate for an individual patient.
8.4. Roles of Generalist Physicians and
Cardiologists
Insufficient evidence exists to allow for recommendations
about the most appropriate roles for generalist physicians and
cardiologists in the care of patients with HF. Several studies
indicate that primary care physicians as a group have less
knowledge about HF and adhere to guidelines less closely
than cardiologists.805–807 Some studies have noted better
patient outcomes in patients cared for by cardiologists than
in those cared for by generalist physicians,808,809 whereas
another study reported that cardiologists deliver more
costly care that is accompanied by a trend toward im-
proved survival.810 Despite these observations, primary
care physicians with knowledge and experience in HF
should be able to care for most patients with uncompli-
cated HF. By contrast, patients who remain symptomatic
despite basic medical therapy may benefit from care
directed by consulting physicians who have special exper-
tise and training in the care of patients with HF.
Do generalist physicians and cardiologists provide similar
levels of care for the noncardiac comorbid conditions fre-
quently present in patients with HF? What is the optimal time
for referral to a specialist? What is the most effective system
of comanagement of patients by generalists and cardiolo-
gists? What is the most cost-effective entry point into a
disease-management program? Regardless of the ultimate
answers to these questions, all physicians and other health-
care providers must advocate and follow care practices that
have been shown to improve patient outcomes. If a physician
is not comfortable following a specific recommendation (e.g.,
the use of beta blockers), then the physician should refer the
patient to someone with expertise in HF. A collaborative
model in which generalist and specialist physicians work
together to optimize the care of patients with HF is likely to
be most fruitful.
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Appendix 3. Rematch Trial Abbreviations
ACCF American College of Cardiology HDL high-density lipoprotein
ACE angiotensin converting enzyme HF heart failure
ACEI angiotensin converting enzyme inhibitor HIV human immunodeficiency virus
AHA American Heart Association ICD implantable cardioverter-defibrillator
ARB angiotensin II receptor blocker LBBB left bundle-branch block
ATPase adenosine triphosphatase LV left ventricular
BNP B-type natriuretic peptide LVEF left ventricular ejection fraction
CPAP continuous positive airway pressure LVH left ventricular hypertrophy
CRT cardiac resynchronization therapy MI myocardial infarction
DCM dilated cardiomyopathy Na-K sodium-potassium
DIG Digitalis Investigation Group NYHA New York Heart Association
EF ejection fraction RBBB right bundle-branch block
EPO erythropoietin REMATCH Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure
FHx CM family history of cardiomyopathy RVEF right ventricular ejection fraction
HCM hypertrophic cardiomyopathy STICH Surgical Treatment for Ischemic Heart Failure
HCV hepatitis C viral infection VT ventricular tachycardia
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Correction
In the article by Hunt et al, “2009 Focused Update Incorporated Into the ACC/AHA 2005
Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the
American College of Cardiology Foundation/American Heart Association Task Force on Practice
Guidelines,” which published ahead of print on March 26, 2009, and appeared in the April 14,
2009 issue of the journal (Circulation. 2009;119:e391–e479), a correction was needed.
On page e414, in the left column, the third full paragraph, the last sentence of the paragraph
read, “Diuretics are generally combined with moderate dietary sodium restriction (3 to 4 g daily).”
It has been changed to read, “Diuretics are generally combined with moderate dietary sodium
restriction.”
This correction has been made to the current online version of the article, which is available at
http://circ.ahajournals.org/cgi/content/full/119/14/e391.
DOI: 10.1161/CIR.0b013e3181d7a6b3
(Circulation. 2010;121:e258.)
© 2010 American Heart Association, Inc.
Circulation is available at http://circ.ahajournals.org
e258
In the article by Hunt et al, “2009 Focused Update Incorporated Into the ACC/AHA 2005 
Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the 
American College of Cardiology Foundation/American Heart Association Task Force on 
Practice Guidelines,” which published ahead of print on March 26, 2009, and appeared in 
the April 14, 2009, issue of the journal (Circulation. 2009;119:e391–e479), a correction 
is needed. 
 
On page e414, in the left column, the third full paragraph, the last sentence of the 
paragraph reads, “Diuretics are generally combined with moderate dietary sodium 
restriction (3 to 4 g daily).” It should be changed to read, “Diuretics are generally 
combined with moderate dietary sodium restriction.”  
